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Abstract 
 
The prevalence of fungal infections is on the rise due to the increase of 
immune suppressed individuals.  Neutrophils are key immune cells in the 
fight against fungal infections.  The study of neutrophil biology is hampered 
by the short lived nature of the cells and the fact that they cannot be easily 
genetically modified.  In this thesis, I generate and characterise myeloid 
precursor cell lines that can be genetically manipulated and differentiated 
into functional neutrophils.  These in vitro generated neutrophils were 
adoptively transferred into live animals and tracked during inflammatory 
responses.  Clec7a, a cell surface β-glucan receptor found on myeloid cells, 
and its role in immune response to fungal infections has been well 
characterised in macrophages and dendritic cells but less so on neutrophils.  
In this thesis, a model for elucidating the role of Clec7a on neutrophils was 
developed using primary cells and was able to show that Clec7a deficiency on 
neutrophils impairs recognition of zymosan and C. albicans but that this 
impairment was largely overcome by serum opsonisation of the particles.  
The in vitro generated neutrophils were comparably tested and, although the 
cells have their limitations, they largely supported the conclusions found 
using primary cells. 
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1.1 Fungal infections 
1.1.1. Fungal Morphology 
Fungi are a diverse kingdom of eukaryotic organisms.  They share certain features with both 
plants and animals but are distinct from either (Table 1.1).   In nature fungi can exist in two 
main forms; the hyphal form, which consists of thin filaments of fungal cells called hyphae 
and a mass of these filaments is known as the mycelium, and the unicellular yeast form 
(Adams 2004).  Both hyphae and yeast can be pathological in humans (Diamond, Krzesicki et 
al. 1978; Lehmann 1985) and fungal species that can alternate between both these forms 
are known as dimorphic (San-Blas and San-Blas 1984).  Conidia (non-motile fungal spores 
that are produced via mitosis and, if the conditions are favourable, are a means of asexual 
reproduction) can also be pathogenic and in the case of Aspergillus spp, conidia are the 
primary route of human infection (Dagenais and Keller 2009).  Although there are thousands 
of fungal species only a small percentage of them are pathogenic to humans (Box 1). 
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 Animal Fungi Plant 
Nuclear Envelope Present Present Present 
Mitochondria Present Present Present 
Chloroplasts Absent Absent Present 
Vacuoles Absent Present Present 
Cell Wall Absent Present: 
Non-cellulose 
polysaccharides 
Present: 
Cellulose  
Sterol Cholesterol Ergosterol Stigmasterol, 
Sitosterol & 
Campesterol 
Nutrition Heterotrophic Heterotrophic Autotrophic  
Table 1.1: Differing characteristics of animals, fungi and plants.  Table created from information gathered 
from various sources (Whittaker 1969; Klionsky, Herman et al. 1990; Smits, van den Ende et al. 2001; Odds, 
Brown et al. 2003; Alberts 2008; Jacquier and Schneiter 2012) 
 
 
21 
 
 
Box 1: Fungal species that commonly cause clinical infections in patients with compromised immune systems.  
Table created from information gathered from various sources (Powell, Drutz et al. 1983; Wheat, Batteiger et 
al. 1990; Wheat 1994; Milla, Wielinski et al. 1996; Denning 1998; Hajjeh, Conn et al. 1999; Chen, Sorrell et al. 
2000; Muller, Trusen et al. 2002; Douglas 2003; Crum, Lederman et al. 2004; Netea, Gow et al. 2006; Aide 
2009; Moyes and Naglik 2011) 
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1.1.2. Prevalence 
Healthy individuals are usually protected from fungal infections.  The first barriers to 
infection are the anatomical barriers, i.e. the skin and mucosal surfaces.  If these fail, then 
the immune system can overcome the fungal pathogens through four main mechanisms; 
complement, phagocytes, antibodies and cell mediated immunity.  When both barriers fail 
then fungal infections can occur and become systemic (Richardson 2005). 
The rate of pathological human fungal infections is on the rise.  In the United States, the 
incidence of fungal sepsis increased by 207% between 1979 and 2000 (Martin, Mannino et 
al. 2003).  This can be attributed to the increase in invasive medical practices, such as 
surgery and indwelling catheters that break down the anatomical barrier to fungi 
(Richardson 2005) and to the increase in the number of patients that have compromised 
immune systems, usually as a result of HIV/AIDS, the use of immunosuppressive drugs for 
organ donor recipients, cancer treatments and other medical interventions (Romani 2004).  
These patients become susceptible to opportunistic pathogens that would normally not 
cause disease.  The mortality rate for opportunistic fungal infections exceeds 50% in some 
human studies and has been shown to be up to 95% in bone marrow transplant patients 
infected with Aspergillus spp (Romani 2004).  It has been suggested that the impact of 
fungal infections on human health is highly underestimated and that some fungal diseases 
kill at least as many people as tuberculosis or malaria (Brown, Denning et al. 2012). 
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1.1.3 Classes of Infection 
Fungal infections can be classified into several different groups (Kimura and McGinnis 1998): 
1. Superficial Mycoses 
This type of infection involves fungi that colonize the hair.  The Piedraia hortae, 
fungus forms a fruiting body called an ascostroma around a hair shaft. The 
ascostroma is tightly attached to the hair shaft and only minimal tissue damage at 
the site where the ascostroma is attached to the hair shaft is observed (Kimura and 
McGinnis 1998). 
2. Cutaneous Mycoses 
This type of infection is usually limited to non-living tissues such as the surface of the 
skin, nails or hair.  There is observable tissue damage and an immune response can 
be measured (Kimura and McGinnis 1998).  This type of infection can be so 
innocuous as to leave patients unaware that they are affected.  Examples include 
Microsporum (athlete’s foot) and Trichophyton (ringworm) (Anaissie, McGinnis et al. 
2003). 
3. Subcutaneous Mycoses 
This type of infection affects the living skin and underlying tissues and is caused by 
traumatic introduction of the pathogen to the dermis.  It can lead to a chronic 
infection and the appearance of abscesses.  This type of infection rarely becomes 
systemic (Kimura and McGinnis 1998).  Examples include chromoblastomycosis 
which is caused by fungi such as Phialophora verrucosa and Fonsecaea pedrosoi 
(Bonifaz, Carrasco-Gerard et al. 2001). 
4. Systemic Mycoses 
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Fungal pathogens that have entered the body and are able to infect internal organs 
are known as systemic infections. These types of infections are able to disseminate 
between different organs and can be fatal if vital organs are infected (Kimura and 
McGinnis 1998). Examples include histoplasmosis which is caused by fungi from the 
genus Histoplasma (Aide 2009)and Coccidioidomycosis, which is caused by 
Coccidioides immitis (Galgiani 1993). 
5. Candidiasis 
This is a class of infections caused by fungi from the genus Candida, usually Candida 
albicans, which is a ubiquitous and commensal fungus.  It is found on the skin, nails 
and mucous membranes of humans.  Involvement may be localized to mucosal 
membranes or become systemic. In healthy individuals, Candida infections occur in 
all age groups, but are most common in the new-born and the elderly (Schulze and 
Sonnenborn 2009; Moyes and Naglik 2011).  
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1.1.4. Current Treatments 
Historically, research into treatments for fungal infections has been sparse.  This can be 
attributed to observation that prior to the 1980s, the incidence of serious fungal infections 
was relatively low, especially in comparison with bacterial infections (Sheehan, Hitchcock et 
al. 1999).  However, due to the increase in incidence (Chapter 1.1.2), research and 
development of antifungal agents has increased (Ghannoum and Rice 1999). The first agent 
with antifungal properties, griseofulvin, was isolated in 1939 but it was not approved for 
clinical use until 1958 (Sheehan, Hitchcock et al. 1999). Since then several different classes 
of antifungal agents have been discovered and taken into the clinic (Table 1.2).  Fungal cells 
are eukaryotic cells that are very similar to mammalian cells in terms of their biochemical 
reactions (Romani 2004).  This can make the treatment of invasive fungal infections difficult 
as drugs that do kill fungal cells can also be very toxic to human cells and can produce 
severe side effects in patients.  For example, amphotericin B, used in the treatment of 
systemic fungal infections, is known to cause significant nephrotoxicity as well as fever, 
chills, headache and vomiting (Dismukes 2000).  Other than the side effects produced by 
antifungal agents, one of the major obstacles to comprehensive treatment is the growing 
rise in resistance to current treatments (Ghannoum and Rice 1999).   
 
 
 
 
 
 
 
26 
 
Class Example Mechanism of Action 
Allylamines Terbinafine Inhibits early steps of ergosterol biosynthesis, leading to an 
increase in membrane permeability and disruption of fungal 
cell. 
Azoles Fluconazole Inhibition of cytochrome P-450-dependent 14α-sterol 
demethylase, an enzyme required in the biosynthesis of 
ergosterol, leading to ergosterol depletion and membrane 
disruption. 
Cell wall 
inhibitors 
Echinocandins Inhibits biosynthesis of cell wall components.  Echinocandins 
inhibit 3β-glucan synthase, which results in structural changes 
in the cell wall that can ultimately lead to cell death. 
Morpholines Amorolfine Inhibits ergosterol biosynthesis. 
Nucleic acid 
inhibitors 
5-flourocytosine Disrupts pyrimidine metabolism as well as interfering with 
RNA, DNA and protein synthesis in fungal cells. 
Polyenes Amphotericin B Interacts with sterols in the outer membrane of fungal cells 
leading to cellular death.  Fungal cells without sterols in their 
outer membrane are not susceptible to polyenes and 
inhibitory action of polyenes can be disrupted by the addition 
of sterols into the growth medium of fungal cultures.  
Amphotericin B interactions are thought to cause pores in the 
outer membrane. 
Table 1.2: Different classes of antifungal agents and their proposed mechanism of action.  Table created 
from information gathered from various sources (Ghannoum and Rice 1999; Sheehan, Hitchcock et al. 1999; 
Onyewu, Blankenship et al. 2003). 
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1.2. Immunity to Fungal Infections 
 
The human body is usually able to mount an immune response that destroys fungal 
pathogens that invade living tissues, which is demonstrated by the observation that risk 
factors for the development of systemic fungal infections include patients that have 
undergone solid organ transplantation, patients with HIV or AIDS and patients who for 
underlying medical reasons exhibit some form of immune suppression (Patel and Paya 1997; 
Procop and Roberts 2004; Fishman 2007; Morris, Wei et al. 2008; Walzer, Evans et al. 2008; 
Neofytos, Fishman et al. 2010).  In order to destroy fungal pathogens the immune system 
must first recognise the pathogen as an invading foreign body.  The innate immune system 
recognises pathogen-associated molecular patterns (PAMPs), which are a host of molecules 
common to most microbial species (Table 1.3).  These PAMPs are recognised by pattern 
recognition receptors (PRRs) that can be either soluble or attached to plasma membranes 
on the cell surface or on intracellular compartments (Akira, Uematsu et al. 2006). 
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PAMP PRR Pathogen 
Lipopolysaccharide (LPS) TLR4 Gram negative bacteria 
Lipoteichoic acid TLR2:TLR6 Heterodimer Gram positive bacteria 
Lipopeptides TLR2:TLR1 or TLR2:TLR6 
Heterodimers 
Lipoarabinomannan TLR2 
Peptidoglycan TLR2 
Flagellin TLR5 Flagellated bacteria 
Glucans Clec7a &  TLR2 Fungi 
Mannan Mannan Binding Lectin , TLR4 & 
Clec4n 
CpG DNA TLR9 Fungi and Bacteria 
Env Protein TLR4 Viruses 
Double stranded RNA Melanoma Differentiation-
Associated protein 5 (MDA5) & 
TLR3 
Single stranded RNA Retinoic acid inducible gene-I 
(RIG-I), TLR7 & human TLR8 
Table 1.3: Examples of PAMPs and associated pathogens.  Table created from information gathered from 
various sources (Schwandner, Dziarski et al. 1999; Underhill and Ozinsky 2002; Adams 2004; Crozat and 
Beutler 2004; Brown 2006; Dalpke, Frank et al. 2006; Netea, Van der Meer et al. 2006; Sheng, Pouniotis et al. 
2006; Thompson and Locarnini 2007; Farhat, Riekenberg et al. 2008; Kawai and Akira 2009).  
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1.2.1 Haematopoiesis and Innate Immune Cells with Major Roles in Antifungal Defence 
 
Haematopoiesis 
Haematopoiesis is the generation of blood cells including all immune cells (Figure 1.1), 
which primarily takes place in the bone marrow.  All blood cells are generated from a 
multipotent stem cell and a host of cytokines and growth factors are involved in the growth 
and differentiation of these cells (Robb 2007).  These cells are able to self-renew and expand 
to enable a constant population of stem cells present for the continual production of blood 
cells as required in a lifetime (Reya 2003). The multipotent haematopoietic stem cell can 
differentiate into either the common myeloid progenitor (CMP) or the common lymphoid 
progenitor (CLP).  These cells are primitive progenitor cells and are able to generate all 
blood cells. The CLP generates the lymphoid cells e.g. B cells, T cells and natural killer (NK) 
cells, and is also able to generate dendritic cells.  The CMP has the potential to generate all 
myeloid cells e.g. neutrophils and macrophages, dendritic cells, red blood cells and platelets.  
Neutrophils and macrophages have important roles in immunity to fungal infections and 
they will be looked at in a little more detail. 
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Figure 1.1: Haematopoiesis:  Schematic showing haematopoiesis; the generation of all blood cells, including all 
the immune cells in the body, from a multipotent haematopoietic stem cell (eBioscience 2012). 
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Polymorphonuclear Neutrophilic Leukocytes 
Polymorphonuclear neutrophilic leukocytes, commonly known as neutrophils, are an 
integral part of the innate immune system. Neutrophils are important in the clearance of 
fungal infections, and neutropenia (a severe deficiency in the number of neutrophils 
circulating in the blood) is associated with increased susceptibility to bacterial and fungal 
infections (Warnock 1998).   
There are 3 - 5.5 x 109 neutrophils per litre of blood, which makes neutrophils by far the 
most abundant white blood cell (60-70%) in the blood. They have an irregular shaped and 
lobed (polymorphic) nucleus and contain granules.  Neutrophils are initially generated in the 
bone marrow and then circulate in the blood.  During an immune challenge these short lived 
cells migrate and extravasate to sites of infection with the help of chemoattractants such as 
interleukin-8 (IL-8) (released by macrophages and monocytes) (Baggiolini, Loetscher et al. 
1995) and C5a (a potent anaphylatoxin produced by complement activation) (Snyderman, 
Phillips et al. 1970; Becker 1972).   
Neutrophil Mediated Killing 
Neutrophils are one of the first cells to migrate to the infection site.  They circulate in the 
blood and follow chemoattractants such as C5a and IL-8.  These proteins diffuse from the 
infection site and create a concentration gradient which the neutrophils are able to follow 
to the infection site.  They also activate the neutrophil, leading to the increase of the 
adhesion molecule, Complement Receptor 3 (CR3) integrin, which is a heterodimer of 
CD11b and CD18, and a down-regulation of L-selectin (CD62L) (Jutila, Rott et al. 1989; 
Humbria, Diaz-Gonzalez et al. 1994)on the cell surface which then encourages trafficking of 
the cells to the site of inflammation and extravasation (Witko-Sarsat, Rieu et al. 2000).  Once 
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the neutrophil has left the blood stream and reached the site of infection it can act in 
several ways to promote pathogen killing. 
At the site of infection, neutrophils can recognise pathogens, using a variety of cell surface 
associated PRRs (e.g. Toll like receptors TLRS (Table 1.4)), and are able to phagocytose them.  
One such receptor, a major focus of this thesis, is Clec7a or dectin-1, which has been shown 
to recognise beta-glucans (Brown and Gordon 2001; Brown, Taylor et al. 2002; Taylor, Tsoni 
et al. 2007). These PRRs are discussed in more detail below.  Recognition of microbes is also 
largely facilitated by complement opsonisation and CR3, which will be discussed in more 
detail below. 
Once pathogens have been phagocytosed, they form intracellular phagosomes that then 
fuse with azurophilic and secondary specific granules in the cytoplasm to form 
phagolysosomes (Ricevuti, Mazzone et al. 1993; Perskvist, Roberg et al. 2002).  The contents 
of these granules include proteases, antimicrobial proteins, components of the respiratory 
burst reaction, therefore these granules are usually toxic enough to kill most pathogens 
(Faurschou and Borregaard 2003).  Examples of the contents of these granules include 
myeloperoxidase, serine proteases, and antibiotic proteins (Fouret, du Bois et al. 1989; 
Faurschou and Borregaard 2003). Another process that takes place within the cell that 
results in pathogen killing is the respiratory burst (Sbarra and Karnovsky 1959).  This results 
in a number of reactive oxygen species (ROS) being produced, e.g. superoxide anion, 
hydroxyl radical and hydrogen peroxide, all of which are toxic to the pathogen (Babior, 
Kipnes et al. 1973; Chanock, el Benna et al. 1994).   Neutrophils are able to release the 
contents of their granules into the extracellular space in a process called degranulation.  
This process facilitates migration of the neutrophils by releasing enzymes that degrade the 
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extracellular matrix, as well as potentially killing any extracellular pathogens that have not 
been phagocytosed (Witko-Sarsat, Rieu et al. 2000; Faurschou and Borregaard 2003).  
Neutrophils have also been shown create extracellular traps that can capture and kill 
pathogens including hyphal fungi.  The cells send out fibres that contain granule proteins 
and chromatin into the extracellular matrix, trapping and killing pathogens that have evaded 
phagocytosis (Urban, Reichard et al. 2006).  
Reactive Oxygen Species and the Respiratory Burst 
The term reactive oxygen species (ROS) is used to describe a range of reactive molecules 
and free radicals (Table 1.4) that are derived from molecular oxygen.   Although they are 
produced as by-products of normal metabolic processes primarily aerobic respiration, they 
can cause considerable damage to cells and even cause cell death (Valencia and Moran 
2004; Orrenius, Gogvadze et al. 2007).  Phagocytes, particularly neutrophils take advantage 
of these destructive chemical species to kill invading microbes in the phagolysosome (Figure 
1.2) (Bylund, Brown et al. 2010). When stimulated by an invading pathogen, these 
phagocytes undergo a process known as respiratory burst, where they increase their 
consumption of molecular oxygen and generate ROS (Sbarra and Karnovsky 1959; Reeves, 
Nagl et al. 2003).  This involves the formation and activation of NADPH oxidase on the 
membrane of specific/gelatinase granules.  This enzyme then uses cellular oxygen to 
produce ROS species inside the granule to await fusion with the phagosome.  The 
phagosome fuses with the specific/gelatinase granules as well as with azurophil granules 
which contain myeloperoxidase (MPO) (Bylund, Brown et al. 2010).  The mixing of the MPO 
with the ROS leads to the production of further ROS such as the hypochlorate ion and 
singlet oxygen (Klebanoff 1967; Klebanoff 1968; Reeves, Nagl et al. 2003)(Table 1.4).  
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Neutrophils deficient in MPO have been characterised as “low responders” when measuring 
ROS production (Aniansson, Stendahl et al. 1984).Other models of ROS production via MPO 
include radical diffusion, where the contents of the specific/gelatinase granules, diffuses 
through the cytoplasm and enters the azurophil granules, and granule fusion, where the 
specific/gelatinase granules  and the azurohil granules directly fuse (Bylund, Brown et al. 
2010). 
Reactive Oxygen Species Chemical Formula 
Oxygen O2 
Singlet oxygen 1O2
 
Superoxide anion .O2
- 
Hydroxyl radical .OH 
Hydroxyl ion OH- 
Hydrogen peroxide H2O2 
Peroxide anion .O2
-2 
Hypochlorate anion OCl- 
Table 1.4: Examples of Reactive oxygen species found within the cell. 
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Figure 1.2: Different models for the generation of ROS.  A prerequisite for the detection of ROS is that the 
oxygen radicals (O2
−
, H2O2) are present in the same compartment as MPO. This could be accomplished in the 
following ways: (A) fusion of both speciﬁc granules, containing NADPH oxidase, and azurophil granules, 
containing MPO, with the phagosomal membrane during maturation of the phagolysosome; (B) diffusion of 
oxygen radicals generated in  granules across membranes and through the cytosol, ending up in azurophil 
granules to mix with MPO; and/or (C) direct fusion between speciﬁc/gelatinase and azurophil granules in the 
absence of phagosome formation. Figure taken from (Bylund, Brown et al. 2010). 
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Macrophages 
Macrophages are phagocytic cells that are present in a wide variety of tissues (Table 1.5).  
Traditionally, macrophages were identified as originating from hematopoietic stem cells in 
the bone marrow (van Furth and Cohn 1968; Fogg, Sibon et al. 2006; Geissmann, Manz et al. 
2010).  Historically they were thought to undergo further differentiation until they leave the 
bone marrow and enter the blood as monocytes.  After which, they then circulate in the 
blood for several days before they migrate to tissues and differentiate into tissue resident 
macrophages (Volkman and Gowans 1965).  However some studies have shown that there is 
a separate lineage of macrophages, that develop in the embryonic yolk sac, prior to the 
development of hematopoietic stem cells, and that persists into maturity (Bertrand, Jalil et 
al. 2005; Schulz, Gomez Perdiguero et al. 2012). Other studies have shown that some tissue 
resident macrophages are derived from this embryonic yolk sac and localized proliferation is 
important for keeping these populations stable (Ginhoux, Greter et al. 2010). Recent studies 
have shown that tissue resident peritoneal macrophages are able to undergo bursts of 
localized proliferation.  After acute inflammation, resident peritoneal macrophages have 
been shown to replenish their numbers via localized proliferation (Davies, Rosas et al. 2011).  
This localized proliferation has also been observed after parasitic infection with Brugia 
malayi  (Jenkins, Ruckerl et al. 2011).   
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Macrophage Tissue Resident 
Alveolar macrophages Alveolar sacs of the lungs 
Kupffer cells Liver 
Inflammatory monocyte derived 
macrophages 
Recruited to any site that is undergoing 
acute inflammation 
Microglia CNS, i.e. brain and spinal column 
Osteoclasts Bones 
Peritoneal macrophages Peritoneal cavity 
Splenic macrophages Spleen 
Table 1.5: Examples of different tissues resident macrophages and their locations in the body. 
As well as having a diverse role in both innate and adaptive immunity, macrophages are also 
responsible for a host of homeostatic processes in the body including the phagocytosis of 
erythrocytes and apoptotic bodies, and they are involved in other processes such as  tissue 
remodelling and repair after injury (Erwig and Henson 2008; Cambos and Scorza 2011; 
Liddiard, Rosas et al. 2011).   
Macrophages play a significant role in distinguishing self from non-self and are able to 
recognise non-self cells via a host of PRR (Taylor, Martinez-Pomares et al. 2005).  When the 
immune system is challenged, macrophages are able to respond in several ways.  They can 
phagocytose pathogens and destroy them in the phagolysosome and are then able to 
present antigen fragments to the adaptive immune system.  As well as destruction via 
phagocytosis, they are able to release a range of pro-inflammatory cytokines including, 
tumour necrosis factor alpha (TNFα), interleukine-1 beta (IL-1β), interleukin-6 (IL-6) and IL-8.  
Macrophages are key in the generation and recruiting neutrophils to the site of fungal 
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infections via their release of cytokine such as IL-8 (Baggiolini, Loetscher et al. 1995).  
Macrophages also play a very important role in phagocytising apoptotic neutrophils, which 
is important for resolving inflammation (Michlewska, Dransfield et al. 2009).  
 
1.2.2. Pattern recognition receptors 
 
PRRs Important in Fungal Recognition 
Having studied the literature it is clear to see that due to the complex nature of fungal 
pathogen PAMPs and redundancy in the immune system there are several different PRRs 
that are important in immunity to fungal infections.  Of the TLRs, TLR1, TLR2, TLR4, TLR6 and 
TLR 9 have been shown to play some role in recognition and response to fungal PAMPS (See 
below).  Of the other PRRs, Clec7a and Clec4n have also been shown to be important in 
recognition of fungal PAMPs (See below).   
 
Scavenger Receptors 
Scavenger receptors are a diverse family of pattern recognition receptors that recognize a 
host of different polyanionic ligands including pathogen-derived ligands (Mukhopadhyay 
and Gordon 2004).  They are expressed on a variety of tissue resident macrophages and 
epithelial cells.  These receptors are important in the clearance or “scavenging” of 
substances no longer of use to the host such as modified host molecules or apoptotic cells 
(Peiser, Mukhopadhyay et al. 2002). They have also been implicated in the recognition of 
microbial PAMPs (Peiser, Mukhopadhyay et al. 2002).  Of relevance to fungal recognition, 
 
 
39 
 
the scavenger receptors SCARF1 and CD36 are thought to be β-glucan binding receptors that 
mediate immune response to C. neoformans and C. albicans (Means, Mylonakis et al. 2009). 
Retinoic acid inducible gene-1 (RIG-I) Like Receptors 
The RIG-I like receptor family are a group of PRRs that are located in the cytoplasm and that 
recognise, bind and initiate anti-viral response to the RNA sequences of viruses (Takeuchi 
and Akira 2010).  There are three member of this receptor family; RIG-I, MDA5 and LGP2 
(Kawai and Akira 2009).  Once activated these receptors signal via interferon- promoter 
stimulator 1 (IPS-1) to induce the activation of several transcription factors including 
interferon regulatory factor 3 (IRF3) and IRF7, which leads to the production of type I 
interferons and NF-κB which controls the production of  inflammatory cytokines (Kawai, 
Takahashi et al. 2005).  Mice deficient for RIG-I and MDA5 have been shown to be more 
susceptible to viral infection by RNA viruses compared to wild type mice (Kato, Takeuchi et 
al. 2006). 
NOD Like Receptors 
NOD like receptors (NLRs) recognise PAMPs and endogenous molecules in the cell cytosol 
(Martinon and Tschopp 2005; Meylan, Tschopp et al. 2006).  However, NOD2 has been 
shown to associate with the plasma membrane and a truncated form of NOD2 that does not 
associate with the plasma membrane is associated with Crohn’s disease (Barnich, Aguirre et 
al. 2005).  So far at least 22 human and 34 mouse NLR proteins have been identified and the 
physiological function of most of these is poorly understood (Ting, Lovering et al. 2008), but 
some have been identified.  The first NLRs identified as intracellular PRRs were NOD1, which 
recognises bacterial peptidoglycan containing diaminopimelic acid (Chamaillard, Hashimoto 
et al. 2003; Girardin, Boneca et al. 2003), and NOD2 which also detects bacterial 
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peptidoglycan but through a muramyl dipeptide motif (Girardin, Boneca et al. 2003; 
Inohara, Ogura et al. 2003). 
Cytosolic DNA Sensor 
Double stranded DNA in the cytoplasm, usually as a result of DNA viruses or certain bacteria, 
can promote anti-viral and inflammatory responses independent of TLR9 and RLR pathways 
(Ishii and Akira 2006; Stetson and Medzhitov 2006).    Transfection of DNA into the 
cytoplasm of cells has been shown to result in the production of IFN-β (Ishii, Coban et al. 
2006; Stetson and Medzhitov 2006), inflammasome activation (Muruve, Petrilli et al. 2008) 
and cell death (Stacey, Ross et al. 1993).  Prior to 2009, the cytosolic DNA sensor had not 
been identified and the protein, DNA-dependent activator of IFN-regulatory factors (DAI), 
was suggested as a candidate sensor (Takaoka, Wang et al. 2007).  However, it was shown 
to be redundant as DAI deficiency in mice does not affect immune response to dsDNA in the 
cytosol (Ishii, Kawagoe et al. 2008).  Since then the protein, absent in melanoma 2 (AIM2), 
has been identified as the major receptor for cytosolic dsDNA (Fernandes-Alnemri, Yu et al. 
2009; Hornung, Ablasser et al. 2009; Roberts, Idris et al. 2009).  AIM2 recognition of 
cytosolic dsDNA results in the activation of the inflammasome via the adaptor molecule ASC 
and knockdown of AIM2 abrogates inflammasome activation in response to vaccinia virus 
(Fernandes-Alnemri, Yu et al. 2009; Hornung, Ablasser et al. 2009).  Recognition of dsDNA by 
AIM2 has also been shown to induce pyroptosis, which is a caspase-1 dependent 
inflammatory form of cell death (Fernandes-Alnemri, Wu et al. 2007), via its interaction with 
the ASC adaptor molecule (Fernandes-Alnemri, Yu et al. 2009). 
Toll like receptors 
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The toll like receptors (TLRs) are a family of conserved cellular receptors that recognise and 
mediate response to PAMPs and other ligands (Akira, Uematsu et al. 2006).  Each TLR binds 
different agonists that results in the MyD88 or TRIF dependent NF-κB, MAPK or type 1 
interferon signalling, that induces the production of proinflammatory cytokines (Cook, 
Pisetsky et al. 2004; Akira, Uematsu et al. 2006; Kawai and Akira 2009).  Different TLRs 
recognise different agonists.  The main TLRs so far implicated in fungal recognition are TLR2, 
TLR4 and TLR9 (Romani 2004). 
TLR response to fungi occurs in a species and morphotype specific manner.  TLR2 signalling, 
which leads to increased production of cytokines such as TNFα and IL-1β, is activated by the 
yeast of C. albicans and by the conidia and hyphae of A. fumigatus (Netea, Van Der Graaf et 
al. 2002). TLR4 recognises and responds to the hyphae of C. albicans and the hyphae of A. 
fumigatus but not the conidia (Wang, Warris et al. 2001).  Both TLR2 and TLR4 have been 
shown to work cooperatively with other receptors to recognise and bind fungal particles.  
TLR2 works with Clec7a in order to recognise and bind zymosan (Brown, Herre et al. 2003; 
Gantner, Simmons et al. 2003), while TLR4 works in conjunction with CD14 to recognise A. 
fumigatus hyphae (Huffnagle and Deepe 2003).  Polymorphims in human TLR1, TLR4 and 
TLR 6 have been associated with increased risk of invasive aspergillosis after stem cell 
transplantation (Kesh, Mensah et al. 2005; Bochud, Chien et al. 2008).  TLR9 has been shown 
to be able to recognise fungal DNA (van de Veerdonk, Kullberg et al. 2008).  Human 
monocytes that have had their TLR blocked and TLR9 deficient mouse macrophages show 
less cytokine production when stimulated with C. albicans than cells which still have 
functional TLR9 (van de Veerdonk, Netea et al. 2008).  TLR9 is also able to recognise the 
DNA of A. fumigatus and C. neoformans, resulting in the activation of myeloid cells and the 
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secretion of pro-inflammatory cytokines (Nakamura, Miyazato et al. 2008; Ramirez-Ortiz, 
Specht et al. 2008). These studies highlight the importance of TLRs in defence against fungal 
pathogens. 
C-Type Lectin like Receptors 
Clec7a  
Cleac7a, also known as Dectin-1, is a cell surface receptor that is broadly expressed on 
myeloid cells, predominantly macrophages, monocytes, dendritic cells and neutrophils 
(Brown, Taylor et al. 2002).  It is a beta-glucan receptor and recognises 1-3 linked beta-
glucans that are present in the cell wall of fungi (Brown and Gordon 2001).  It consists of a 
carbohydrate recognition domain, an extracellular stalk region, a transmembrane domain 
and a signalling intracellular domain with immunoreceptor tyrosine-based activation motif 
(ITAM) (Ariizumi, Shen et al. 2000).  Clec7a exists in two major isoforms (Heinsbroek, Taylor 
et al. 2006).  While Clec7a.A has all domains including the extracellular stalk region, Clec7a.B 
is missing this stalk region (Figure 1.3). Studies have shown that a Clec7a deficient 
macrophages are impaired in their ability to recognise fungal particles e.g. zymosan, and 
respond by producing less TNF than wild type macrophages (Taylor, Tsoni et al. 2007).  
Clec7a deficient mice have also been shown to be impaired in their ability to clear an 
infection by C. albicans (Taylor, Tsoni et al. 2007), and although there has been some 
conflicting data (Saijo, Fujikado et al. 2007), data from human studies supports the evidence 
that Clec7a is important for clearance of C. albicans (Ferwerda, Ferwerda et al. 2009; 
Plantinga, van der Velden et al. 2009).  Although the function of Clec7a on macrophages and 
dendritic cells have been well characterised (Brown, Taylor et al. 2002; Grunebach, Weck et 
al. 2002; Willment, Lin et al. 2003; Adams 2004; Herre, Marshall et al. 2004; Gantner, 
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Simmons et al. 2005; Underhill, Rossnagle et al. 2005; Yadav and Schorey 2006; Taylor, Tsoni 
et al. 2007), their role on neutrophils is less understood. However, a study has shown that 
blockade of Clec7a on human neutrophils resulted in a significant decrease in the ability of 
neutrophils to kill C. albicans (Kennedy, Willment et al. 2007). Interestingly, humans 
deficient in Clec7a are more susceptible to chronic mucocutaneous candida infections, 
however, the dectin-1-deficient human neutrophils were reported to have no defect in C. 
albicans recognition or killing (Ferwerda, Ferwerda et al. 2009).   
Clec4n 
Clec4n, also known as dectin-2, is PRR that is predominantly expressed on some DC subsets, 
tissue macrophages and inflammatory monocytes (Taylor, Reid et al. 2005).  It couples to 
the immunoreceptor tyrosine-based activation motif (ITAM) containing, FcRγ, to enable 
signalling and it recognises α-mannans (Sato, Yang et al. 2006; Robinson, Osorio et al. 2009; 
Saijo and Iwakura 2011), which are a key component of fungal cell wall.  Clec4n plays a role 
in the immune response to fungal infection, as demonstrated by the observation that 
Clec4n-/- mice have an increased susceptibility to systemic C.albicans infection, due to 
decreased levels of cytokine production and Th17 response (Robinson, Osorio et al. 2009; 
Saijo and Iwakura 2011).  This is further supported by evidence that shows that patients 
with deficiencies in IL-17A and IL-17F suffer from recurrent C.albicans infections (Puel, 
Cypowyj et al. 2011).  The collaborative nature of PRR is demonstrated in the observation 
that blockade of Clec4n in Clec7a-/- mice showed a decrease in the Th1 response (Robinson, 
Osorio et al. 2009).  This cooperative behaviour in BMDC makes Clec4n a useful PRR to 
consider when exploring the role of Clec7a on neutrophils. 
Clec4e 
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Clec4e, also known as MINCLE, is a type II transmembrane protein that is expressed on 
activated macrophages (Matsumoto, Tanaka et al. 1999).  Like Clec4n, it couples to the 
adaptor protein, FcRγ, to enable signalling (Yamasaki, Ishikawa et al. 2008). This PRR is able 
to recognise α-mannose from fungal Malassezia spp.(Yamasaki, Matsumoto et al. 2009), and 
trehalose dimycolate, which is a mycobacterial glycolipid (Ishikawa, Ishikawa et al. 2009).   
Clec4e has also been shown to bind C. albicans yeast cells (Bugarcic, Hitchens et al. 2008) 
and is important in host immune response to C. albicans as mice deficient in Clec4e showed 
a significantly increased susceptibility to systemic candidiasis (Wells, Salvage-Jones et al. 
2008).  An extra function of Clec4e is its ability to recognise damaged cells by sensing 
spliceosome-associated protein 130 (SAP130), which is a soluble factor released by necrotic 
cells (Yamasaki, Ishikawa et al. 2008). 
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Figure 1.3: Schematic of the main Clec7a isoforms. Both isoforms consist of an extracellular c-type-lectin-like 
domain, which binds β-1,3-glucans, a transmembrane domain and a cytoplasmic tail with an ITAM-like motif.  
The isoforms differ in that Clec7a.A also contains an extracellular stalk domain that is missing in the Clec7a.B 
isoform. 
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1.3. Complement Cascade and Fungal Immunity 
 
The complement cascade is a vital component of the immune system.  It can be initiated via 
three main pathways which all converge and lead to the production of C3 convertase (Figure 
1.2) (Dunkelberger and Song 2010).  One of its effector functions is the generation of the 
membrane-attack complex on the pathogenic cells.  This results in numerous pores being 
created in the cell membrane and the eventual lysis and destruction of the pathogen (Rus, 
Cudrici et al. 2005), although some pathogens have developed strategies to avoid this 
attack.  An example of this is seen with Streptococcus group A, which has a  thick 
peptidoglycan layer that resists penetration into the cell membrane by the membrane-
attack complex (Frank 2001).  
On the path to the generation of the membrane attack complex, various protein fragments 
are formed.  One of these fragments is C3b, which becomes known as inactivated C3b 
(iC3b), when it covalently attaches to the pathogen(Sarma and Ward 2011).  iC3b is an 
opsonin and this means it is able to bind to pathogenic cells and flag them for opsonisation 
by phagocytic cells, i.e. neutrophils and macrophages.  iC3b is recognised on these 
phagocytes by complement receptor 1,2 and 3(CR1, CR2, CR3 and CR4) (Ahearn and Fearon 
1989; Ueda, Rieu et al. 1994; Gasque 2004).   The complement cascade can lead to the 
recruitment of inflammatory cells to the site of infection.  C5a has been described as a 
potent chemoattractant, especially for neutrophils (Snyderman, Phillips et al. 1970; Becker 
1972).  The C5aR (CD88) is expressed on a wide range of cells including most myeloid cells 
(Monk, Scola et al. 2007).   
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Fungal cells walls are rich in mannans.  The mannan binding protein (MBP) binds to the 
mannans in the fungal cells and this is able to activate the complement cascade, leading to 
the effector functions described above (Kozel 1996). 
As with the case of PRR, activation of the complement cascade by fungi can be species and 
morphotype specific (Kozel 1996).  Encapsulated C. neoformans is a potent activator of the 
complement system as, when incubated with serum, C3 fragment production increases 
compared to unencapsulated C. neoformans from approximately 2x106 fragments per yeast 
cell to 107 fragments per yeast cell (Young and Kozel 1993).  It is also worth noting that this 
activation apparently occurs solely via the alternative pathway as the kinetics of C3 binding 
to encapsulated C. neoformans is not affected by ethylene glycol tetraacetic acid (EGTA), 
which chelates Ca2+ required for the classical pathway (Kozel 1996).  This is in contrast to C. 
albicans where the classical, alternative and MBP pathways are thought to be involved in 
complement activation (Kozel 1996). 
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Figure 1.2: Complement cascade.  The three initial complement pathways converge and result in the 
production of C3 convertase.  This in turn leads to pathogen killing via the recruitment of inflammatory cells, 
the generation of the membrane-attack complex on pathogenic cells and opsonisation of pathogens that can 
then be recognised and phagocytosed by immune cells. 
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1.4. Immortalisation of Primary Cells 
 
Primary cells can be difficult to culture, and in the case of neutrophils, the cells cannot be 
reliably cultured for more than a day due to their short half-life.   Researchers often need to 
generate fresh cultures from primary cells regularly and this can be a time consuming and 
costly practice.  One way around this is the use of immortalised cell lines that never reach 
senescence.  There are two traditional ways of generating immortalised cells: 
1. Viral gene induction 
This uses the insertion of viral genes, such as Epstein–Barr virus (EBV) (Miller 1982; 
Oh, Oh et al. 2003) and the Simian Virus 40 (SV40) T antigens (Jha, Banga et al. 1998) 
into the primary cells.  These genes are thought to work primarily by inactivating 
tumour repressor genes (e.g. p53 and Rb) (Dobbelstein and Roth 1998; Ahuja, Saenz-
Robles et al. 2005; Paschos, Smith et al. 2009)and this same effect can be achieved 
by using siRNA targeted to these genes (Yang, Rosen et al. 2007). However, some 
studies have shown that SV40 is able to induce telomerase activity in infected cells 
(Foddis, De Rienzo et al. 2002).   
2. Telomerase Reverse Transcriptase protein (TERT) expression 
Another technique that is used to immortalise primary cells is inducing expression of 
the human TERT protein (Lee, Choi et al. 2004).  This protein, a subunit of the human 
telomerase protein, is usually inactive in somatic cells but when exogenously 
expressed it maintains sufficient telomere length to keep replicative senescence at 
bay (Lee, Choi et al. 2004).  This technique is used for cells that are particularly 
sensitive to telomere length i.e. human cells. 
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These techniques are not always successful however, and other avenues need to be 
explored to allow for the immortalisation of a wider range of cell types. Class I Hox 
homeodomain transcription factors have been shown to promote expansion of 
haematopoietic progenitors and their expression is deregulated in human and 
mouse myeloid leukaemia (Wang, Calvo et al. 2006).  Overexpression ofHoxa9 and 
Hoxb6 have been used to previously immortalise haematopoietic progenitors (Calvo, 
Sykes et al. 2000; Fischbach, Rozenfeld et al. 2005) and Hoxb8 is known to block 
differentiation of primary myeloid progenitors (Blatt, Aberdam et al. 1988; 
Knoepfler, Sykes et al. 2001).  This makes the Hox genes good candidates as 
immortalising factors of haematopoietic progenitor cells. 
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1.5. Studying Neutrophils 
Studying neutrophil biology has generated a few challenges.  The short lived nature of these 
cells means that they cannot be cultured for more than a few hours.  In mouse models, this 
results in the large numbers of mice being culled for primary neutrophils, which can be very 
expensive and leads to a large loss of animal life.  This then raises ethical questions about 
animal welfare.  A key strategy in minimising animal suffering in biomedical research is the 
application of the three R’s; Replacement: this refers to the use of non-animal models 
wherever possible; Reduction: this refers to using methods that enable the researcher to 
obtain as much information from the fewest number of animals necessary; Refinement:  
this refers to using methods that minimise and reduce animal suffering as well as increasing 
animal welfare.  The use of cell lines to replace animal use is common place in biomedical 
research but the current technologies are limited. 
There are already granulocyte producing cell lines available but there are certain problems 
associated with them that can make them unreliable.  The HL-60 cell line was derived from 
peripheral blood leukocytes of a 36-year-old Caucasian female with acute promyelocytic 
leukaemia (Collins, Gallo et al. 1977).  Although differentiation of these cells to neutrophil-
like cells is possible under certain conditions, the cell line comes with certain problems 
including, spontaneous differentiation, difficulty in reproducing differentiation within the 
one lab setting and differences in differentiation success across separate labs (Fleck, 
Romero-Steiner et al. 2005).  Another cell line, 32Dcl3, a murine myeloblastic, IL-3 
dependent cell line, can produce cells that are similar to primary murine neutrophils, 
however, these neutrophil-like cells are unable to generate superoxide in response to 
appropriate stimuli (Guchhait, Tosi et al. 2003). 
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A more reliable and reproducible method for generating large number of neutrophils would 
be very useful in the study of neutrophil biology.  Wang et al. 2006 attempts to address 
these issues by generating a conditionally-immortalised neutrophil precursor cell line 
(Wang, Calvo et al. 2006).    This method greatly improves on what is already available as the 
immortalisation of the cells is conditional and can be switched off by removal of the 
conditional factor, oestrogen, from the culture.  This removes any problems associated with 
constitutive presence of the ‘immortalising factor’ after forced differentiation and should 
theoretically produce more mature neutrophils (Wang, Calvo et al. 2006). However, 
although some work has been done, these cells have not yet been extensively 
immunologically characterised.  If neutrophils generated from this cell line are functionally 
equivalent to primary murine neutrophils, the numbers of animals culled for primary 
neutrophils could be significantly reduced and study of neutrophil function would be greatly 
enhanced. 
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1.6. AIMS 
 
This work plans to address the following aims: 
 To generate and immunologically characterise conditionally immortalised neutrophil 
precursor cell lines. 
 To explore the role of clec7a on neutrophils in the recognition of and response to 
fungal cells. 
 To use neutrophils generated from a conditionally immortalised neutrophil precursor 
cell line to model innate immune responses. 
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Chapter 2 
Materials and Methods 
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2.1: Reagents 
2.1.1. General Reagents 
Reagent Supplier 
Bio-Gel P-100 Gel, Fine 
Polyacrylamide Beads 
BIO-RAD Labs 
Bovine Serum Albumin (BSA) Sigma 
Chloroform Sigma 
Dimethyl sulfoxide (DMSO) Sigma 
Ethanol VWR 
Ethylenediamine Tetraacetic Acid 
(EDTA) 
USB 
Human Fibronectin Sigma 
Formaldehyde Sigma 
Fugene 6 Reagent Roche 
Hank’s Balanced Salt Solution 
(HBSS) 
Invitrogen 
Heparin Sigma 
HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid ) 
Invitrogen 
Hexadimethrine bromide 
(polybrene) 
Sigma 
Isopropanol VWR 
Phosphate Buffered Saline (PBS) Invitrogen 
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Rabbit serum Invitrogen 
Sodium Azide Sigma 
Sodium Citrate Sigma 
 
2.1.2. Cell Culture 
Cell Lines 
Reagent Supplier Notes 
Phoenix cells Obtained 
from Garry 
Nolan  
A HEK293T, human embryonic kidney, cell line that has been 
transformed to enable it to package MMLV viral DNA in 
capsids (Swift, Lorens et al. 2001).  These cells are adherent 
and grown in DMEM with 10% (v/v) FCS, 50 units/ml 
penicillin, 50 µg/ml streptomycin and 2 mM  glutamine. 
MyPH8-B6  Home 
made 
Neutrophil progenitor cell line.  These cells grow in 
suspension and are grown in OptiMem, 10% (v/v) FCS, 50 
units/ml penicillin, 50 µg/ml streptomycin, 2 mM glutamine, 
30 μM β-mercaptoethanol) with 10 ng/ml SCF and 1 uM β-
estradiol. 
 
Media 
Reagent Supplier 
Dulbecco's Modified Eagle Medium (DMEM) Invitrogen 
Iscove's Modified Dulbecco's Medium (IMDM) Invitrogen 
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Opti-Mem Invitrogen 
RPMI 1640 Invitrogen 
 
Cytokines 
Reagent Supplier Notes 
Granulocyte colony-stimulating 
factor (G-CSF) 
Peprotech Recombinant mouse G-CSF 
Granulocyte-macrophage colony-
stimulating factor (GM-CSF) 
Peprotech Recombinant mouse GM-CSF 
Interleukin 5 (IL-5) Peprotech Recombinant mouse IL-5 
Interleukin-3 (IL-3) Peprotech Recombinant mouse IL-3 
Interleukin-6 (IL-6) Peprotech Recombinant mouse IL-6 
Stem Cell Factor (SCF) Peprotech Recombinant mouse SCF 
 
Antibiotics 
Reagent Supplier 
Ampicillin Sigma 
Penicillin/Streptomycin Invitrogen 
Puromycin Sigma 
Zeocin Invitrogen 
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Other Cell Culture Reagents 
Reagent Supplier 
β-estradiol Sigma 
β-mercaptoethanol Sigma 
Fetal Calf Serum (FCS) Invitrogen 
L-glutamine Invitrogen 
 
2.1.3. Cell Stimulants and Activators 
Reagent Supplier Notes 
Candida 
albicans SC5314 
Obtained from 
Ken Haynes, 
Imperial College 
London 
A strain of C.albicans. 
Curdlan 
microparticles 
Wako Pure 
Chemical 
Industries, Ltd. 
Curdlan particles bought then converted into 
microparticles via sonication (Rosas, Liddiard et al. 
2008). 
Ionomycin Invitrogen Induces intracellular calcium ion increases in cells 
Zymosan Invitrogen An insoluble preparation of particles made from the 
cell wall of Saccharomyces cerevisiae. 
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2.1.4. Dyes and Colourimetric Indicators 
Reagent Supplier Notes 
3’-(-p-aminophenyl) 
fluorescein (APF) 
Invitrogen A reactive oxygen species (ROS) indicator that becomes a 
fluorescent when in the presence of the ·OH, ONNO- and -
OCL.  This makes it a specific indicator of respiratory burst 
reactions. 
Carboxyfluorescein 
succinimidyl ester 
(CFSE) 
Invitrogen Cell dye that is excited by the blue laser at 488 nm and emits 
at 517 nm. 
Cell Trace Calcein 
Violet 
Invitrogen Cell dye that is excited by the violet laser at 405 nm and 
emits at 452nm. 
CellTrace DDAO-
succinimidyl ester 
Invitrogen Cell dye that is excited and emits at the far red of the 
spectrum. 
Draq5 DNA Dye BIO 
Status Ltd 
A cell permeant DNA dye that can be used on live cells. 
Fura 2 AM Invitrogen Calcium ion indicator 
Fura red Invitrogen Calcium ion indicator 
NIM-DAPI NPE 
Systems 
The cell impermeant DNA dye DAPI in a nuclear isolation 
medium (NIM) 
SYTO® RNASelect™ Invitrogen A cell-permeant nucleic acid stain that selectively stains 
RNA. 
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2.1.5. Molecular Biology 
Reagent Supplier 
Agarose powder Sigma 
Competant E.coli  TOP10 Invitrogen 
DNA ladder 100bp Invitrogen 
Ethidium Bromide Sigma 
Lysogeny broth (LB) Sigma 
Super Optimal broth (SOC Medium) Invitrogen 
Tris/Borate/EDTA (TBE) Buffer (10X stock) Invitrogen 
TRIzol Reagent Invitrogen 
 
2.1.6. Kits 
Reagent Supplier 
Dead Cell Removal Kit Miltenyi Biotec 
Fluo-4 NW Calcium Assay Kit Invitrogen 
Mouse IL-6 ELISA Kit BD Biosciences 
MACS Murine Lineage Depletion Kit Miltenyi Biotec 
RNeasy Mini Kit QIAGEN 
RT-PCR Kit Ambion 
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2.2: Viral DNA Constructs 
Vector Source Description 
pMXs-IP T. Kitamura (Kitamura 1998)  MMLV derived third generation 
retroviral vector with internal 
ribosomal entry site (IRES) upstream of 
the puromycin resistance cassette. 
pMXs-IP:FL-ER-
Hoxb8 
Dr. Phil Taylor Flag (FL)-tagged estrogen receptor 
binding domain (ER)-Hoxb8 fusion 
gene cloned into pMXs-IP 
pMXs-IZ Dr. Phil Taylor/Dr. K. 
Liddiard  
(Rosas, Liddiard et al. 2008) 
Modification of pMXs-IP in which the 
puromycin resistance cassette has 
been replaced with zeocin resistance. 
pMXs-IZ:clec7aA.1 Dr. Phil Taylor/Dr. K. 
Liddiard  
(Rosas, Liddiard et al. 2008) 
pMXs-IZ containing clec7aA.1 isoform 
(Heinsbroek, Taylor et al. 2006) 
pMXs-IZ:clec7aB.1 Dr. Phil Taylor/Dr. K. 
Liddiard  
(Rosas, Liddiard et al. 2008) 
pMXs-IZ containing clec7aB.1 isoform 
(Heinsbroek, Taylor et al. 2006) 
pMXs-IZ:clec7aB.2 Dr. Phil Taylor/Dr. K. 
Liddiard  
(Rosas, Liddiard et al. 2008) 
pMXs-IZ containing clec7aB.2 isoform 
(Heinsbroek, Taylor et al. 2006) 
pMX- µ -calpain-
EGFP 
Prof. Maurice Hallet/ 
Kimberley Lewis 
µ-Calpain-EGFP construct subcloned 
into pMX-IRES-GFP retroviral vector. 
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2.3: Antibodies 
Epitope Antibody Specificity Company Notes 
Ly-6G,  
Ly-6C 
Gr-1 PE 
(clone RB6-
8C5) 
Mouse BD 
Biosciences 
Pharmingen 
Marker that is highly 
expressed on neutrophils, but 
also on other cells, including 
monocytes and eosinophils 
(Tepper, Coffman et al. 1992; 
Fleming, Fleming et al. 1993; 
Lagasse and Weissman 1996).  
Ly-6G Ly-6G PE or PE-
Cy7 (clone 
1A8) 
Mouse BD 
Biosciences 
Pharmingen 
Largely neutrophil restricted 
marker (Fleming, Fleming et al. 
1993). 
F4/80, 
r1 
F4/80 PE or 
APC (clone A3-
1) 
Mouse AbD Serotec ‘Pan-macrophage’ marker 
(Austyn and Gordon 1981). 
CD11b CD11b FITC 
(clone 5C6)  
Mouse Home made A generic myeloid cell marker, 
CD11b is a subunit of 
complement receptor 3 
(Lagasse and Weissman 1996; 
Melo, Catchpole et al. 2000). 
CD11b CD11b APC or 
APC-Cy7 (clone 
M1/70)  
Mouse BD 
Biosciences 
Pharmingen 
A generic myeloid cell marker, 
CD11b is a subunit of 
complement receptor 3 
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(Lagasse and Weissman 1996; 
Melo, Catchpole et al. 2000). 
Heat stable 
antigen 
CD24 FITC 
(clone M1/69) 
Mouse BD 
Biosciences 
Pharmingen 
Heat stable antigen (Aigner, 
Ruppert et al. 1995). 
CD45.1 CD45.1 APC 
(clone A20) 
Mouse BD 
Biosciences 
Pharmingen 
‘Pan-leukocyte’ marker that 
recognises the CD45.1 
polymorphic variant (Johnson, 
Greenbaum et al. 1989). 
C5a 
receptor 
CD88 PE (clone 
10/92) 
Mouse AbD Serotec C5a receptor (Monk, Scola et 
al. 2007). 
CD11c CD11c PE Mouse BD 
Biosciences 
Pharmingen 
Subunit of complement 
receptor 4, high expression of 
which in mice is often 
associated with dendritic cells, 
but is also seen on other cells 
such as NK cells, alveolar 
macrophages and activated 
monocytes and macrophages 
B7.1 CD80 
Biotinylated 
(clone 16-
10A1) 
Mouse BD 
Biosciences 
Pharmingen 
Co-stimulatory antigen 
(Bluestone 1995). 
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B7.2 CD86 
Biotinylated 
Mouse BD 
Biosciences 
Pharmingen 
Co-stimulatory antigen 
(Bluestone 1995). 
FCεR1 FCεR1 
Biotinylated 
(clone Mar-1) 
Mouse eBiosciences IgE receptor 1; mast cell 
marker (Yamaguchi, Hirai et al. 
2001). 
SCF 
receptor 
CD117 APC or 
Biotinylated 
(clone 2B8) 
Mouse BD 
Biosciences 
Pharmingen 
SCF receptor (Ikuta and 
Weissman 1992). 
Clec7a Clec7a 
Biotinylated 
(clone 2A11)  
Mouse Home made β-glucan receptor 
Clec7a Clec7a Alexa647   
(clone 2A11) 
Mouse AbD Serotec β-glucan receptor 
Clec7a Clec7a (Clone 
259931) 
Human R & D Systems β-glucan receptor 
Clec7a Clec7a (Clone 
GE2) 
(Willment, 
Marshall et al. 
2005) 
Human Home made β-glucan receptor 
Dectin-2 Clone D2.11E4 
Biotinylated 
Mouse Home made A mannose binding receptor 
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Ly-6B.2 Ly-6B.2 FITC or 
PerCP (clone 
7/4) 
Mouse Home made Neutrophil and inflammatory 
monocyte marker (Rosas, 
Thomas et al. 2010). 
Ly-6B.2 Ly-6B.2 PE or 
Alexa647  (clone 
7/4) 
Mouse AbD Serotec Neutrophil and inflammatory 
monocyte marker (Rosas, 
Thomas et al. 2010). 
CXCR2 CXCR2 PE 
(clone 242216) 
Mouse R & D Systems Receptor for the 
chemoattractant IL-8  
CD66 CD66 PE Human  Neutrophil marker 
Fcγ RII/III 
(CD16&32) 
Clone 2.4G2 Mouse Home made Used as blocking antibody to 
reduce background binding of 
antibodies to Fc receptor 
expressing cells. 
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2.4. General Methods 
2.4.1. Mice 
129S6/SvEv and 129S6/SvEv.Clec7a–/–mice were obtained from in house colonies belonging 
to Dr Phil Taylor. C57BL/6 and Balb/c mice were obtained from Harlan UK. Dectin-1-deficient 
(Clec7a–/–) mice were also available backcrossed to the C57BL/6 genetic background for 8 
generations. CD11b-deficient mice (Itgam–/–) on the C57BL/6 genetic background were 
generated as previously described by (Coxon, Rieu et al. 1996), and cells from these mice 
were obtained from Prof. Marina Botto (Imperial College London). All animals were handled 
in accordance with institutional and UK Home Office guidelines. 
2.4.2. Antibody Staining of Cells for Flow Cytometric Analysis 
The cells were blocked with ‘flow cytometry block’ (5% (v/v) heat-inactivated rabbit serum; 
0.5% (w/v) BSA; 2 mM NaN3; 5 mM EDTA in PBS) with 2.4G2 at 4 µg/ml for 30 minutes on 
ice.  A 96 well v-bottomed plate was chilled and after blocking 50µl of cells were placed in a 
well and 50 µl of 2x antibody, diluted in ‘flow cytometry wash’ (0.5% (w/v) BSA; 2 mM NaN3; 
5 mM EDTA in PBS), was added to the cells.  The cells were incubated on ice, for 1 hour, in 
the dark.  After incubation the cells were centrifuged (350 x g, 5minutes) and washed 3x 
with flow cytometry wash then fixed with 1% formaldehyde.  For biotinylated antibodies, 
the cells are washed twice with flow cytometry wash after the hour incubation with the 
primary antibodies, then they were incubated for 30 minutes with the appropriate 
streptavidin conjugate before the final washes and fixing. 
2.4.3 Flow Cytometry 
All flow cytometric collection was performed using either the FACScalibur flow cytometer 
(BD), Cell Lab Quanta SC MPL flow cytometer (Beckman Coulter) or the CyAn ADP 3 laser 
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Analyser (Beckman Coulter) and data was analysed using Summit (Beckman-Coulter) or 
FlowJo (Treestar) software. The Cell Lab Quanta SC is a blue (488nm) laser machine, with 
the option of a mercury lamp for UV excitation, that simultaneous performs absolute counts 
on the acquired samples. The CyAn ADP Analyzer has three lasers (405nm, 488nm and 
642nm) and 9 colour parameters. 
2.4.4 Cytospin Preparation of Cells  
Approximately 5x104 - 105 cells in 100 µl final volume were added to the assembled cytospin 
cassette (Thermo-Fisher).  The cells were spun for 3 minutes at 500 rpm.  The cells were 
spun as soon as possible after loading to ensure evenly distributed cells on the cytospin.  
The slide was removed from the cassette and the cells allowed to air dry.  The air dried cells 
were then stained using the 3-colour ‘Hemacolour’ cell staining solutions (Merck, see 
below): 
Stain 1: Methanol Fixative  30 seconds dipping the slide up and down 
Stain 2: Eosin   10-30 seconds dipping the slide up and down 
Stain 3: Methylene Blue 10-30 seconds dipping the slide up and down 
The slide was gently rinsed with tap water to remove the excess stain then allowed to air 
dry.  A cover slip was placed over the cells using DPX mounting medium (Fisher) and the 
cells analysed under the microscope (Leica DMLB with 40x and 100x oil immersion 
objectives). 
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2.4.5. Cell Culture Methods 
Freezing Cell Stocks 
Cells were frozen, using a Nalgene cryogenic freezing container, in sterile freezing medium 
(FCS + 5% DMSO).  The cells were initially frozen at -80 °C before transfer to liquid nitrogen 
for long term storage. 
Defrosting Cell Stocks 
Frozen cells were defrosted in a 37°C water bath then 10ml of growth medium was added 
and the cells centrifuged (350 x g, 5 minutes). The supernatant was aspirated and the cells 
re-suspended in 10-20ml of growth medium. 
Trypsinization of Adherent Cells 
The growth medium was aspirated from the adherent cells and the cells were washed twice 
with sterile PBS.  The PBS was aspirated and enough trypsin added to cover the cells at the 
bottom of the flask (0.75 ml for 75 cm3 flasks and 1.5 ml for 175 cm3 flasks).  The flask was 
agitated and the cells incubated with the trypsin for approximately 1-5 minutes.  Growth 
medium (10 ml) was added to the cells to stop the trypsin reaction and the cells washed 
with PBS ready for use. 
Passaging Cell Lines 
Cells were split to avoid media exhaustion and death.  The timing of splitting differed but 
usually the cells were split every 2-3 days.  Fresh medium was placed in a new flask and 
cultured cells added to the flask.   
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2.4.6. Molecular Biology Methods 
Preparation of LB of Agar Plates 
Pre-prepared solid LB agar was made by autoclaving of LB agar tablets (Sigma) in H2O as 
instructed by the manufacturer followed by solidification by cooling. When required, solid 
LB agar was dissolved in a microwave and allowed to cool, but not sufficiently to allow it to 
set. Ampicillin was then added to a working concentration of 100 µg/ml.  After gentle 
swirling to ensure full mixing of the ampicillin, the liquid LB agar was poured into circular 
plates and allowed to solidify ready for use. 
Transformation of Competent E.coli with DNA 
Vector DNA (<10 ng) was added to a tube containing competent E.coli TOP10 (15 µl) 
(Invitrogen) on ice and left to incubate for 30 minutes.  The tube was then heat shocked for 
30 seconds at 42°C then placed back on ice for 2 minutes.  SOC medium (100 µl) (2% 
tryptone, 0.5% yeast extract, 10 mM sodium chloride, 2.5 mM potassium chloride, 10 mM 
magnesium chloride, 10 mM magnesium sulphate, 20 mM glucose) was added to the cells 
and agitated for 30 minutes at 37°C.  The cells were plated onto LB agar plates containing 
ampicillin and incubated at 37°C overnight. 
Plasmid DNA amplification 
Plasmid DNA was amplified and prepared using the QIAGEN® plasmid maxi-prep kit as 
directed by the manufacturer’s protocol. 
DNA gel electrophoresis 
A 2.5% agarose gel was prepared by dissolving 2.5g of agarose powder in 100ml of 0.5 x 
Tris/Borate/EDTA (TBE) buffer in a glass conical flask.  Ethidium bromide (0.1 µg/ml) was 
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added to the dissolved agarose and the flask swirled to mix.  The dissolved agarose was then 
poured into casts with combs for the wells and allowed to set at room temperature until 
solid and ready for use.  The gels were placed in gel electrophoresis running apparatus 
(Embi Tec Run-one electrophoresis cell) and running buffer of 0.5 x TBE with 0.1 µg/ml 
ethidium bromide was poured over the gels until covered.  The markers and samples were 
then loaded and gels run at 100V until the appropriate resolution of bands was evident. 
RNA extraction 
RNA extraction using the RNeasy Mini Kit was performed on cell pellets according to the 
manufacturer’s protocol. 
TRizol Reagent: 
Cells were centrifuged (350 x g, 5 minutes) and resuspended at 106/ml in TRIzol Reagent 
(Invitrogen).  RNA was extracted according to the TRIzol reagent manufacturer’s protocol.  
In brief, this involved homogenization of the cell lysate via vigorous and repetitive pipetting 
(at this point, homogenized samples can be stored at -80°C for later use ), phase separation 
of RNA from DNA and proteins using chloroform, RNA precipitation with 100% isopropanol 
and washing of RNA with 75% ethanol (ethanol diluted in DEPC water).  The RNA was 
dissolved in DEPC water and the concentration was measured using the nanodrop 
spectrophotometer (Thermo Scientific).   
RT-PCR 
RT-PCR was performed with the RETROscript kit (Ambion) and performed according to the 
two-step RT-PCR company protocol.   The first step involved reverse transcription of the 
RNA to produce cDNA.  The second step involved the PCR amplification of the cDNA for 
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analysis. The following Clec7a primers that discriminate between the Clec7a.A and Clec7a.B 
isoforms (Heinsbroek, Taylor et al. 2006) were used (394 bp and 269 bp respectively): 
 Forward primer: 5’ ACCGGATCCCAAGTGCTCTGCCTACCTAG 3’ 
 Reverse primer: 5’ GGAATCCTGTGCTTTGTGGT 3’ 
β2 microglobulin primers were used as a positive control (Rosas, Thomas et al. 2010). 
2.4.7. Growth of C. albicans SC5314  
Yeast Peptone dextrose (YPD) agar plates were made in the same way as LB agar plates after 
mixing LB agar powder (Sigma) in H2O (as directed by the manufacturer) and autoclaving to 
sterilise and dissolve. C. albicans SC5314 was streaked onto set YPD agar plates and 
incubated at 37°C overnight to enable growth and isolation of individual colonies. Single 
colonies were cultured in a shaking incubator for 16 h at 37°C in 50 ml of YPD broth.  Live C. 
albicans was washed extensively in PBS before being fluorescently labelled (see below). 
2.4.8. Fluorescent Labelling of Zymosan and C.  albicans SC5314 
Zymosan (Invitrogen) was labelled with either Alexa Fluor 405-succinimidyl ester 
(Invitrogen) or FITC (Sigma). For Alexa Fluor 405 labelling, 1 mg of dye was dissolved in 35 µl 
DMSO.  The dye solution was added to 10 mg of zymosan suspended in 1 ml borate buffer 
(0.2M sodium tetraborate, 0.2M boric acid, pH8.2).  The resulting suspension was incubated 
at room temperature, in the dark and kept rotating overnight.  The particles were then 
washed (1500 x g, 5 minutes) with PBS until all traces of the dye had been removed 
(minimum four washes).  Fluorescent-zymosan was aliquoted and stored below -70oC until 
needed.  
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FITC labelled zymosan was provided by Dr. Phil Taylor and was produced as follows.   
Zymosan at 10mg/ml was resuspended in 0.3M sodium bicarbonate buffer pH9.2 was mixed 
with FITC to a working concentration of between 2 and 50 µg/ml depending on desired 
labelling intensity and incubated on a rotator for 3 hours at room temperature.  Unbound 
FITC was removed by repeated washing with PBS until the wash fraction was free from FITC 
colouring before resuspension in PBS. Fluorescent-zymosan was aliquoted and stored below 
-20oC until needed.  
Live Candida albicans SC5314 yeast were labelled with Pacific Orange succinimidyl ester 
(Invitrogen).  C. albicans at 3.2x108/ml in 1 ml PBS was mixed with 50 µl of 1 mg/ml pacific 
orange dye dissolved in DMSO.  After mixing, the suspension was left to incubate in the 
dark, at room temperature for 30 minutes, on a rotator.  The labelled C.albicans was then 
washed (350 x g, 5 minutes) four times with excess PBS or medium and resuspended in 
medium for use. 
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2.5. Generation and Characterisation of Conditionally Immortalised Cell lines 
2.5.1. Preparation of pMXs-IP:FL-ER-Hoxb8 retrovirus for conditional-immortalisation of 
neutrophil precursors 
Phoenix cells (a HEK293T, human embryonic kidney, cell line that has been transformed to 
enable it to package MMLV viral DNA in capsids) were incubated in 6 well plates (1.5-2x106 
/well) in DMEM with 10% FCS, 150 units/ml penicillin, 50 µg/ml streptomycin, 2 mM  
glutamine (37 °C, 5% CO2) overnight.  The pMXs-IP:FL-ER-Hoxb8 viral DNA (See Table 2.2), or 
pMXs-IP empty vector, were mixed with FuGene 6 transfection reagent (Roche) in DMEM.  
The medium of the phoenix cells was aspirated and 2ml of DMEM with 10% FCS, 50 units/ml 
penicillin, 50 µg/ml streptomycin, and 2 mM glutamine was added.  A Fugene:DNA complex 
was formed by the incubation, for 5 minutes at room temperature, of 6µl Fugene and 94µl 
of DMEM (the Fugene was added directly into the medium and not allowing any to touch 
the sides) followed by the addition of 1µg of DNA and a further incubation at room 
temperature for at least 15 minutes after mixing by swirling. The DNA:Fugene complex was 
then added to the phoenix cells and left to incubate (37°C, 5% CO2) for 48 hours.  The 
replicate supernatants were harvested, polybrene (5 μg/ml) was added and the supernatant 
filtered with a 0.45 µm filter.  The supernatants were stored at -80°C in appropriately sized 
aliquots until required. 
2.5.2. Purification of lineage (lin)- cells from mouse bone marrow and pre-stimulation for 
infection 
The femurs from mice were cleaned and the marrow was flushed out with sterile MACS 
Buffer (0.5% (w/v) BSA, 5mM EDTA in PBS) using a syringe and a 25 gauge needle.  The cells 
were counted and lin- cells were enriched using the MACS murine lineage depletion kit 
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(Miltenyi Biotec), following the company protocol.  In brief, this involved depletion of bone 
marrow cells using biotinylated antibodies against the following: CD5, CD45R (B220), CD11b, 
Gr-1, 7/4 and Ter-119 followed by magnetic separation over a MACS column.  The cells were 
counted, centrifuged (350 x g, 5 minutes) and resuspended in pre-stimulation medium 
(IMDM, 15% (v/v) FCS, 50 units/ml penicillin, 50 µg/ml streptomycin, 2 mM  glutamine, 
10ng/ml IL-3, 20ng/ml IL-6, 25ng/ml SCF) at 106 /ml.  The cells were incubated (37°C, 5% 
CO2) for 3 days prior to infection (see  below). 
2.5.3. Retroviral infection and cell propagation of pre-stimulated lin- cells  
The wells of a 12 well plate were coated with 10µg/ml fibronectin (Sigma; 2 hours, 37 °C).  
The pre-stimulated lin- cells were counted and resuspened in progenitor outgrowth medium 
(POM) (OptiMem, 10% (v/v) FCS, 50 units/ml penicillin, 50 µg/ml streptomycin, 2 mM 
glutamine, 30 μM β-mercaptoethanol) with 10 ng/ml SCF and 1 uM β-estradiol), to a 
concentration of 2x106/ml.  Cells (5x105 cells in 250 µl) were placed in each well and 850 µl 
of the viral vector, the empty vector or the mock transfected supernatant were added to 
each well.  The cells were centrifuged (1500 x g, 90 minutes, 25 °C) to promote infection.  
After centrifugation, POM with SCF and β-estradiol (3 ml) was added to each well and 
incubated (37 °C, 5% CO2) for 2 days. 
After 2 days the replicates were pooled, centrifuged (350 x g, 5 minutes) and resuspended in 
POM with SCF, β-estradiol and 1.5 µg/ml puromycin.  Previous work done by Dr. Kate 
Liddiard confirmed 1.5 µg/ml as the best dose for selection as lower doses showed some 
premature differentiation of progenitors, while higher doses were too harsh and killed too 
many cells. The cells were then allowed to grow over 10 days with regular replenishing of 
the medium.  When using C57BL/6 lin- cells, only the cells infected with the pMXs-IP:FL-ER-
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Hoxb8 vector survived puromycin selection and on day 10 the puromycin was removed and 
the cells cultured in POM with SCF and β-estradiol.  On addition of puromycin a large 
proportion of the cells died, but within 3 days growth was noticeable and by day 10 a 
robustly growing cell culture was evident.  These cells were named myeloid progenitor 
Hoxb8 from C57BL/6 (MyPH8-B6) cells.   
2.5.4. Cell growth and maintenance of MyPH8 cells 
MyPH8 cells can be maintained in culture, in POM with SCF and β-estradiol, as progenitors, 
indefinitely with regular passaging (usually every 2-3 days).  When passaging, cells were 
usually diluted at a 1:10 ratio for general maintenance of the cell line.   Cell stocks were kept 
frozen (-80°C or in liquid nitrogen) and a new vial was defrosted and kept in culture every 3 
months in order to avoid genetic drift and abnormal function of the cell line.  Cells are 
frozen and defrosted as described in 2.4.5. 
2.5.5. Retroviral infection of MyPH8-B6 cells 
The undifferentiated cells were counted and 5x105 cells were centrifuged (350 x g, 
5minutes) and resuspended in 1.5 ml neat viral supernatant containing 10 ng/ml SCF and 1 
uM β-estradiol.  The cells were added to a well of a sterile 6-well plate and centrifuged 
(1500 x g, 90 minutes, 25°C).  After centrifugation, 2 ml of POM containing SCF and β-
estradiol was added to each well and the plates incubated for 2 days (37°C, 5% CO2).  After 2 
days incubation, the cells were either selected with antibiotics (50 µg/ml zeocin, when using 
the pMXs-IZ vector) or sorted with a MoFlo Legacy cell sorter (Beckman-Coulter), depending 
on the specific viral vector that was used to infect the cells (discussed in detail in the 
appropriate results sections). 
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2.5.6. Differentiation of MyPH8-B6 cells into neutrophils 
MyPH8-B6 cells were washed three times with sterile PBS (350 x g, 5 minutes) to remove 
the β-estradiol.  The cells were then counted and resuspened (5x104 – 105 cells/ml) in 10ml 
POM containing SCF+G-CSF (both at 20 ng/ml).  The cells were monitored and 5 ml medium 
was added to the cells every day for four days.  By day four the majority of the cells had 
differentiated into morphologically recognisable neutrophils. 
2.5.7. Purification of MyPH8-B6 derived neutrophils 
MyPH8-B6 derived neutrophils were purified using a ‘Dead Cell Removal Kit’ (Miltenyi 
Biotec), CD117 depletion and subsequent magnetic separation.  Cells were taken out of 
culture and counted.  The cells were then resuspended at 106 cells/ml, in sterile ‘FACS Block’ 
(5% heat-inactivated rabbit serum; 0.5% BSA; 2mM NaN3; 5mM EDTA in PBS) containing 
4µg/ml anti-FcγRII/III (2.4G2), and incubated at 4°C for 10 minutes.  An equal amount of 
‘FACS Block’ containing 10 µg/ml of biotinylated anti-CD117 (working concentration 5 
µg/ml) was added to the cells.  The suspension was mixed and incubated at 4°C, in the dark 
for 30 minutes.  The cells were then washed three times with sterile PBS (350 x g, 5 
minutes).  The cells were then resuspended in dead cell removal and streptavidin coated 
microbeads (107 cells/100µl), mixed and incubated at room temperature for 15 minutes.  A 
suitable amount of 1x binding buffer, provided in the kit, was added to the cell suspension 
and the cells applied to a pre-prepared (column had been rinsed with 1x binding buffer) 
magnetic column within a magnetic field.  The cells were allowed to flow through via gravity 
and the column washed three times with 1x binding buffer. Biotin labelled cells (CD117+ 
progenitors and dead cells) stay within the magnetic field while live, differentiated 
neutrophils pass through the field and are collected for further use. 
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2.5.8. DNA/RNA cell cycle analysis 
A 100 µl aliquot of cells was added to 100 µl NIM-DAPI solution (NPE Systems) and the cells 
left to stain for 30 minutes at room temperature.  The cells were then collected and 
analysed using the ‘Quanta’ flow cytometer (Beckman-Coulter).  For DNA and RNA analysis, 
105 cells were suspended in 1ml of NIM-DAPI solution containing 500nM SYTO RNASelect 
(Invitrogen).The cells were incubated for 30 minutes at room temperature than analysed via 
flow cytometry using the CyAn ADP. 
 
2.6. In vivo Experimental Methods 
2.6.1. Zymosan peritonitis  
129S6/SvEv mice were used for all experiments designed to look at the role of dectin-1 on 
neutrophils in vivo.  The mice were given i.p. injections of 2x107 particles of FITC-labelled or 
unlabelled zymosan 7 days, 3 days, 18 hours and 4 hours before the mice were sacrificed 
and the cells harvested via peritoneal lavage.  Some mice were not injected with zymosan as 
controls.  The cells were counted using the Cell Lab Quanta and stained with F4/80-PE, 
CD11b-PerCPCy5.5 and 7/4-Alexa 647 for differential counting on the FACScalibur (BD).  The 
remainder of the cells that were not stained were centrifuged (350 x g, 5 minutes) and the 
supernatant collected for IL-6 analysis. 
2.6.2. IL-6 ELISA 
Supernatants from in vivo studies were tested for the presence of IL-6 as a marker of 
inflammation using an IL-6 ELISA kit obtained from BD Biosciences.  The purified anti-IL-6 
capture antibody was diluted to 1/250 in PBS and 100 µl of which was added to each well of 
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a 96-well protein-binding ELISA plate.  The plate was sealed and incubated overnight in the 
fridge (4°C).  The following day the capture antibody was removed and the plate washed 3 
times with wash buffer (PBS with 0.5% tween).  The plate was then blocked with 200 µl of 
blocking solution (PBS with 10% FCS) in each well, sealed and incubated at room 
temperature for 1 hour.   IL-6 standards were diluted according to kit protocol in blocking 
solution during the incubation period.  Experimental samples were also diluted in blocking 
solution.  After blocking, the plate was washed 3 times with wash buffer then 100 µl of 
standards and samples were added to each well. The plate was sealed and incubated for 2 
hours at room temperature.  Standards were plated in duplicate and samples in triplicates.  
A working enzyme solution was prepared, just before use, according to kit protocol, that 
consisted of streptavidin-HRP antibody and the anti-IL-6 detection antibody diluted to 
1/500.  After incubation the plate was washed 5 times with wash buffer and 100 µl of the 
working enzyme solution was added to each well.  The plate was sealed and incubated for 1 
hour at room temperature.  The TMB substrate solutions were brought to room 
temperature then and equal amount of solution A and solution B were mixed.  The plate 
was washed 5 time with wash buffer then 100 µl of premixed TMB substrate was added to 
each well and the plate allowed to develop in the dark.  Once satisfied with colour 
development, the substrate reaction was stopped with 50 µl of 2N H2S04 and the optical 
density of the plate read (endpoint test wavelength: 450 nm; reference wavelength: 570 
nm) using a Multiskan spectrum plate reader (Thermo-Fisher).  A linear standard curve was 
calculated and used to determine quantity of IL-6 present in experimental samples.  
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2.6.3. BIOgel peritonitis 
Preparation of BIOgel P100 (BIO-Rad Labs)  
BIOgel P100 Fine acrylamide beads (BIO-Rad) were suspended in tissue culture endotoxin 
tested water (2% w/v) in a glass bottle.  The suspension was then autoclaved.  Once cool the 
BIOgel is ready for use and was stored at 4oC. 
Elicitation of neutrophils with BIOgel P100  
Mice were injected intraperitoneally with 1ml of 2% (w/v) BIOgel in pure H2O, which led to 
high numbers of neutrophils being recruited to the peritoneal cavity.  Approximately 16-18 
hours later the mice were sacrificed and the peritoneal cavity lavaged with 5mM EDTA in 
PBS.  The cells were strained through a 40 µm cell strainer to remove BIOgel particles.  This 
process resulted in neutrophil preparations that were approximately 70-80% pure. 
2.6.4. In vivo adoptive transfer model 
In vitro generated neutrophils were  labelled with CellTrace DDAO-succinimidyl ester 
(DDAO; Invitrogen) either alone or at the same time as Calcein Violet (Invitrogen). 
DDAO-SE (Invitrogen) cell labelling 
Cells were washed (350 x g, 5 minutes) twice with PBS then resuspended at 107 /ml in PBS.  
An equal amount of 1 µM DDAO was added to the cell suspension (working concentration 
0.5 µM) and the cells left to incubate in the dark, at room temperature for 10 minutes.  
After incubation, the labelled cells were washed with POM four times and then suspended 
ready for use. 
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DDAO-SE and Calcein Violet Cell Labelling 
Calcein violet dye was prepared by adding 42 µl of DMSO to a 25 µg vial of dye and mixing 
vigorously.  From this stock solution 40 µl of dye was taken and added to 1.25 ml of PBS to 
produce a final stock solution as per company protocol.  Cells were washed (350 x g, 5 
minutes) twice with PBS then resuspended at 5x106 /ml in PBS.  An equal amount of 1 µM 
DDAO (working concentration 0.5 µM) and 10 µl of the calcein violet stock solution was 
added to the cell suspension and the cells left to incubate in the dark, at room temperature 
for 30 minutes.  After incubation, the labelled cells were washed with POM four times prior 
to use. 
Adoptive Transfer 
In vitro generated neutrophils from different genotypic backgrounds were labelled with 
different fluorescent dyes, mixed in a 1:1 ratio and resuspended in PBS (5x106 of each type 
per 100 µl).  Adult C57BL/6 mice were injected i.v. (performed by Dr. P Taylor) with 100 µl of 
the mixed cells followed by an i.p. injection with 100µl of 1mg/ml FITC zymosan 
(approximately 2x107 particles), or 1ml of 4% Thioglycollate Broth (Sigma), or appropriate 
volume of PBS control.  After 3 hours, the mice were sacrificed and the peritoneal cells were 
recovered by lavage with 5 ml of 5 mM EDTA in PBS. Total cell counts were performed and 
differential analysis was performed by flow cytometry as described above using the CyAn 
ADP analyser and Summit software (both Beckman-Coulter). 
Statistical Analysis of In Vivo Adoptive Transfers 
For analysis of the behaviour of co-injected cell lines in the in vivo adoptive transfer model a 
two-tailed paired t-test was used and P values are displayed with the results.  Analysis was 
conducted with GraphPad Prism (*=P<0.05; **=P<0.01; *** = P<0.001). 
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2.7. Functional Assays 
2.7.1. Measurement of intracellular calcium ion changes 
Flow-Cytometric Assay 
The calcium indicator dye Fluo-4  from the Fluo-4 NW Calcium Assay Kit (Invitrogen) was 
prepared according to the manufacturer’s instructions.  Fura red solution (Invitrogen) was 
added to the prepared Fluo-4 solution at a concentration of 1/500 (working concentration 
1/1000).  MyPH8-B6 derived neutrophils were centrifuged and resuspended in assay buffer 
(1x HBSS + 20nM HEPES, provided in the Fluo-4 NW Calcium Assay Kit) at 2.5x106 cells/ml  
then 0.5ml of calcium indicator solution was added to 0.5ml of cells (125,000 cells).  The 
cells were incubated (37 °C, 5% CO2), with the calcium indicator solution, for 30 minutes, to 
allow uptake of calcium indicator dyes into the cell, then placed in a 5 ml flow cytometry 
collection tube.  Stimulants, zymosan (working concentration of 100 µg/ml) or ionomycin 
(working concentration of 1ug/ml), were diluted in 1 ml assay buffer to give 2x the working 
concentration; this was mixed with 1ml of cells and immediately analysed via flow 
cytometry. 
Live Imaging Ca2+-Flux and Phagocytosis Assay 
MyPH8-B6 derived neutrophils were centrifuged and 107 cells were resuspended in 1 ml of 
differentiation medium. Fura2AM (1µl) (InvitroGen) was added to the neutrophils, which 
were then mixed and incubated for 30 minutes (37 °C, 5% CO2).  A few drops of cell 
suspension were added to a glass coverslip on a heated stage (37 °C) and the neutrophils 
allowed to adhere to the glass.  Zymosan particles were added to the coverslip and allowed 
to sediment among the cells.  A micropipette was used to collect a zymosan particle, via a 
slight negative pressure, and the particle brought lightly into contact with an adhered 
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neutrophil.  Once adherence between the cell and particle had been visually confirmed by 
gentle movement of the micropipette, which would disrupt the neutrophil shape once 
adherence was complete, the particle was released from the micropipette by removing the 
negative pressure and the progression of phagocytosis was monitored.  Zymosan 
phagocytosis was observed using a Nikon Eclipse inverted microscope (Nikon) and recorded 
on video tape by a red sensitive camera (Watec, Japan).  The cells were viewed under a 
100X objective, and the excitation wavelengths (340nm and 380nm) selected using a rapid 
monochromator (Delta RAM, PTI, Surbiton, UK), which was connected to the microscope. 
The images at each excitation wavelength were collected using an intensified CCD camera 
(IC100 PTI, Surbiton, UK) and the ratio image calculated using Image Master software (PTI, 
UK). 
2.7.2. 3’-(-p-aminopheny) Fluorescein (APF) Assays 
3’-(-p-aminopheny) fluorescein (APF) is a reactive oxygen species indicator that is not 
fluorescent until it reacts with the hydroxyl radical, peroxynitrite anion or the hypochlorite 
anion.  To load the cells with this indicator, the cells were incubated in POM containing APF 
(5 µM) at 37 °C for 30 minutes.  After loading the cells with APF, 40 µl of stimulant diluted in 
reaction medium (POM), was added to each well and the plate was placed in a 37 °C water 
bath for 15 minutes (except for when a timecourse assay was performed – see below).  Cells 
were typically stimulated with curdlan microparticles (100 µg/ml), zymosan (100 µg/ml; this 
corresponds to approximately a 20 particle per leukocyte ratio based on the assumption of 
6,000 leukocytes per µl of whole blood), mouse serum opsonised zymosan (100 µg/ml), live 
Candida albicans SC5314 (1:20, cell:Candida ratio, based on the above-mentioned 
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assumption) and mouse serum opsonised live Candida albicans SC5314 (1:20, cell:Candida 
ratio). 
Timecourse Assay 
MyPH8-B6 derived neutrophils were washed in reaction medium (POM), counted and 
resuspended at 106/ml in reaction medium containing APF (5 µM).  After APF loading, the 
cells were placed in a 37 °C water bath until needed, then a 1 ml aliquot of cells was put in a 
FACS tube.  The typical amount of stimulant, as described above, was added and mixed by 
pipetting up and down, then the tube was placed immediately on the flow cytometer and 
acquisition begun.  The cells were collected at a constant rate of approximately 100 events 
per second for 15 minutes. 
MyPH8-B6 Derived Neutrophil Assay 
MyPH8-B6 cells were differentiated over 4 days in differentiation medium.  The cells were 
washed, counted and then resuspended at 105 cells per 60 µl of reaction medium containing 
APF (5 µM) and placed in a v-bottomed 96 well plate (105 cells per well).  After loading with 
APF as described above, the cells were then stimulated.  During these incubations the plate 
was covered with a sterile plate cover. The cells were then immediately put on ice and 100 
µl of ‘2X staining solution’ containing both 7/4-Alexa647 (125 ng/ml),diluted in reaction 
medium, and left on ice in the dark for at least 20 minutes.  The cells were then analysed by 
flow cytometry. 
Inflammatory Cells Assay 
Mice were injected i.p. with 1 ml 2% (w/v) BIOgel and 16-18 hours later a peritoneal lavage 
was performed using 5 ml of reaction medium (see above) and the cells immediately placed 
on ice.  The cells were then filtered using a 40 µm cell strainer to remove BIOgel particles 
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and then the cells were pooled.  The cells were washed 3 times  with reaction medium(350 x 
g, 5 minutes, 4 °C) and were suspended at 105 cells per  60 µl of reaction medium containing 
APF (5 µM) and placed in a v-bottomed 96 well plate (105 cells per well).  After loading with 
APF as described above, the cells were then stimulated. During these incubations the plate 
was covered with a sterile plate cover. The cells were then immediately put on ice and 100 
µl of ‘2X staining solution’ containing both ly-6G-PE (0.5 µg/ml) and 7/4-Alexa647 (125 
ng/ml) diluted in reaction medium, and left on ice in the dark for at least 20 minutes.  The 
cells were then analysed by flow cytometry as described above. 
When using anti-dectin-2 (D2.11E4 (Taylor, Reid et al. 2005)) or its rat IgG2a control (AbD 
Serotec) in blocking studies, the antibodies were included at 10ug/ml in the APF 
preincubation step and the assays were otherwise conducted as described above. 
Whole Blood Assay 
Blood was collected in heparin (5 µl/ml of blood; working concentration of 50 U/ml; Sigma) 
or in 0.8% (w/v) sodium citrate (1 ml/ml of blood).  Blood (20 µl) was added to 100 µl of 
reaction medium (OptiMem, 10% heat inactivated FCS, 1% penicillin/streptomycin, 1% L-
glutamine and 30 µM β-mercaptoethanol) in a v-bottomed 96 well plate (Greiner Bio-one).  
The blood was washed 3 times with 100 µl of reaction medium (350 x g, 5 minutes, room 
temperature).  Reaction medium (60 µl) containing APF (5 µM) was added to the cells, the 
plate covered with a sterile plate cover and the cells left at 37 °C, in a 5% CO2 incubator, for 
30 minutes.  Stimulant diluted in reaction medium (40 µl) was then added to the blood and 
the plate covered with a sterile plate cover.  The plate was placed in a 37 °C water bath for 
15 minutes.  The cells were then immediately put on ice and 100 µl of ‘2X staining solution’ 
containing both ly-6G-PE (0.5 µg/ml- diluted in reaction medium) and Draq5 (10 µM, Bio 
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Status Limited) and left on ice in the dark for at least 20 minutes.  The cells were then 
analysed directly by flow cytometry and without prior cell washing to prevent the effects of 
centrifugation on particle:cell interactions. Slower flow rates on flow cytometric acquisition 
ensure reduced background fluorescence from the unbound and unwashed antibody 
present during acquisition as this is diluted by the sheath fluid. 
 
2.8. Protocols for Human Neutrophil Collection and Functional Assays 
2.8.1. Collection of Salivary Neutrophils 
Sterile PBS (5 x 10 ml) was used to thoroughly rinse the mouth of the donor.  The resulting 
PBS was then spat out into a 50 ml falcon tube and the cells filtered using a 40 µm filter to 
remove any debris from the mouth and produce a single cell suspension.  The presence of 
neutrophils was confirmed via cytospin preparations and the cells inserted into the 
appropriate assay.  Blocking receptors with antibodies were performed at 37°C for 30 
minutes prior to stimulation of the cells.  In the case of the APF assays, blocking was 
performed in conjunction with the APF loading stage.  Human neutrophils were identified by 
their expression of CD66. 
2.8.2. Collection of Human Blood Neutrophils 
Blood was collected (10 ml) in a 50 ml syringe containing an equal amount of sterile PBS 
with 0.8% (w/v) sodium citrate (an alternative anti-coagulant to heparin (Bournazos, Rennie 
et al. 2008)).    The cells were then lysed with ACK lysis buffer (0.15M NH4Cl, 10mM KHCO3 
and 0.1mM EDTA, in ddH2O, pH 7.2-7.4) counted and inserted into appropriate assay.  
Blocking receptors with antibodies were performed at 37°C 30 minutes prior to stimulation 
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of the cells.  In the case of the APF assays, blocking was performed in conjunction with the 
APF loading stage.  Human neutrophils were identified by CD66 expression. 
2.8.3. Collection of Inflammatory Neutrophils via the Skin Window Technique 
Inflammatory neutrophils were collected via a skin window as previously described (Marks, 
Radulovic et al. 2007).  The forearm of the donor was cleaned with medical sterilising 
alcohol wipes then gently sanded down to the capillary bed (visible capillaries but prior to 
bleeding) with grade C sandpaper.  A sterile piece of cellulose filter paper, that had been 
pre-soaked in sterile PBS, was placed over the wound and the arm wound wrapped in 
parafilm to prevent drying of the filter paper.  The arm was then securely wrapped in a 
bandage to keep the filter paper in place.  18-24 hours later, the wound was unwrapped and 
the filter paper placed in a 50 ml falcon tube containing 10 ml sterile PBS and agitated (the 
tube was placed on a rotator and allowed to rotate for at least 5 minutes) to release the 
cells.  The filter paper was discarded and the PBS filtered using a 40 µm filter.  The presence 
of neutrophils was confirmed via cytospin preparations and the cells used in the appropriate 
assay.  Blocking receptors with antibodies were performed at 37°C 30 minutes prior to 
stimulation of the cells.  In the case of the APF assays, blocking was performed in 
conjunction with the APF loading stage.  Human neutrophils were identified using CD66 
staining. 
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2.9 Statistical Tests  
 
The T test was used when directly comparing two columns using only one parameter.  This 
gives a p value that indicates significance.  The Mann-Whitney U test is also used to 
compare two columns using only one parameter.  This test was used in instances where the 
individual columns had large sample sizes, as it is less likely to indicate false significance 
generated by outliers.  As with the T test, this gives a P value that indicates significance.  The 
two way anova with Bonferri post-tests was used when comparing multiple columns using 
two or more parameters.  It gives a p value for whether each parameter has an effect, a p 
value for whether the different parameters are interacting and individual p values 
comparing each column to every other column.  All p values that were equal or less than 
0.05 indicated significance.  All analysis was conducted with GraphPad Prism (*=P<0.05; 
**=P<0.01; *** = P<0.001). 
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Chapter 3 
Generation and Characterisation of 
Conditionally-Immortalised Myeloid 
Progenitor Cell Lines 
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3.1. Introduction 
The use of animal models, whilst controversial, is an important tool in biomedical research.  
It enables the researcher to conduct experiments that would otherwise be ethically and 
morally unacceptable in humans and therefore increases the scope of research.  However, 
in order to reduce animal suffering and loss of life, the guiding principles of animal based 
research are summarised in the three R’s, which are outlined below: 
1. Replacement: This refers to the use of non-animal models wherever possible. 
2. Reduction: This refers to using methods that enable the researcher to obtain as 
much information from the fewest number of animals necessary. 
3. Refinement:  This refers to using methods that minimise and reduce animal suffering 
as well as increasing animal welfare. 
The primary aims of this chapter were to characterise a model of in vitro neutrophil 
production for two reasons: 
1. To simplify production of normal and genetically manipulated neutrophils to model 
innate immune responses. 
2. To place the principles of the 3Rs at the forefront of the study of neutrophil biology. 
A protocol for generating conditionally-immortalised myeloid progenitor cell lines has been 
developed by other researchers using retroviral infection of precursors with an oestrogen-
dependent Hoxb8 fusion gene (Wang et al. 2006).  In the presence of oestrogen and stem 
cell factor (SCF), the cells grow and remain as progenitors.  Once oestrogen is removed the 
cells are then able to differentiate into myeloid cells, and when the lines were established in 
the presence of SCF, this is predominantly into neutrophils.  These conditionally-
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immortalised progenitor derived neutrophils were reportedly more mature than other cell 
line models, possibly due to the fact that the immortalisation factors are not maintained 
during differentiation, although to date no functional characterisation has been reported 
and details of differentiation potential are sparse.  Hence, the objectives of this chapter 
were: 
1. Reproduce the studies of Wang et al., generating conditionally-immortalised 
neutrophil precursors from mouse bone marrow. 
2. Determine the differentiation potential of conditionally-immortalised neutrophil 
precursors to produce a pure population or neutrophils under a number of relevant 
in vitro conditions. 
3. Assess the biological activity of the precursor-derived neutrophils in a series of 
functional assays relevant to neutrophil biology, using fungal recognition as a model. 
4. Evaluate the usefulness of the precursor-derived neutrophils as a genetically 
tractable system for the study of neutrophil function in vitro. 
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3.2. Generation of Retrovirally Transduced Cell Lines from Mouse Bone Marrow 
Femurs taken from mice were flushed and lineage marker negative stem cells enriched 
using the MACS murine lineage depletion kit (Miltenyi Biotec) (figure 3.1).  The enriched 
lineage negative (lin-) bone marrow (BM) stem cells (Figure 3.1.C) were expanded for 3 days 
in IL-3, IL-6 and SCF and then retrovirally transduced with viral supernatant containing a 
DNA construct encoding a Hoxb8:oestrogen receptor binding domain fusion protein and a 
puromycin resistance cassette (Figure 3.2) (Methods 2.5). 
Forty-eight hours after transduction, the cells were cultured in the presence of oestrogen 
and those which had taken up the virus were selected with 1.5 µg/ml of puromycin for 7-10 
days.  This led to the production of puromycin resistant proliferating cell lines, which after 
puromycin withdrawal, continued to proliferate in oestrogen containing media and hence 
were suitable for further characterisation.  
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Figure 3.1: Flow cytometric analysis of lineage (lin) depletion of mouse BM cells: A) plot showing BM cells 
straight from the femur stained with CD117-APC ; B) plot showing BM cells that were removed by the MACS 
lineage depletion protocol; C) plot showing BM cells that have been depleted of lin
+
 cells and hence enriched 
in CD117
+
 cells.  Numbers within the gate denote percentage of cells that are CD117
+
 and results are typical of 
the enrichments performed during this thesis.   
 
 
 
 
 
 
 
 
 
Figure 9: Flow cytometry plots of lineage depleted murine BM cells: A) plot showing BM cells 
straight from he f mur; B) plot showing BM cells that were removed by th  MACS lineage depletion 
protocol; C) plot showing BM cells that have been depleted of lin
+
 cells and hence enriched in CD117
+
 
cells.  Numbers within the gate denote percentage of cells that are CD117
+
.   
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Figure 3.2:  Viral DNA construct used to transduce lin
-
 BM cells for the production of a neutrophil progenitor 
cell line.  The viral construct (top), expresses its transgene as part of a bicistronic transcript with puromycin 
resistance (puro
R
) cassette driven from an internal ribosomal entry site (IRES). This enables expression of both 
coding sequences off of the single transcript.  The transgene, a FLAG (FL)-tagged oestrogen receptor binding 
domain (ER)-Hoxb8 fusion gene, should hence be expressed in all cells which are puromycin resistant.  The 
Gly400Val mutation reduces oestrogen binding, reducing background activation by ensuring that the gene is 
only activated in environments with artificially high concentrations of oestrogen which is used in this thesis. 
This vector has previously been used to make macrophage precursor cell lines (Rosas, Liddiard et al. 2008; 
Rosas, Osorio et al. 2010) and expression of the transgene was shown using an anti-FLAG antibody and 
western blotting (Rosas, unpublished).  This vector was made by Dr. Phil Taylor and is described in detail 
elsewhere (Rosas, Liddiard et al. 2008). 
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3.3. Generation of Cell Lines from 129S6/SvEv Mice 
Since Clec7a-deficient (Clec7a–/–) mice were generated on the isogenic 129S6/SvEv genetic 
background (Taylor, Tsoni et al. 2007) and it was planned to use these animals to make cell 
lines and model the role of Clec7a in the innate immune responses of neutrophils (Chapter 
4), initial attempts were made to generate neutrophil precursors from 129S6/SvEv mice.  
Attempts at generating this cell line using femurs from 129S6/SvEv mice were unsuccessful 
and resulted in the production of a cell line that was highly granular and ‘mast cell-like’ in 
appearance (figure 3.3. A).  These cells expressed high levels of the mast cell markers CD117 
(SCF Receptor) and FcεR1 (IgE Receptor 1) both in the presence and absence of oestrogen 
(figure 3.4)  This supports the conclusion that the cells are of the mast cell lineage and that 
they do not differentiate after removal of oestrogen and are therefore not conditionally-
immortalised.  Similar results were obtained with 2 prior attempts made to generate these 
cells by other group members and empty vector controls produced similar results, indicating 
that this was a natural outgrowth of mast cell-like cells, which can be grown from BM with 
SCF, and not related to Hoxb8 activity. 
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Figure 3.3: Cytospin preparations of lin- cells transduced with viral construct containing Hoxb8. A) Typical 
appearance of ‘mast cell-like’ cell line produced using lin
–
 cells from 129S6/SvEv mice with viral DNA containing 
the oestrogen receptor binding domain-Hoxb8 fusion gene and cultured in the presence of oestrogen and SCF.  
Note the heavy staining granules characteristic of mast cells.  Similar results were obtained with an empty 
vector.  Picture is representative of 3 individual experiments.  B) MyPH8 cells derived from lin
–
 BM cells of 
C57BL/6 mice (MyPH8-B6), with a typical myeloid appearance of a large central nucleus and no visible 
granules. All cells were stained with eosin and methylene blue (Methods 2.4.4). Picture is representative of 
many experiments with >5 cell lines. 
 
 
 
 
 
 
A) B)
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Figure 3.4: Cell surface expression of CD117 and FcεR1 on ‘mast cell-like’ progenitors.  Histograms showing 
the cell surface expression, determined by flow-cytometry, of mast cell associated markers by the mast cell-
like cell line produced from lin
–
 cells from 129S6/SvEv.  Grown in the presence of oestrogen and SCF, the cells 
express high level of CD117 and FcεR1.  On removal of oestrogen these cells still express high levels of both 
receptors.  Data representative of 2 experiments, shaded histograms represent receptor-specific staining and 
bold lines denote isotype control staining. 
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3.4. Generation of Cell Lines from C57BL/6 and Balb/c mice 
The procedure for the production of neutrophil precursors had been published as successful 
in relation to other mouse strains, specifically C57BL/6 and Balb/c (Wang, Calvo et al. 2006).  
Given the bias in 129 mice for the production of mast cells (Yamashita, Charles et al. 2007), 
subsequent attempts were made to generate cell lines from C57BL/6 and Balb/c mice.  The 
Clec7a-deficient mice in Cardiff are also available backcrossed onto the C57BL/6 background 
(for 8 generations; >99.6% C57BL/6). Repeating the protocol with femurs from both 
C57BL/6 and Balb/c mice resulted in cells with a typical myeloid appearance of a large 
mostly circular or slightly irregular nucleus and largish cytoplasmic area and a distinct lack of 
the granules seen in cells derived from 129S6/SvEv mice (Figure 3.3.B). The cells were 
named Myeloid Progenitor Hoxb8 (MyPH8).  BM cells, from these strains, that were 
transduced with an empty vector control did not continue to grow in the presence of 
oestrogen, due to a lack of Hoxb8 immortalisation and BM cells that were mock transduced 
did not continue to grow or survive puromycin selection. 
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3.5. Differentiation Studies on Myeloid Progenitor Cell Line 
To verify whether the MyPH8 cell lines produced in these studies were, as published, a 
neutrophil progenitor cell line, differentiation studies using several different cytokine 
combinations (Table 3.1) were carried out on the C57BL/6 variant (MyPH8-B6).  The cells 
were washed to remove oestrogen and resuspended in differentiation medium containing 
the appropriate cytokines.  The cells were fed every two days and differentiation was 
followed for up to 5 days. 
Best results at optimal time point 
Cytokines 
(20ng/ml) 
Expansion 
(Fold increase) 
Neutrophil purity 
(%) 
Neutrophil total 
number 
SCF 21.42 80.38 5,355,000 
SCF + G-CSF 61.11 89.6 15,277,500 
G-CSF 4.2 97.06 1,050,000 
SCF + IL-5 100.8 23.52 25,200,000 
IL-5 4.62 25.9 1,155,000 
SCF + GM-CSF 408.24 57.5 102,060,000 
GM-CSF 137.34 58.17 34,335,000 
Table 3.1:  Summary of differentiated MyPH8-B6 cells.  Table showing the cytokine combinations used to 
differentiate MyPH8-B6 cells, the fold increase of cell counts, the percentage of cells that are neutrophils and 
the total neutrophil number.  Cultures were started with 250,000 cells.  “Best results at Optimal time point” 
refers to day number at which neutrophil purity is at its highest, cell numbers are at their highest and just 
before the culture begins to die. Data is derived from the experiments shown in Figure 3.7. 
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Differentiation of the cell line resulted in the generation of neutrophils as assessed by 
cytospin preparations (Figure 3.5) and cell surface expression of murine neutrophil markers 
such as Ly-6B.2 (Figure 3.6).  The cells were counted daily (Figure 3.7A) and neutrophil 
percentage determined using flow-cytometry (Figure 3.7B).  Cells differentiated without SCF 
in the differentiation medium (with one exception) showed an immediate detrimental effect 
as a large proportion of these cells died (Figure 3.7A).  These cells were able to recover from 
the large scale death; however, they produced much lower numbers of cells than those 
differentiated with SCF.  However, this effect was not seen in cells differentiated with GM-
CSF.  In the cells differentiated with SCF in the medium there was a steady increase in cell 
number with the greatest increase seen in cells differentiated with SCF + GM-CSF.    
Neutrophil purity was determined by looking at the percentage of cells that expressed Ly-
6B.2.  As shown in Figure 3.7B, cells differentiated with G-CSF in the medium produced the 
greatest neutrophil purity, with cells differentiated in G-CSF alone reaching a neutrophil 
percentage of over 97%; however, this was accompanied by extensive cell death and hence 
poor yields.  Cells differentiated in SCF+G-CSF reached a percentage of approximately 90% 
purity, with substantially improved yields.  Cells differentiated with GM-CSF in the medium, 
whilst providing high yields, only reached limited purity levels of approximately 50-60%.  
Cells differentiated in the presence of IL-5 only managed to produce purity levels of 
approximately 20-30%.  Cells that were differentiated in medium containing only SCF 
managed to reach purity levels of over 80% (Figure 3.7B). 
A further experiment looking at improving neutrophil purity, without a large death event, by 
growing in SCF+G-CSF for 2 days then removing the SCF and growing until day 5, prevented 
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the cell death, but showed no significant increase in neutrophil purity or yield compared to 
cells grown in SCF+GCSF for the full 5 days (data not shown).   
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Figure 3.5: Cytospin preparation of differentiated of MyPH8-B6 cells.  Examples of cells that were 
differentiated in SCF+G-CSF for 4 days and then stained with eosin and methylene blue.   The nuclear 
morphology is typical of mouse neutrophils.  Selected examples are shown and are representative of many 
experiments with at least 5 different cell lines.   
 
 
Figure 3.6: Cell surface expression of Ly-6B.2, a murine neutrophil marker. A)  Undifferentiated progenitor 
cells grown in oestrogen and SCF do not show any Ly-6B.2 expression. B&C) The majority of cells differentiated 
in SCF (B) or SCF+G-CSF (C) for 5 days, show Ly-6B.2 expression.  Red histogram shows cells labelled with Ly-
6B.2 antibody, white histogram shows cells labelled with an isotype control antibody.  Data is representative of 
3 independent experiments. 
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Figure 3.7: Differentiation of MyPH8-B6 cells over 5 days with 7 different cytokine combinations. A)  The 
growth curve of MyPH8-B6 cells treated with different cytokines over 5 days.  The fall in growth seen in day 3 
of cells grown in SCF+GM-CSF is an artefact in this experiment due to overgrowth.  B) Graph showing the 
percentage of cells in the culture that are Ly-6B.2
+
 neutrophils.  The results from this preliminary experiment 
were used to inform future experiments. 
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Cell cycle (Figure 3.8 and 3.9) analysis was performed to determine whether the neutrophils 
derived from the conditionally-immortalised cell line were ‘terminally-differentiated’, which 
is characterised by cessation of cell division. The cells, differentiated as above, were stained 
with NIM-DAPI (Beckman-Coulter) and their nuclear DNA content was analysed on a 
‘Quanta SC MPL’ flow cytometer, which has a mercury lamp for UV excitation of the DNA 
binding DAPI.  After 5 days of differentiation, all cytokine combinations, except those 
containing IL-5, had noticeably decreased the proportion of their cells in S and G2/M phases, 
consistent with terminal-differentiation (Figure 3.8).  IL-5 seems to slow down terminal-
differentiation as supported by the low percentage of neutrophils and the higher 
percentage of cells in S and G2/M phases in comparison to all cytokine combinations.  This 
could be due to the outgrowth of a percentage of cells (see Figure 3.7A), whose potential to 
differentiate later was not investigated.   
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Figure 3.8:  Percentage of differentiated cells in S and G2/M phases of the cell cycle over 5 days of 
differentiation.  Data was compiled from the analyses shown in Figures 3.9B, C & D (below).  The percentage of 
cells in the S and G2/M phase gradually decreases over time.  This is an indicator of terminal differentiation, as 
cells stop dividing.  Data is representative of 2 independent experiments. 
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Figure 3.9A:  Nuclear DNA analysis of SCF, SCF+ GCSF and G-CSF differentiated cells.  Nuclei were isolated 
from differentiated cells and analysed with a NIM-DAPI stain.  Sub G0 cells refer to dead or dying cells; G0 are 
those that are resting and not in the process of division; G1 cells are in the cell cycle but it not possible to 
distinguish between G0 and G1 in this assay; S phase cells are preparing for division and are therefore 
increasing their DNA content; and G2/M cells have double the DNA content of G0/G1 cells and are ready to 
divide.  Data are representative of 2 independent experiments. 
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Day 1 
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Figure 3.9B:  Nuclear DNA analysis of SCF + IL-5 and IL-5 differentiated cells. Differentiated cells had their 
nuclei isolated and analysed with a NIM-DAPI stain.  Sub G0 cells refer to dead or dying cells; G0 are those that 
are resting and not in the process of division; G1 cells are in the cell cycle but it not possible to distinguish 
between G0 and G1 in this assay; S phase cells are preparing for division and are therefore increasing their 
DNA content; and G2/M cells have double the DNA content of G0/G1 cells and are ready to divide.  Data are 
representative of 2 independent experiments. 
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Figure 3.9.C:  Nuclear DNA analysis of SCF + GM-CSF and GM-CSF differentiated cells. Differentiated cells had 
their nuclei isolated and analysed with a NIM-DAPI stain.  Sub G0 cells refer to dead or dying cells; G0 are those 
that are resting and not in the process of division; G1 cells are in the cell cycle but it not possible to distinguish 
between G0 and G1 in this assay; S phase cells are preparing for division and are therefore increasing their 
DNA content; and G2/M cells have double the DNA content of G0/G1 cells and are ready to divide.  Data are 
representative of 2 independent experiments. 
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After analysis of the different cytokine combinations and their effectiveness at generating 
neutrophils, the use of G-CSF or IL-5 without SCF was discontinued as inefficient due to the 
large scale death event on day 1 resulting in low cell yields.  SCF + IL-5, SCF + GM-CSF and 
GM-CSF alone were also discontinued as they produced poor neutrophil purity, regardless 
of the very large yields, as they would require a further purification step to produce cells 
that are pure enough for most functional assays.  Cells differentiated in SCF alone and 
SCF+G-CSF produced reasonable yields of at least 80% purity and these were selected for 
further study.  These cells were differentiated over 5 days and labelled with different 
antibodies to look at neutrophil generation and maturity (Figure 3.10 and 3.11). 
As expected, MyPH8-B6 progenitors all express CD117 (stem cell factor receptor, SCFR) 
(Figure 3.10).  However, differentiation with SCF or SCF+G-CSF resulted in two populations 
of cells, one that does not express CD117 and a smaller subset that does.  Cells that do not 
express CD117 are Ly-6B.2+ consistent with their differentiation into neutrophils.  The 
second subset of cells that are CD117+ are also Ly-6B.2-, which is indicative of a small 
residual population of undifferentiated progenitor cells.  This correlates with microscopic 
analysis of cytospin preparations.  As well as looking at CD117 expression a range of other 
antibodies were also looked at to assess normal neutrophil expression and maturation 
(Figure 3.11).  Residual progenitor populations in the differentiated cell preparations were 
screened out by gating on Ly-6B.2+ cells.  Differentiated neutrophils show clear positive 
expression of neutrophil markers such as Ly-6G and Gr-1 (which binds to both Ly-6G and Ly-
6C), with no distinct difference between cells differentiated in SCF alone or SCF+G-CSF) 
(Figure 3.11A).  The differentiated cells were also positive for CD11b, which is a subunit of 
CR3, CD24, which is known to mediate myeloid cell binding to P-selectin (Aigner, Ruppert et 
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al. 1995)and CD80 a co-stimulatory molecule known to be involved in regulation of T cell 
activation (Mencacci, Montagnoli et al. 2002)(Figure 3.11B) with no differences between the 
two cytokine combinations (Figure 3.11A).  The expression of CD88 (the C5a receptor) 
Clec7a (the β-glucan receptor) and CXCR2 (receptor for the chemokine macrophage 
inflammatory protein 2-alpha (MIP-2α/CXCL2)) was seen to be different with the two 
cytokine combinations.  Cells differentiated in SCF alone showed no, or only minimal, 
surface expression of the above markers, however those differentiated in SCF+G-CSF 
showed some low surface expression of the same markers.  CD88 expression on these 
SCF+G-CSF differentiated neutrophils has since been repeated and shown to be greater than 
seen here (Karsten, Pandey et al. 2012). 
 
3.5. DNA/RNA Profiling 
To provide further evidence of terminal differentiation, cells differentiated in SCF+G-CSF for 
4 days were stained with NIM-DAPI, to which had been added Syto RNASelectTM (Methods 
2.5.8).  The cells were then analysed in the flow cytometer (Figure 3.12).  The nuclei of 
differentiated cells contained many more cells with a DNA content consistent with the 
G0/G1 stage of cell cycle than undifferentiated cells as shown previously, but they also 
contained much less RNA.  This reduction of nuclear RNA is consistent with that seen in 
terminally-differentiated and quiescent cells (Figure 3.12). 
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Figure 3.10:  Expression of CD117 (SCFR). A) Progenitor cells show high CD117 expression as expected. B) Ly-
6B.2
+  
neutrophils differentiated in SCF alone show greatly reduced CD117 expression, however  C) a small 
population of Ly-6B.2
- 
cells show CD117 expression levels comparable to undifferentiated progenitors.  This 
population is also present in cells differentiated in SCF+G-CSF (E).  D) Ly-6B.2
+  
 neutrophils differentiated in 
SCF+G-CSF show almost no expression of CD117. F) Dot plot of SCF+G-CSF differentiated cells showing the two 
distinct CD117
+
 and Ly-6B.2
+ 
populations. Red histogram shows cells labelled with Ly-6B.2 antibody, white 
histogram shows cells labelled with an isotype control antibody.  Data is representative of at least 3 
independent experiments. 
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Figure 3.11A:  Expression profile of MyPH8-B6 progenitors, cells differentiated in SCF and cells differentiated 
in SCF+G-CSF. Data for individual histograms is representative of at least 3 independent experiments and the 
plots of in vitro-differentiated cells are pre-gated on Ly-6B.2
+
 cells to restrict analysis to neutrophils.  Data is 
representative of at least 2 individual experiments. 
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Figure 3.11B:  Expression profile of MyPH8-B6 progenitors, cells differentiated in SCF and cells differentiated 
in SCF+G-CSF. Data for individual histograms is representative of at least 3 independent experiments and the 
plots of in vitro-differentiated cells are pre-gated on Ly-6B.2
+
 cells to restrict analysis to neutrophils.  Data is 
representative of at least 2 individual experiments. 
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Figure 3.12: DNA/RNA Profile of MyPH8-B6 derived cells.  A) Progenitor cells show a larger proportion of cells 
in with greater quantities of DNA and RNA which is an indication of cells that are still dividing.  B) Neutrophils 
show less DNA and RNA than the progenitors. The plots in (A) and (B) are gated based on DNA content to 
identify the cells in G0/G1 and these events are shown in a histogram of RNA content (left panel). The arbitrary 
horizontal line within the gates used highlights the difference in RNA content of cells within these gates and is 
consistent with quiescence of the differentiated neutrophils. Data is representative of 2 individual 
experiments. 
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3.6. Purification of Viable MyPH8-B6-derived Neutrophils 
During the differentiation process, cell death is common due to the short lived nature of 
neutrophils and occasional sub-optimal cell culture conditions (such as exhaustion of 
cytokine/growth factor).  There is also a residual population of progenitors, possibly still 
dividing, after differentiating for 4 days.  Peak neutrophil purity was achieved after 4 days in 
the presence of G-CSF and peak yields achieved when SCF was also present.  To consistently 
achieve high purities of live neutrophils differentiated in SCF+G-CSF for 4 days, a protocol 
for dead cell removal, using a Miltenyi Biotec Dead Cell Removal Kit, was combined with a 
progenitor depletion step.  To achieve this, anti-CD117 labelled with biotin was also added 
to the cells to aid in the removal of residual progenitors at the same time as the dead cell 
removal and the cells magnetically separated (Figure 3.13).  Anti-CD117 negative selection 
was decided on as opposed to Ly-6B.2 positive selection because anti-CD117 does not bind 
to differentiated neutrophils but Ly-6B.2 does.  Ly-6B.2 binding could lead to premature 
neutrophil activation, which could render the cells invalid for certain assays.  In the extreme 
example shown for illustration purposes (Figure 3.13), the percentage of dead cells was 
significantly reduced from approximately 40% to less than 10% after magnetic separation.  
The percentage of neutrophils, as determined via Ly6B.2 expression and flow cytometric 
analysis, was further enriched from 90% to over 95% (Figure 3.13).  Although this system 
was successful in the removal of dead cells and in improving neutrophil purity, it was never 
used for assays, as optimal cell culture conditions, where the cells were frequently fed and 
not allowed to overgrow or exhaust the growth medium, were subsequently established 
and purities of >90% and viabilities of >80% were routinely achieved. 
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Figure 3.13: Percentage of cells that are either live or dead (determined by trypan blue exclusion) and 
neutrophils (Neuts) (determined by Ly-6B.2 staining) before and after purification with the dead cell 
removal kit and anti-CD117 depletion. Cells that were not purified from suboptimal culture conditions (non-
optimised) were 40% dead with 90% of the cells being neutrophils. After purification and anti-CD117 
depletion, only 10% of the cells were dead with over 95% of the cells being neutrophils.  Typically, with good 
culture conditions >90% neutrophil purity and >80% viability were achieved without the need for dead cell and 
progenitor removal.  Data representative of 2 independent experiments. 
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3.7. Recognition and Response of in vitro Generated Neutrophils to the Yeast 
Particle Zymosan 
A preliminary experiment in which MyPH8-B6 derived neutrophils were stimulated with 
either serum-opsonised or non-opsonised, fluorescently labelled, zymosan particles at 37°C, 
or 4°C was performed.  The cells and zymosan particles were either centrifuged at 350 x g 
for 5 minutes to form a pellet and to some extent force an interaction or left in suspension 
for 5 minutes prior to the assay.  After 30 minutes at the appropriate temperature, the 
interaction was analysed using flow-cytometry.  MyPH8-B6-derived neutrophils were able to 
bind both opsonised and non-opsonised zymosan particles, but the extent to which the cells 
were able to bind was determined by the temperature and whether the particles were 
opsonised or not (Figure 3.14 and 3.15) 
When the interaction was forced by centrifugation, there was greater zymosan binding than 
when left in suspension. At both temperatures, interactions with zymosan were much 
greater when the particles were opsonised as opposed to non-opsonised particles (Figure 
3.14).  The percentage binding seen in the suspension assay is poor compared to that which 
was observed in later experiments, which is probably due to poor opsonisation of the 
zymosan, as a result of the serum used for opsonisation being very old with diminished 
complement activity.   Subsequent assays requiring serum opsonisation used fresh serum or 
serum that had been stored in aliquots at -80oC for a maximum of one week. 
In order to determine the rate at which neutrophils can bind and respond to zymosan, Alexa 
Fluor 405 (A405) labelled zymosan particles were added to a suspension of MyPH8-B6 
derived neutrophils that had been preloaded with 3’-(-p-aminophenyl) fluorescein (APF) 
(methods Table 2.1 and methods 2.12) and immediately acquired on a flow cytometer until 
 
 
117 
 
a stable plateau in the association was reached.  The cells were kept at 37°C immediately 
prior to addition of zymosan and acquisition.  Opsonised zymosan was able to bind to 
approximately 60% of cells within the 30 seconds, after which point, the binding plateau 
was reached (Figure 3.16A, left).  Non-opsonised zymosan remained at baseline level for the 
full length of collection (Figure 3.16A, right).  Production of ROS, as measured by APF 
fluorescence, for cells that had bound zymosan became evident after about 1 minute 20 
seconds (Figure 3.16B), approximately 1 minute after the initial association was evident.  
The speed of both binding and response was unexpectedly fast and due to this speed all 
subsequent binding and APF experiments were only 15 minutes long (Figure 3.16C).   
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Figure 3.14:  Flow cytometric plots showing the percentage of MyPH8-B6 neutrophils that have associated 
with either non-opsonised or serum opsonised zymosan, at either 4°C or 37°C.  After 30 minutes incubation, 
cells in suspension showed much less binding than cells that had been pelleted and opsonised zymosan 
showed a greater ability to bind cells than non-opsonised zymosan.  Data from a single preliminary experiment 
to indicate neutrophil ability to bind to zymosan. 
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Figure 3.15: Graphical analysis of the data shown in Figure 3.14 showing the percentage of MyPH8-B6 
neutrophils that have associated with either non-opsonised or serum opsonised zymosan, at either 4°C or 
37°C.  After 30 minutes incubation, cells in suspension showed much less binding than cells that had been 
pelleted and opsonised zymosan showed a greater ability to bind cells than non-opsonised zymosan.  Data 
represents mean ± SEM of triplicates.   
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Figure 3.16: Zymosan binding and ROS production of MyPH8-B6 differentiated neutrophils. A) Percentage of 
MyPH8-B6 derived neutrophils binding to zymosan over time.  Data represents mean ± SEM of 3 replicates and 
is representative of 4 independent experiments.  B) Flow cytometric plots showing that conversion of APF to 
its fluorescent form is restricted to cells that are interacting with zymosan and that this increases with time of 
incubation.  C)  Graphs showing the difference in zymosan binding and percentage of cells that have bound 
zymosan and are in respiratory burst, between cells stimulated with opsonised or non-opsonised zymosan.  
Data shown is calculated from the endpoint of a kinetic assay.  Data represents mean ± SEM of 3 replicates and 
is representative of 3 independent experiments.  Statistical analysis: Two tailed T test.  
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3.8. Measurement of Intracellular Calcium Ions 
Neutrophils are known to respond with an immediate increase in intracellular calcium ions 
(Ca2+) in response to certain stimuli (Dewitt and Hallett 2002).  In order to determine the 
ability of MyPH8-B6 to show this rapid increase in Ca2+, MyPH8-B6 derived neutrophils were 
loaded with fluo-4 and fura-red for 30 minutes, at 37°C.  The cells were left unstimulated or 
were stimulated with ionomycin (an ionophore that allows the transport of Ca2+ through the 
plasma membrane) as a positive control or fluorescently labelled zymosan.  On addition of 
stimulant, the cells were immediately acquired on the flow cytometer and samples were 
collected over at least 5 minutes.  Ca2+ measurements were obtained by taking the ratio of 
fluo-4/fura-red, since the fluorescence of Fluo-4 increases and Fura-red decreases in the 
presence of Ca2+  (Figure 3.17).  
Unstimulated cells showed a low level baseline of intracellular calcium as expected (Figure 
3.17A).  On addition of 1µg/ml ionomycin, the levels of intracellular calcium immediately 
increased by a significant amount and remained at that level for the duration of the 
acquisition (Figure 3.17B).  Neutrophils that were mixed with opsonised zymosan showed 
two distinct populations; cells that were not associated with zymosan particles and cells that 
were.  Neutrophils that were not associated with zymosan particles showed a baseline level 
of intracellular Ca2+, as seen with unstimulated cells (Figure 3.17C), while those that were 
associated with zymosan particles showed increased levels of intracellular Ca2+ (Figure 
3.17D).  This data shows that MyPH8-B6 derived neutrophils are capable of Ca2+ signalling in 
response to zymosan association. 
These results were further explored by looking at intracellular calcium changes, on a cell by 
cell basis as opposed to whole populations, via microscopy.  MyPH8-B6 derived neutrophils 
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were loaded with fura-2AM for 30 minutes, at 37°C.  The cells were then allowed to stick to 
a glass slide and opsonised and non-opsonised zymosan particles were introduced to 
individual cells using a micropipette.  Calcium changes were recorded in real time as 
phagocytosis progressed (Figure 3.18).  Cells introduced to opsonised zymosan showed a 
rapid global increase in intracellular calcium ions and efficient phagocytosis of the zymosan 
particle (Figure 3.18A).  The pattern of intracellular calcium changes seen by these cells was 
similar to that seen previously when human cells were introduced to iC3b-opsonised 
zymosan (Dewitt and Hallett 2002).  Cells introduced to non-opsonised zymosan showed a 
much more erratic and unpredictable calcium signal (Figure 3.18B) as previously reported 
(Dewitt and Hallett 2002). 
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Figure 3.17: Intracellular calcium ion measurements (ratio of fluo-4/Fura-Red) of MyPH8-B6 derived 
neutrophils. A) Unstimulated neutrophils show a baseline low level of intracellular calcium ions, which 
increases on addition of 1µg/ml ionomycin (B).  C) Cells that have been mixed with opsonised fluorescently 
labelled zymosan but that have not associated with zymosan show a baseline level of intracellular calcium ions, 
while cells from the same sample that have associated with zymosan particles show an increased level of 
intracellular calcium ions (D).  Blue/turquoise lines denote the median of the calcium dye ratio. Data is 
representative of 2 individual experiments. 
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Figure 3.18: Global intracellular calcium changes within a single cell after introduction to a single zymosan 
particle with a micropipette.  Calcium changes are measured by taking the ratio of fluorescence of fura-2 at 
two different excitation wavelengths (340nm/380nm).  A) Phagocytosis of opsonised zymosan takes place in 
concert with the rapid increase of intracellular calcium within the cells and its slower decrease.  A blue cell 
shows the calcium levels of the cell at rest.  The yellow circle represents the zymosan particle.  The green 
indicates elevated calcium levels.  This data is representative of 6 cells.  B) Non-opsonised zymosan produced 
an erratic and unpredictable pattern of intracellular calcium. This data is representative of 4 cells. 
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3.9. Transduction of MyPH8-B6 Progenitors to Generate Cells with Uniform 
Transgene Expression 
In an attempt to establish how easily the neutrophils could be genetically-modified, MMLV-
derived retroviruses were used to transduce the precursor cells.  MyPH8-B6 cells were 
transduced with a viral vector containing the calpain 1-GFP fusion gene (Nuzzi, Senetar et al. 
2007).  This work was done in conjunction with Kimberley Lewis, a PhD student of Prof. M 
Hallett who was studying the localisation of calpain-1 in neutrophils.  The objective was to 
exploit her GFP tagged construct to examine the feasibility of genetic modification with a 
readily detectable transgene whilst hopefully generating a useful reagent for her studies.  
MyPH8-B6 cells were spin-infected with viral supernatant containing the calpain-1-GFP 
construct (Figure 3.19) in the presence of SCF and oestrogen.  The GFP domain on the 
construct allowed for the transduced cells to be selected and sorted using a MoFlo Legacy 
flow cytometric cell sorter within Central Biotechnology Services, School of Medicine.  The 
process of sorting the cells improved the percentage of GFP positive cells from 4% to over 
98% (Figure 3.20).  The cells were left in culture and percentage of GFP positive cells was 
assessed over the course of a few days.  These cells were confirmed to be reasonably stable 
as approximately only 0.5% of cells lost GFP expression every 2 days (data not shown). 
After sorting, GFP+ MyPH8-B6 progenitors were differentiated for 4 days according to 
normal protocols.  Over the 4 days GFP expression decreased over time as Ly-6B.2 
expression increased (Figure 3.21).  By day 4 the expression of GFP was low and only a small 
number of neutrophils were detectable via microscopy. However, GFP could be readily 
detected for all 4 days via flow-cytometric analysis.  This demonstrates that although the 
expression of the transgene decreases, it is still at detectable levels. 
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Figure 3.19: Viral DNA construct containing a calpain-1-EGFP fusion domain used to transduce MyPH8-B6 
progenitors, to produce a cell line which can be differentiated into transgenic neutrophils (Nuzzi, Senetar et al. 
2007). 
 
 
 
Figure 3.20: Flow-cytometric plots showing the GFP expression of MyPH8-B6 progenitors.  Before cell sorting, 
4% of cells expressed the transgene (left) but after sorting 98% of cells expressed the transgene (right).   
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Figure 3.21: Differentiation time-course of MyPH8-B6 cells transduced to express GFP.  Expression decreases 
over the 4 days of differentiation and although difficult to detectable via microscopy by day 4, detection is still 
possible via flow cytometry.  Data is representative of one of two experiments. The confocal microscopy 
analysis was performed by Kimberley Lewis as part of her PhD studies of Calpain-1 localisation (note that the 
day 4 differentiated neutrophil has adhered and spread on the glass). 
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3.10. Adoptive Transfer of Neutrophils into Live Animals  
In order to investigate whether it would be possible to adoptively transfer in vitro generated 
neutrophils into a live animal for in vivo study, in vitro generated neutrophils were 
fluorescently labelled and injected intravenously prior to induction of a model of acute 
peritoneal inflammation.  Neutrophils generated from MyPH8-B6 were labelled with 
CellTrace™ DDAO-SE a fluorescent far red cell label and neutrophils generated from MyPH8-
B6.Itgam-/- cells (see Chapter 5 for characterisation) were labelled with both DDAO-SE and 
CellTrace™ calcein violet AM (the experiment was subsequently repeated with a ‘dye-
swap’).  The two neutrophil populations were premixed and 5x106 of each cell type were i.v. 
injected into wild type C57BL/6 mice. Immediately after the i.v. injection the mice received 
100 µg (~2x107 particles) of FITC-labelled zymosan, i.p, or PBS as a control for the 
inflammatory response.  The peritoneal cavity was then lavaged after 3 hours and the 
cellular composition analysed via flow cytometry. 
Animals injected i.p. with PBS showed very limited recruitment of neutrophils into the 
peritoneal cavity while those injected with zymosan did (Figure 3.22).  In vitro generated 
neutrophils from both cell lines could be identified via DDAO-SE and calcein violet labelling 
(Figure 3.22A).  Itgam-/- neutrophils (DDAO+, calcein violet+) showed a decreased ability to 
bind zymosan than the wild type neutrophils (DDAO+, calcein violet-) (Figure 3.22A)  
Endogenous neutrophils were identified using Ly-6G and Ly-6B.2 antibody staining (Figure 
3.22B).   
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Figure 3.22: Adoptive transfer of in 
vitro generated neutrophils into 
C57BL/6 animals. A) Flow cytometric 
plots of in vitro generated neutrophils 
that were identified from peritoneal 
lavages 3 hours after zymosan 
induced recruitment into the 
peritoneal cavity. The left panel shows 
the absence of DDAO
+
 adoptively-
transferred cells when control PBS i.p. 
injections were performed and the 
middle panel shows their recruitment 
when zymosan was administered i.p. 
The right panel indicates the typical 
division within the recruited DDAO
+
 
cells for calcein violet labelling 
(indicated by percentages outside of the gates) and the percentage of these two cell types that were zymosan 
associated (indicated by percentages within the gates. B) Identification of DDAO
-
 native neutrophils from 
C57BL/6 mice, shows the substantial recruitment of Ly-6G
+
Ly-6B.2
+
 neutrophils and Ly-6G
-
Ly-6B.2
+
 
inflammatory monocytes after zymosan administration (middle panel), but not after control PBS injection (left 
panel). The right panel shows notable association of zymosan with the recruited endogenous neutrophils at 
this time point. C) Graphs showing the quantification of the in vitro generated neutrophils that were recruited 
into the peritoneal cavity of live mice.  Almost three times more Itgam
-/-
 neutrophils (DDAO
+
, calcein violet
+
) 
were recruited into the peritoneal cavity than wild type neutrophils (DDAO
+
, calcein violet
-
).  D) Graph showing 
the percentage of in vitro generated neutrophils that were associated with zymosan particles.  Itgam
-/-
 
neutrophils showed a decreased ability to bind zymosan than the wild type neutrophils.  Exact P values are 
shown and were obtained by 2-tailed paired t-test. Data represent one of two identical experiments with FITC-
zymosan in which dye swaps were performed. 
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3.11. Conclusion 
This chapter demonstrates the successful reproduction of the conditionally-immortalised 
neutrophil precursor cell line originally generated by Wang et al. 2006.  The first cell lines 
were attempted using 129S6/SvEv mice.  However this proved unsuccessful as it generated 
highly granulated mast-cell like cells.  The reason for this is unclear but studies have shown 
that mice from the 129 genetic background show significant differences in their mast cell 
biology.  129S6/SvEv mice have significantly increased serum IgE levels, increased 
responsiveness to anaphylactic challenge and increased levels of FcεR1 than C57BL/6 mice 
(Yamashita, Charles et al. 2007).  This suggests a significant bias towards mast cell 
production that could be responsible for the highly granular cells produced (Krishnaswamy 
and Chi 2005).   
The progenitor cell lines were generated using a viral DNA construct containing an 
oestrogen receptor binding domain-Hoxb8 fusion gene.  The potential for this method to 
produce other myeloid cells has been reported (Wang, Calvo et al. 2006).  In our laboratory, 
macrophage precursors are routinely generated that are differentiated into mature 
macrophages with GM-CSF or M-CSF, by changing the growth medium used to establish the 
cells from Opti-MEM containing SCF to RPMI 1640 containing GM-CSF (Rosas, Liddiard et al. 
2008; Rosas, Osorio et al. 2010). 
I was able to differentiate the neutrophil precursors into neutrophils by growing them in 
SCF+G-CSF containing medium for 4 days.  Although it has been reported that these cell 
lines should be able to produce other myeloid cells, by changing the cytokine combinations 
(Wang, Calvo et al. 2006) used for differentiation, I found that this cell line was primarily a 
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neutrophil producing cell line and scope for generating other cell lines was limited in the 
time frames and conditions studied, although this was not extensively pursued. 
Progenitors grown in SCF+G-CSF for 4 days produced high neutrophil purities and resulted in 
a large number of cells produced. Although other cytokine combinations gave greater 
neutrophil purity (G-CSF) and others gave greater cell expansion (SCF + GM-CSF), none gave 
the same combination of high purity and cell numbers that was seen with SCF+G-CSF. With a 
little optimisation (ensuring cell numbers were not so high as to deplete media or that 
growth factors were added in excess during the differentiation period), this protocol 
generates the high purities and viabilities that are required for a viable replacement for 
animals in research to be adopted by other laboratories.   
Neutrophils are considered terminally differentiated cells.  The in vitro generated 
neutrophils derived from the conditionally immortalised cell lines had DNA and RNA 
contents that were consistent at the very least with cessation of cell cycle and a quiescent 
like phenotype.  
Neutrophils from conditionally-immortalised precursor cells were able to bind and 
phagocytose zymosan and exhibited calcium mobilisation (both confirmed by both flow-
cytometry and live microscopy) and respiratory burst.  These are key functions of primary 
neutrophils that these in vitro neutrophils can perform.  
Neutrophils generated in vitro were successfully adoptively transferred into live animals and 
were successfully identified after culling. In addition, functional differences could be 
recorded in these in vivo studies when CD11b-deficient (Itgam-/-) cells were used. 
Specifically it was demonstrated that there was almost three times as many CD11b deficient 
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in vitro generated neutrophils located in the peritoneal cavity than wild type neutrophils.  
This is consistent with the published research that CD11b deficient neutrophils accumulate 
in the peritoneal cavity in response to a challenge due to reduced apoptosis of the cells 
(Coxon, Rieu et al. 1996), and adds further information by confirming an in vivo defect in 
fungal particle recognition in the absence of CD11b. 
In addition to these studies reported here, collaborators in Prof. Marina Botto’s laboratory 
in London demonstrated the usefulness of these cell lines in a chemotactic assay across an 
endothelial barrier towards MIP-2 (McDonald, Cortini et al. 2011). The receptor for MIP-2 is 
CXCR2, which was found selectively on the SCF+G-CSF differentiated cells (Figure 3.11B). 
Additionally, they demonstrated a reduced propensity for the Itgam-/- cells to die after 
migration, when compared to wild type cells, which reflects the phenotype of primary 
Itgam-/- neutrophils (Coxon, Rieu et al. 1996). In a currently unpublished collaborative study 
conducted with Prof. Jörg Köhl (Lübeck, Germany) these cells have been similarly shown to 
migrate towards recombinant C5a (Karsten, Pandey et al. 2012), consistent with their 
expression of CD88/C5a receptor. 
Taken together these studies indicate that the cells can be effectively used in carefully 
controlled studies and can readily identify phenotypes in genetically-deficient in vitro 
generated neutrophils that have been previously reported with primary cells. 
In conclusion, I have validated this method of producing conditionally immortalised 
neutrophil progenitors and shown that it produces a reasonable model of a mouse 
neutrophil that exhibits many of the properties of a primary mouse neutrophil.  A further 
advantage of these cells is that the progenitors can be frozen and a cell stock kept and 
thawed for future use.  However, they also exhibit some alterations, such as low Ly-6G and 
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Clec7a expression that indicate that they may not represent a fully mature mouse 
neutrophil. In spite of this, they are currently one of the best in vitro models of mouse 
neutrophils and have the further advantage that they can be readily genetically-modified for 
functional studies, which is a significant step forward as there are no comparable methods 
of producing genetically modified neutrophils without the need to generate new mouse 
colonies (see also chapter 5). 
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Chapter 4: Analysis of the Role of Clec7a 
(Dectin-1) in Fungal Particle Recognition 
on Primary Neutrophils 
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4.1. Introduction 
The incidence of human fungal infections is on the increase especially those caused by 
normally non-pathogenic species, e.g. Candida albicans.  This is due to the increasing 
numbers of people that have a compromised immune system due to HIV, the use of 
immunosuppressants and other medical interventions (Romani 2004).   
Fungal cell walls are predominantly composed of carbohydrates, including β-glucans, but 
also glycoproteins, lipids and inorganic salts.  Study of β-glucan interactions has traditionally 
used zymosan, which is a particle made from the cell walls of Saccharomyces cerevisiae, 
which contains β-glucans as well as other polysaccharides, proteins and lipids (Di Carlo and 
Fiore 1958).  As well as using zymosan to model β-glucan recognition, this chapter also uses 
curdlan microparticles, which are a selective clec7a agonist (Rosas, Liddiard et al. 2008).         
Clec7a is a cell surface receptor that recognises β-glucans (Brown and Gordon 2001; Brown, 
Taylor et al. 2002). It is a type II transmembrane protein with a C-type lectin-like domain and 
it contains an immunoreceptor tyrosine-based activation-like motif on its cytoplasmic tail 
(Ariizumi, Shen et al. 2000).  Clec7a is broadly expressed on myeloid cells, predominantly 
macrophages, monocytes and neutrophils (Taylor, Brown et al. 2002; Taylor, Tsoni et al. 
2007).  Opsonic recognition of β-glucans and fungal particles is known to proceed via 
complement receptor 3 (CR3: CD18/CD11b) (Brown 2006).  Until relatively recently, CR3 was 
thought to be the primary non-opsonic β-glucan receptor (Xia, Vetvicka et al. 1999).  More 
recent studies demonstrated that Clec7a is a major non-opsonic β-glucan receptor on 
macrophages (Brown, Taylor et al. 2002). However, additional β-glucan receptors that have 
been proposed are SCARF-1 and CD36 (Means, Mylonakis et al. 2009). 
The main aims of this chapter are as follows: 
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1. To develop a model for studying the relative contributions of Clec7a and CR3 
(including via complement opsonisation) in β-glucan recognition by neutrophils in 
vivo and ex vivo. 
2. To explore the contribution of Clec4n (dectin-2) in neutrophil recognition and 
response to fungal particles. 
3. To explore the function of Clec7a on distinct populations of human neutrophils. 
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4.2. Establishing Parameters for In Vivo Exploration  
A series of experiments were performed to determine the parameters required for 
neutrophils to interact with fungal particles in vivo and hence for the contribution of Clec7a 
to these inflammatory and recognition processes to be assessed. 129S6/SvEv mice were 
injected intraperitoneally (i.p.) with 2x107 FITC-labelled zymosan.  The peritoneal cells were 
then harvested at different time points and analysed. In lower dose models (≤2x106), 
inflammatory cell recruitment and cytokine production in this model has a partial 
dependency on Clec7a (Taylor, Tsoni et al. 2007), which I found to be reproducible in an 
experiment where mice were injected with 105 particles of FITC-labelled zymosan (data not 
shown).  Cells taken from the peritoneal lavage of an animal that had not been injected i.p. 
with zymosan showed a prominent population of tissue resident macrophages as confirmed 
by high expression of F4/80 (Austyn and Gordon 1981; Taylor, Martinez-Pomares et al. 
2005) and almost no neutrophils (Figure 4.1.A).  After injection with zymosan, neutrophils 
were identified by Ly-6G and Ly-6B.2 expression and 4 hours after injection neutrophils 
proved to be the predominant cell present (Figure 4.1.B).  After 18 hours, the predominant 
cell type was still the neutrophil, however, number had started to decrease while monocyte 
(Ly-6B.2+ and Ly-6G-) numbers had started to rise (Figures 4.1. C). By days 3 and 7 post-
injection, cells of the monocyte/macrophage lineage had become predominant, with very 
low numbers of neutrophils (Figure 4.1.D & E). 
Quantification of cell numbers showed that of the time points examined, neutrophil 
numbers peaked at the 4 hour time point (Figure 4.2.A) but quickly decreased down to 
baseline levels by day 3.  The percentage of neutrophils associated with zymosan followed 
this same pattern with the peak at 4 hours (Figure 4.2.B).  All cells of the 
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monocyte/macrophage lineages showed a sharp decline at 4 hours but then a steady 
increase, with the peak at day 3.  This sharp decline is probably a result of the macrophage 
disappearance reaction due to acute inflammation that has been previously reported (Barth, 
Hendrzak et al. 1995).  Monocyte/macrophage numbers then seem to settle back to 
baseline by day 7, although this population almost certainly represents a mixed population 
of cells (Davies, Rosas et al. 2011).  The percentage of monocyte/macrophages that are 
associated with zymosan show a steady increase, until they peak at day 3 (Figure 4.2.B).  
This late association of zymosan with macrophages is likely explained by one of two, not 
mutually exclusive, mechanisms: the phagocytic clearance of dying neutrophils that have 
previously phagocytosed zymosan or the re-appearance of tissue resident macrophages, 
which still contain zymosan (Davies, Rosas et al. 2011). 
It is clear from this data that the greatest association between zymosan and neutrophils is 
occurring at the 4 hour time point.  As that is the interaction of interest, all further 
experiments looking at the role of Clec7a on neutrophils was performed with cells taken 4 
hours after i.p. injection. 
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Figure 4.1: Flow-cytometric plots showing peritoneal cells from 129S6/SvEv mice.  A) Resident peritoneal 
cells from an animal that has not been injected with zymosan.  The gated region shows resident macrophages 
as denoted by high F4/80 staining.  There is no distinct population of neutrophils as shown by the lack of a 
distinct population showing high Ly-6B.2 and no F4/80 staining.  B) Recruited peritoneal cells 4 hours after i.p. 
injection with FITC-zymosan.  The Ly-6G
+
Ly-6B.2
+ 
cells denote a large population of infiltrating neutrophils 
while the Ly-6G
-
Ly-6B.2
+ 
show a smaller population of infiltrating monocytes.  At this time point the majority of 
the zymosan particles are associated with neutrophils.  C) Recruited peritoneal cells 18 hours after i.p. 
injection with FITC-zymosan.  Neutrophil numbers are lower than at 4 hours while monocytes numbers have 
increased (See Figure 4.2 below).  Plots are representative of at least 2 mice per time point. 
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Figure 4.1: Flow-cytometric plots showing peritoneal cells from 129S6/SvEv mice.  D) Recruited peritoneal cells 
3 days (72 hours) after i.p. injection with FITC-zymosan.  Present are: F4/80 high macrophages (1), composed 
of residual F4/80
high
Ly-6B.2
-
 population of resident macrophages as well as an abundant F4/80
high
Ly-6B.2
low-high
; 
a much smaller F4/80
low
Ly-6B.2
high
 population of monocytes(2); and a F4/80
-
Ly-6B.2
high 
population  of 
neutrophils.  The majority of zymosan association is now with the F4/80
high
 macrophage populations.  Almost 
no zymosan is associated with the residual neutrophils and F4/80
low 
monocytes.  These results are also seen 7 
days (168 hours) after i.p. injection with zymosan, although there are fewer cells associated with FITC-zymosan 
at this time point (E).  Plots are representative of at least 2 mice per time point. 
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Figure 4.2: A) Graphical 
representation of neutrophil and 
monocyte/macrophage numbers 
in the peritoneal cavity before 
and after acute zymosan 
peritonitis. n=3 129S6/SvEv mice 
per group and is representative of 
2 independent experiments.  Data 
is shown as mean±SEM. There is a 
rapid influx of neutrophil on i.p. 
injection with FITC-zymosan, 
which peaks at 4 hours after 
injection.  Neutrophil numbers 
then decrease until approaching 
baseline at 72 hours.  After i.p. 
injection with FITC-zymosan, 
monocyte/macrophage numbers 
rapidly decrease, with the trough 
at 4 hours after injection.  After 
this point numbers slowly increased until approaching baseline levels at 72 hours, albeit that these 
macrophages represent a mixture of macrophage phenotypes at this time (Davies, Rosas et al. 2011).  B)  
Graphical representation of the percentage of neutrophils and monocytes/macrophages present that were 
associated with zymosan.  Zymosan association with neutrophils was greatest 4 hours after injection and had 
all disappeared by day 7.  Zymosan association with the monocyte/macrophage populations gradually 
increased to peak at 72 hours before returning to baseline by day 7.  C) Representative picture of neutrophils 
in a 4 hour inflammatory infiltrate showing zymosan associated and unassociated cells (left panel) and MoFlo 
purified day 3 macrophages (right panel).  The macrophages in the lower panel show examples of association 
with no, one or multiple zymosan particles, although, the percentage of macrophages associated with zymosan 
at this time point is low (see B).   
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4.3. A Model for the In Vivo Study of the Function of Clec7a on Neutrophils During 
Peritonitis Caused by Fungal Infection 
129S6/SvEv and 129S6/SvEv.Clec7a-/- mice were injected i.p. with 2x107 FITC-labelled 
zymosan.  After 4 hours, the peritoneal cavity was lavaged and the recruited cells analysed.  
Supernatants from this lavage were kept and analysed for IL-6 production as a marker of 
cellular activation and inflammation. 
Resident macrophages were identified prior to zymosan injection by high expression of 
CD11b and lack of Ly-6B.2 (Figure 4.3A).  After zymosan injection, the number of resident 
macrophages recovered from the peritoneal cavity was very low (<5% of the numbers in 
naive mice)(Figure 4.3A and 4.4A).  Of the remaining resident macrophages, there were 
more cells from Clec7a-/- mice associated with zymosan particles compared to wild type cells 
(Figure 4.3A and 4.4B).  Neutrophils and monocytes were identified by expression of Ly-6G 
and Ly-6B.2.  Neutrophils were predominantly present while a small population of the cells 
were monocytes.  Both cells type showed noticeable association with zymosan particles 
(Figure 4.3B).   
The numbers of neutrophils present in the lavage 4 hours post injection were significantly 
less in Clec7a-/- mice than in wild type mice.  However, this was reversed for monocytes, 
with Clec7a-/- mice showing a significantly greater number of monocytes than wild type 
mice.   The numbers of neutrophils associated with zymosan particles was significantly lower 
in Clec7a-/- mice than in wild type mice.  There was no significant difference between the 
monocytes.  IL-6 production was also significantly decreased in Clec7a-/- mice (Figure 4.4.C).  
This data suggests that Clec7a has some role in neutrophil interaction with zymosan, but 
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indicates that the inflammatory response is not normal in the Clec7a-/- mice as previously 
reported (Taylor, Tsoni et al. 2007).  
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Figure 4.3: Flow-cytometric plots showing peritoneal cells from 129S6/SvEv mice and 129S6/SvEv.Clec7a
-/- 
mice before and after acute zymosan peritonitis.  A) Mice injected i.p. with FITC-zymosan show a rapid 
disappearance of the majority of the resident macrophages in both wild type and Clec7a
-/- 
animals.  Residual 
resident macrophages show marked association with zymosan particles.  B) Both wild type and Clec7a
-/- 
animals show neutrophil and monocyte recruitment into the peritoneum, 4 hours after i.p. injection with FITC-
zymosan.  The majority of zymosan particles are associated with neutrophils, however some monocytes also 
show association with zymosan. Data shown is from representative mice with the full dataset shown below 
(Figure 4.4). 
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 Figure 4.4: Characterisation of high-dose zymosan peritonitis in Clec7a-deficient mice.  Wild type (closed 
circles) and Clec7a-deficient (Clec7a
–/–
; open circles) 129S6/SvEv mice were injected intraperitoneally with 
2x10
7
 zymosan particles and inflammatory infiltrates examined 4 hours later. A) Graphs showing the number 
of neutrophils, monocytes and residual tissue resident macrophages (Res MØ) in the peritoneal cavity at this 
time. B) Graphs showing the numbers of those cells indicated in (A) above that are associated with FITC-
zymosan.  C) Quantification of IL-6 in the peritoneal lavage fluid of zymosan injected mice. For A, B and C data 
were normalised and pooled from 2 (res MØ and IL-6 analysis) and 3 (Neutrophil and monocyte analysis) 
independent experiments.  Each symbol represents an individual mouse.  Data were analysed by non-
parametric Mann-Whitney U-test. P values: *=P<0.05; **=P<0.01.   
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4.4. Ex Vivo Study of the Function of Clec7a on Primary Neutrophils 
In order to determine whether the apparent defects in neutrophil zymosan interactions 
seen in Clec7a-/- mice described above were due to the intrinsic role of Clec7a on neutrophils 
or defects in recruitment and activation of the neutrophils caused by impaired cellular 
activation and induction of inflammation, an ex vivo assay was developed.  Inflammatory 
cells were recruited into the peritoneum in a Clec7a independent manner using BIOgel 
polyacrylamide beads.  The neutrophils (Ly-6G+ Ly-6B.2+) and monocytes (Ly-6G– Ly-6B.2+) 
were tested for their expression of both Clec7a and CD11b.  Wild type neutrophils and 
monocytes were both positive for Clec7a and CD11b while Clec7a-/- cells were positive for 
CD11b but not Clec7a (figure 4.5).  The cells were preloaded with APF, an indicator of ROS, 
then stimulated with zymosan (2x106 particles), serum-opsonised zymosan, C. albicans 
(2x106 live cells) or serum-opsonised C. albicans.  PBS was used as a negative control.  As 
well as analysing peritoneal neutrophils (figure 4.6), recruited Ly-6B+ monocytes were also 
analysed (figure 4.7).  
Only cells that had interacted with fungal particles produced ROS as a result of the 
respiratory burst (figure 4.8).  Clec7a deficiency significantly (P<0.0001) impairs the ability of 
neutrophils  and monocytes to bind both opsonised and non-opsonised zymosan, and their 
ability to respond via production of reactive oxygen species (figure 4.8.A).  However, the 
effect of Clec7a is not significant in regards to the ability of neutrophils to respond to 
opsonised zymosan.  In all cases opsonisation increases binding of zymosan and in the case 
of neutrophils, opsonisation increases the ability of cells to respond to zymosan.  This 
supports the established important role for CR3 as well as Clec7a mediated binding. 
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When looking at binding and response to live C. albicans, Clec7a deficiency significantly 
impairs the ability of neutrophils and monocytes to associate with live C. albicans .  
Response to C. albicans, by prodcution of ROS, is impaired in neutrophils when associated 
with both opsonised and unopsonised C.albicans.  However in monocytes response is only 
significantly impaired when associated with unopsonised C.albicans (figure 4.8.B).  This 
broadly mirrors the results seen with zymosan particles but shows less dependence on 
Clec7a to initiate respiratory burst in interacting neutrophils. 
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Figure 4.5: Expression of Clec7a and CD11b on the neutrophils of wild type and Clec7a
-/- 
mice.  Both cell types 
express comparable levels of CD11b.  Only wild type cells show clec7a expression. White histograms show 
isotype control staining.  Red histograms show anti-CD11b or anti-Clec7a expression. Data is representative of 
3 independent experiments. 
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Figure 4.6: Flow-cytometric plots showing the association of neutrophils with labelled zymosan or live 
C.albicans and the resulting production of ROS as measured via APF fluorescence. Data representative of 3 
independent experiments. 
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Figure 4.7: Flow-cytometric plots showing the association of inflammatory monocytes with labelled zymosan 
or live C.albicans and the resulting production of ROS as measured via APF fluorescence. Data representative 
of 3 independent experiments. 
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Figure 4.8: Graphical analysis of the recognition and response to zymosan (2x10
6 
particles) and C.albicans 
(2x10
6 
live cells) of primary neutrophils and monocytes.  A) Inflammatory cells were loaded with APF and then 
incubated with serum-opsonised or non-opsonised zymosan for 15 minutes.  After this time the association of 
the inflammatory cells with zymosan was measured by flow-cytometry (upper panels) and in those cells that 
were interacting with zymosan the evidence for fluorescent conversion of APF was also quantified (lower 
panels).  B) The experiments shown in (A) were repeated with live pacific orange-labelled C. albicans.  
Neutrophils and monocytes stimulated with either serum opsonised or unopsonised live C. albicans.  Unops = 
non-opsonised; Ops = opsonised. Both (A) and (B) are representative experiments from 3 independent 
experiments and data shown represented the mean±SEM of triplicates. Both (A) and (B) were analysed by two-
way ANOVA with Bonferroni post-tests. I = Interaction; D = significance of the effect of Clec7a; C = significance 
of effect of complement opsonisation. P values derived from individual Bonferroni post-tests are indicated 
with bracketed pairs of samples.  P values: *=P<0.05; **=P<0.01; *** = P<0.001.   
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4.5. Role of Clec7a and Complement Opsonisation in β-glucan Recognition by 
Peripheral Blood Neutrophils 
Whole blood was collected from 129S6/SvEv and 129S6/SvEv.Clec7a-/- mice in heparin.  The 
cells were washed, preloaded with APF and stimulated with zymosan (2x106 particles), 
opsonised zymosan, C. albicans (2x106 live cells) or opsonised C. albicans. PBS was used as a 
negative control.  Neutrophils were identified via draq5 staining of DNA and ly-6G positive 
staining (figure 4.9).  The neutrophils were collected via flow cytometry and analysed for 
association and production of reactive oxygen species (figure 4.10). 
Clec7a deficiency had no effect on the ability of these cells to associate with or respond to 
zymosan or C. albicans (figure 4.11).  Opsonisation of zymosan increased the ability of the 
neutrophils to associate with and respond to the zymosan however, although association 
with C. albicans was increased by opsonisation of the yeast, response was not affected 
(figure 4.11).  This suggests that Clec7a is not essential for binding or response in peripheral 
blood neutrophils, but that in order for significant binding to occur, opsonisation of the 
particle is required. 
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Figure 4.9:  FACS plot showing the identification of neutrophils from heparinised whole blood using draq 5 
(DNA dye) and Ly6G staining. Non-leukocytes (Draq5
-
) are excluded by a Draq5 threshold gate. 
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Figure 4.10: FACS plots showing individual samples of whole blood neutrophil association with labelled 
zymosan or live C.albicans and the resulting production of ROS as measured via APF fluorescence. Data 
representative of 3 independent experiments. 
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Figure 4.11: Graphical analysis of the recognition and response to zymosan and C. albicans of neutrophils in 
whole blood.  Clec7a deficiency had no effect on the ability of neutrophils to bind or respond to zymosan and 
C.albicans.  No opsonisation of the stimulant resulted in very low levels of recognition, which was restored 
with serum opsonisation.  Unops = non-opsonised; Ops = opsonised. Data is representative experiments from 
3 independent experiments and data shown represents the mean±SEM of triplicates. Data was analysed by 
two-way ANOVA with Bonferroni post-tests. I = Interaction; D = significance of the effect of Clec7a; C = 
significance of effect of complement opsonisation.    
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4.6. Investigations into the Role of Clec7a on Primary Inflammatory and Whole 
Blood Neutrophils Using a Clec7a Specific Agonist 
Both zymosan and C. albicans are recognised by several different receptors on immune cells 
so to look more specifically at Clec7a, curdlan microparticles were used.  Curdlan 
microparticles are particulate β-glucans which are approximately 2.5-3µm in size, can be 
phagocytosed, and are selective Clec7a agonists (Rosas, Liddiard et al. 2008). 
Inflammatory neutrophils and whole blood neutrophils were stimulated with different 
concentrations of curdlan microparticles and the ROS response measured.  Clec7a deficient 
cells, both inflammatory and whole blood, showed a consistent level of baseline ROS 
response up to concentrations of 1 mg/ml (figure 4.12.A). In contrast, wild type 
inflammatory neutrophils were able to respond at all concentrations, from approximately 
25% of cells responding at 30 µg/ml, up to over 60% of cells responding at 1 mg/ml (figure 
4.12.A).  Wild type whole blood neutrophils were much poorer in their ability to respond to 
curdlan microparticles.  These cells showed a baseline response for the lower 
concentrations and at 1 mg/ml, less than 20% of the cells gave an ROS response (figure 
4.12.A).  
To determine the extent to which the use of whole blood and the anticoagulant affect the 
outcome of the assay, inflammatory neutrophils were mixed with whole blood neutrophils.  
Whole blood was taken from CD45.2+ mice, while inflammatory neutrophils obtained from 
CD45.1+ mice. Using the CD45.1 antibody allowed for the differentiation between the two 
blood and inflammatory neutrophils.  This introduced red blood cells into the inflammatory 
assay and therefore any differences seen between the two cell types would be due to the 
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pre-activation of the inflammatory cells.  This also exposed the inflammatory cells to 
heparin. 
Inflammatory neutrophils that had been mixed with whole blood neutrophils in a 1:1 ratio, 
did not show the same level of response as those that had not been mixed with whole blood 
(figure 4.12.B).  They showed the same level of response as whole blood neutrophils.  Whole 
blood cells were collected using heparin as an anticoagulant.  Due to its well reported anti-
inflammatory effects (Young 2008), inflammatory neutrophils that had been collected in the 
absence of heparin, were exposed to the same concentration of heparin as the whole blood 
cells for 10 minutes, then washed, to determine whether heparin has an effect on the ability 
of neutrophils to respond to the curdlan microparticles.  These cells showed a significant 
decrease (t-test: P = 0.0091) in the percentage of cells that responded (figure 4.12.B). 
To address some of these problems the experiment was repeated with sodium citrate as an 
alternative anticoagulant and the blood cells lysed with ACK lysis buffer, after which the 
inflammatory cells were mixed with the blood cells, all prior to loading with APF.  There 
were no differences seen between inflammatory neutrophils and blood neutrophils in this 
assay (figure 4.12.C).   
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Figure 4.12: Blood and inflammatory neutrophil responses to curdlan mp. A) Graph showing the percentage 
of cells responding to curdlan mp by producing ROS in both inflammatory and whole blood neutrophils from 
wild type and Clec7a deficient mice. Wild type inflammatory neutrophils show a much greater ability to 
respond than whole blood and clec7a deficient neutrophils.  Data represents mean ± SEM and is 
representative of 3 independent experiments B) Graph showing the percentage of cells responding to curdlan 
mp (300 µg/ml) by producing ROS in whole blood assay that had been spiked with inflammatory neutrophils in 
an approximate 1:1 ratio.  Data represents mean ± SEM and is representative of 2 individual experiments.  C) 
Graph showing the percentage of cells responding to curdlan mp by producing ROS in an assay with whole 
blood cells that had been collected with sodium citrate, lysed with ACK lysis buffer and mixed with 
inflammatory neutrophils in a 1:1 ratio prior to stimulation.  Data represents mean ± SEM and is representative 
of 3 independent experiments.  Data was analysed using T Test; P values: **=P<0.01.   
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4.7. The Effect of Clec4n (Dectin-2) Blockade on Yeast Particle Recognition by 
Inflammatory Neutrophils 
A role for dectin-2 in neutrophil fungal recognition has not been previously reported, 
perhaps because  it was thought to be minimally expressed by these cells, with most 
expression confined to inflammatory monocytes and tissue resident macrophages (Taylor, 
Reid et al. 2005). I found that inflammatory neutrophils like monocytes express dectin-2, 
though not at comparable levels, with inflammatory monocytes showing greater dectin-2 
expression (figure 4.13). 
Inflammatory neutrophils and monocytes were tested for their ability to respond via ROS 
production to opsonised and non-opsonised zymosan particles. Clec7a-/- cells were used to 
unmask any redundancy in the system and blocking of dectin-2 was achieved by pre-
incubation of the cells with anti-dectin-2 (D2.11E4) and Rat IgG2a was used as an isotype 
control.  Although blocking dectin-2 on neutrophils shows no significant impairment to 
zymosan binding it does significantly impair the ability of neutrophils to respond to non-
opsonised zymosan particles.  This impairment is not seen in response to opsonised particles 
(figure 4.14).  Blocking dectin-2 has a greater effect on inflammatory monocytes by 
impairing their ability to bind non-opsonised zymosan and their ability to respond to both 
opsonised and non-opsonised zymosan (figure 4.14). 
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Figure 4.13: Expression of dectin-2 on the inflammatory neutrophils and monocytes of wild type mice.  Both 
cell types show some expression of dectin-2 but not at comparable levels.  Neutrophils show less expression of 
dectin-2 than monocytes.  White histograms show isotype control staining.  Red histograms show anti-Clec4n 
(D2.11E4) expression. Data representative of 2 independent experiments.   
 
 
 
 
100 101 102 103 104
FL 2 Log Comp
0
379
759
1138
1518
C
o
u
n
ts
100 101 102 103 104
FL 2 Log Comp
0
33
67
101
135
C
o
u
n
ts
Clec4n
Inflammatory 
Neutrophils
Inflammatory 
Monocytes
 
 
161 
 
 
Figure 4.14:  Graphical analysis of the recognition and response to zymosan of primary neutrophils and 
monocytes from Clec7a deficient mice.  The cells were left untreated (white bar), pre-treated with anti-dectin-
2 (grey bar) or pre-treated with a rat IgG2a control antibody (horizontal lines bar). Unops = non-opsonised; 
Ops = opsonised. Data is representative experiments from 3 independent experiments and data shown 
represented the mean±SEM of triplicates. Data was analysed by two-way ANOVA. I = Interaction; D = 
significance of the effect of Clec4n; C = significance of effect of complement opsonisation.   
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4.8. Application of In Vitro APF Model to Human Neutrophils  
i) Extravasated salivary neutrophils 
The model of looking at the role of Clec7a in fungal interactions was applied to primary 
human neutrophils.  Human saliva is a good source of inflammatory neutrophils (al-Essa, 
Niwa et al. 1994), with between 1.1 x107– 2x107 cells harvested.  The cells were loaded with 
APF and stimulated with zymosan and response analysed.   Two different Clec7a-specific 
antibodies (GE2 (Willment, Marshall et al. 2005) and anti-human Clec7a (mAb 259931) by 
R&D Systems) were added to some samples to attempt to block Clec7a.  Laminarin, a 
soluble β-glucan, was also added as a blocking agent. Neutrophils were identified by flow-
cytometry with a CD66-specific staining and confirmed via cytospin preparations (figure 
4.15). It was immediately apparent that these inflammatory neutrophils would not be 
suitable for the APF assay as they showed an extraordinarily high background level of ROS 
production that would mask any genuine results due to zymosan stimulation (figure 4.16).  
The level of zymosan binding was assessed to determine the success of the blocking 
antibodies.  Blocking of Clec7a appeared unsuccessful in reducing zymosan binding with 
neither antibody nor laminarin having a detectable effect in this assay (figure 4.17).   The 
cytospin preparations confirmed the presence of neutrophils, as identified by their highly 
stained, multi-lobed nuclei (figure 4.15B).  Epithelial cells were also present but were 
excluded from the flow-cytometric assay by their lack of CD66 staining. 
ii) Peripheral blood neutrophils 
Human whole blood was used as a source of sterile neutrophils.  The blood was collected in 
sodium citrate to avoid any possible negative effects of heparin and a whole blood APF 
assay was performed.  The assay was successful in that there was no background ROS 
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production and the response seen was clearly as a result of particulate stimulation (figure 
4.18A).  Curdlan microparticles as well as zymosan were used to stimulate these cells.  The 
zymosan was able to elicit a greater APF response than the curdlan microparticles; however, 
no evidence of Clec7a blocking by the antibodies was seen (figure 4.18B).  Blocking also did 
not affect the binding of zymosan (figure 4.18C). 
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Figure 4.15: Identification of human salivary neutrophils. A) Flow-cytometric plots showing CD66 
identification of salivary neutrophils and their association with zymosan. B) Cytospin slides showing cells from 
human saliva.  The picture to the left shows an epithelial cell surrounded by numerous neutrophils, while the 
picture to the right shows close up of two neutrophils with their distinct highly stained, multi-lobed nuclei. All 
cells were stained with eosin and methylene blue.  Data representative of 3 independent experiments. 
  
 
 
 
 
 
 
 
165 
 
 
 
 
 
 
 Figure 4.16: Histograms showing the production of ROS via APF fluorescence in salivary neutrophils.  The 
white histogram shows neutrophils that have been not been treated with APF or stimulated with zymosan. The 
purple crosshatched histogram shows neutrophils treated with APF and not stimulated with zymosan and the 
red histogram shows neutrophils that have been treated with APF and have bound zymosan particles.  Cells 
not incubated with APF and not stimulated with zymosan showed limited autofluorescence.  Both zymosan 
stimulated and unstimulated APF treated neutrophils showed similarly high amounts of APF conversion into 
the fluorescent reporter indicating a high level of basal ROS production in extravasated salivary neutrophils 
that could mask any zymosan induced ROS production. Data is representative of 2 independent preliminary 
experiments to determine background APF fluorescence levels. 
100 101 102 103 104
FL 1 Log
0
57
115
172
230
C
o
u
n
ts
Untreated & Un-stimulated 
Neutrophils
Un-stimulated neutrophils 
treated with APF
Neutrophils treated with APF 
and stimulated with 
opsonised zymosan
APF
 
 
166 
 
  
 
Figure 4.17: Graph showing the percentage of salivary neutrophils that have associated with non-opsonised 
zymosan.   Only a small percentage of neutrophils interacted with the zymosan particles and neither of the 
monoclonal antibodies specific to dectin-1 nor laminarin were able to block this zymosan binding. Data 
representative of 2 independent experiments from 2 different donors.  Data shown represent the mean±SEM 
of triplicates.   
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Figure 4.18: Identification of human peripheral blood neutrophils and their recognition and response 
to curdlan microparticles and zymosan. A) Flow-cytometric plots showing CD66 identification of blood 
neutrophils, their association with zymosan and subsequent APF response. B) Graph showing the percentage 
of curdlan microparticle stimulated cells that have responded by ROS production and the percentage of 
zymosan associated cells that have responded with ROS production.  GE2 shows no blocking action with 
zymosan or curdlan microparticles. Data from single preliminary experiment from a single donor. C) Graph 
showing the percentage of whole blood neutrophils that have associated with zymosan.  Data representative 
of 2 independent experiments from 2 different donors.  Data shown represented the mean±SEM of triplicates.   
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iii) Inflammatory ‘skin window’ neutrophils 
A process of obtaining sterile inflammatory neutrophils, via recruitment through a skin 
window (Marks, Radulovic et al. 2007), produced clearly identifiable neutrophils (figure 
4.20A).     However, this technique produced far fewer neutrophils than saliva extraction, 
with each 6 x 3 cm window producing less than 106 cells. Like the salivary neutrophils, these 
cells showed a significant background production of ROS (figure 4.19).   This is consistent 
with priming effects associated with their extravasation to an inflammatory site and with 
possible further activation in the wound. Binding of these cells to zymosan was extremely 
low and Clec7a blocking antibodies had no effect on the level of binding (figure 4.20B). 
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Figure 4.19: Histograms showing the production of ROS via APF fluorescence in neutrophils derived from the 
skin window technique.  Cells not incubated with APF and not stimulated with zymosan showed background 
autofluorescence (white histogram).  There was no difference observed between the cells incubated with APF 
but not stimulated with zymosan (purple cross-hatched histogram) and the cells incubated with APF and 
bound to zymosan (red histogram).  Both groups of APF loaded cells show a high level of APF expression 
meaning that the background APF expression is too high as to be indistinguishable from APF fluorescence 
induced by zymosan interactions.  Data shows the result of a preliminary experiment to determine background 
APF fluorescence levels. 
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Figure 4.20: Cytospin preparation of ‘skin window’ neutrophils and their association with zymosan.  A) 
Cytospin slide showing human inflammatory neutrophils recruited through the skin via the skin window. Cells 
were stained with eosin and methylene blue. B) Graph showing the percentage of neutrophils that are 
associated with zymosan.  The addition of GE2 and laminarin had no blocking effect on the association of 
zymosan with neutrophils.  IgG1 was used as a negative control for the GE2 antibody.  Data is representative of 
2 independent experiments from a single donor. Data shown represented the mean±SEM of triplicates.   
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4.9. Conclusion 
Zymosan induced peritonitis is typically studied using zymosan doses of at between 2x107-
2x108 particles.  Previous studies with Clec7a–/– mice looked at doses ≤2x106 particles 
(Taylor, Tsoni et al. 2007), where the particles were sufficiently cleared by tissue resident 
macrophages.  An increased dose of zymosan would ‘overwhelm’ the resident macrophages 
and result in the activation of alternative inflammatory responses helping to drive the 
recruitment of inflammatory cells to the peritoneal cavity.  Previous studies with low doses 
of zymosan have shown that Clec7a is involved in the activation of tissue resident 
phagocytes in response to fungal challenges (Taylor, Tsoni et al. 2007; Rosas, Liddiard et al. 
2008). A higher dose of zymosan would allow for the direct study of the role of Clec7a on 
inflammatory neutrophils and monocytes in response to fungal challenges by permitting 
direct interaction of the cells with zymosan after their recruitment to the peritoneal cavity. 
The inflammatory parameters of a high dose model of zymosan peritonitis were established.  
After i.p. injection of 2x107 particles of zymosan, an acute inflammatory response was 
observed typified by a large drop in recoverable resident macrophage numbers and a large 
influx of inflammatory neutrophils and some monocytes.  Neutrophil numbers and 
association with zymosan peaked 4 hours after zymosan injection so this was considered a 
useful time point for the study of neutrophil interactions.  Macrophage interactions with 
zymosan peaked after 3 days and this could either be attributed to the apoptosis of dead 
neutrophils containing zymosan particles or the persistence of tissue resident macrophages 
late into the inflammatory process (Davies, Rosas et al. 2011).   
The role of Clec7a on primary neutrophils was studied with the aid of Clec7a deficient mice.  
Clec7a deficient mice were impaired in their ability to recruit neutrophils to the site of 
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infection in response to zymosan.  These neutrophils were also impaired in their ability to 
bind to zymosan particles.  This could suggest a direct causal link between Clec7a deficiency 
on neutrophils and impaired ability to recognise fungal particles.  However, the significantly 
reduced levels of IL-6 observed in conjunction with lower numbers of neutrophils recruited 
suggest an impaired inflammatory response in general.  This may occur via a lack of Clec7a 
on tissue resident cells, resulting in a reduced inflammatory response to zymosan and 
therefore decreased recruitment and cellular activation of neutrophils.   
In order to specifically look at Clec7a on neutrophils an ex vivo assay with primary 
neutrophils was established.  This ex vivo assay showed that Clec7a deficiency does directly 
impair the ability of inflammatory neutrophils to recognise and respond to fungal particles 
and live C. albicans.  However, in vivo, there are a variety of recognition mechanisms that 
neutrophils utilise to help phagocytose fungal pathogens.  Complement opsonisation is a 
crucial recognition system and the abundance of complement in the in vivo environment 
should ensure effective recognition of an invading organism.  Serum opsonisation of both 
zymosan and C. albicans, in vitro, prior to exposure to the neutrophils significantly increased 
their binding potential.  These data show that although Clec7a does contribute to the 
recognition and response to fungal particles, its role is partially redundant as complement 
opsonisation has a larger effect on particle recognition. Very recently it was shown that 
Clec7a activates CR3 in neutrophils and that both receptors work together to enhance 
neutrophil response to fungal pathogens.  The ability of Mg2+, which activates CR3, to 
restore phagocytosis of zymosan suggests that the reduction of recognition and 
phagocytosis of fungal particles in Clec7a deficient neutrophils is down to a lack of CR3 
activation by Clec7a (Li, Utomo et al. 2011).  My data supports the suggestion that in vivo 
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Clec7a is not essential to clearance of fungal particles and this suggests that the activation of 
CR3 by Clec7a in vivo is also a redundant process.  Further evidence for a partial redundancy 
in the system can be seen in the observation that Clec7a deficient human neutrophils are 
able to phagocytose yeast particles under adherent conditions and in the presence of serum 
(Ferwerda, Ferwerda et al. 2009). 
The method for the whole blood assay produced several challenges that made it difficult to 
draw any conclusions about the differences seen between inflammatory peritoneal 
neutrophils and blood neutrophils.  The use of heparin as an anticoagulant is common; 
however, it has been shown to have negative side effects that could skew the result of any 
assay looking at cellular immunity (Young 2008).  This was overcome by the use of sodium 
citrate as an alternative anticoagulant.  Also the presence of red blood cells in the whole 
blood assay may have blocked interactions between neutrophils and the particulate 
stimulants and led to the diminished responses seen in blood neutrophils in the whole blood 
assay.  This was addressed by first introducing inflammatory peritoneal cells into the whole 
blood assay.  The results suggested that the red bloods cells were interfering with 
cell:particle interactions.  In order to remove this interference, the red blood cells were 
lysed. This seemed to increase the percentage of blood neutrophils that were responding, 
up to the same level of the inflammatory cells.  This could be indicative of two things: 
1. The removal of the red blood cells removes the interference and the natural ability 
of the cells to respond to particulate challenge is restored. 
2. The lysing of the red blood cells resulted in priming of the cells making them more 
able to respond than would otherwise be the case. 
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The attempt to apply this model to primary human neutrophils using similar assay 
conditions was largely unsuccessful due to a mixture of assay specific factors.  Neutrophils 
obtained from the saliva were already responding to challenges from bacteria present in the 
mouth and this made exploring specific cellular responses of any interactions very difficult.  
This same limitation was present with skin window produced neutrophils. Only peripheral 
blood neutrophils exhibited a largely ROS- phenotype after isolation.  In order to specifically 
look at the role of Clec7a on human neutrophils, the blocking of Clec7a was required.  The 
binding of zymosan particles to human neutrophils (isolated from either of the 3 protocols) 
was consistently low and neither antibody blocking (with two distinct monoclonal 
antibodies) or the use of a soluble β-glucan were able to successfully show any blocking of 
Clec7a and this made the study of the receptor on human neutrophils very difficult.  Ideally, 
these studies could be conducted using neutrophils from the blood of naturally Clec7a-
deficient humans (Ferwerda, Ferwerda et al. 2009; Plantinga, van der Velden et al. 2009), 
but these were not available for these studies.  Studies using naturally Clec7a-deficient 
humans have shown that neutrophils are not impaired in their ability to phagocytose and kill 
live C.albicans even in the absence of Clec7a, further highlighting the redundancy Clec7a in 
fungal recognition (Ferwerda, Ferwerda et al. 2009). This is consistent with the lack of 
inhibitory activity of the anti-dectin-1 antibodies and soluble glucans observed in this thesis.  
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Chapter 5: Modelling Innate Immunity 
Using Neutrophils Derived From 
conditionally-Immortalised Cell Lines 
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5.1. Introduction 
In chapter 3, the generation of conditionally-immortalised neutrophil precursor cell lines as 
a means to minimise animal suffering and the loss of animal life in scientific research and 
put the three R’s (replacement, reduction and refinement) at the forefront of all neutrophil 
research was discussed.  The cell line was found to be morphologically and functionally 
similar to primary mouse neutrophils.  To determine whether these cells are viable 
substitutes for the use of primary murine neutrophils in basic research, these cells need to 
be inserted into established models of neutrophil research and their behaviour compared to 
that of primary neutrophils. 
The previous chapter looked at the relative contributions of Clec7a and complement 
opsonisation in the recognition and innate immune response to fungal pathogens.  In this 
chapter, the aim was to use the in vitro generated neutrophils described in chapter 3 to 
explore the mechanisms described in chapter 4 as a means to demonstrate the usefulness 
of these cell lines as an effective replacement for animals in the study of immune response 
mechanisms. 
Clec7a has been shown to exist in two distinct isoforms; Clec7a.A and Clec7a.B.  Both 
isoforms are expressed in human and mouse cells (Willment, Marshall et al. 2005; 
Heinsbroek, Taylor et al. 2006).  In order to study Clec7a, in vitro, conditionally-immortalised 
neutrophil progenitor cell lines were generated from Clec7a-/- mice and reconstitutions 
performed using the two different isoforms and MMLV-derived retroviral vectors. This 
strategy was adopted because of the very low Clec7a expression observed on in vitro 
generated neutrophils (Chapter 3), which already identifies some limitation of in vitro 
neutrophil generation to model immune responses.  
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As further proof of concept, a conditionally-immortalised neutrophil progenitor cell line was 
generated from CD11b-deficient (Itgam-/-) mice and reconstituted with two different human 
CD11b isoforms; G230 and A230 (Sachs et al. 2004 and Macpherson et al. 2010). At the time 
of this study, this polymorphism in Itgam has been linked to susceptibility to autoimmune 
disease (Sachs, Chavakis et al. 2004; Nath, Han et al. 2008; MacPherson, Lek et al. 2011), 
with no mechanistic explanation to explain this. The recognition and immune response to 
fungal pathogens of these cell lines was then explored to determine to what level CD11b 
function had been restored and whether there were any evident functional differences 
between the two isoforms. 
 
5.2. Generation of Clec7a-/- and Itgam-/- Conditionally-Immortalised Neutrophil 
Precursor Cell lines 
Cell lines were generated using femurs from Clec7a-/- and Itgam-/- C57BL/6 mice as described 
in chapter 3 and methods 2.5.   These knock out cell lines were confirmed not to express 
Clec7a or CD11b, respectively (Figure 5.1). 
 
5.3. Transduction of Conditionally-Immortalised Neutrophil Precursors with Clec7a 
The MyPH8-B6 cell line progenitors were transduced with viral DNA constructs containing 
Clec7a.A, Clec7a.B or an empty vector (pMXs-IZ) as described in chapter 3 and methods 
2.5.5.  The cells were then differentiated (methods chapter 2.5.6) and analysed for 
differentiation and expression of Clec7a (Figure 5.2).  The empty vector progenitors 
expressed limited levels of endogenous Clec7a compared to the Clec7a transduced cells.  
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The transduced progenitors both express Clec7a, with the Clec7a.A transduced cell line 
showing greater expression than the Clec7a.B cell line (Figure 5.2).   
In the Clec7a transduced cell lines, Clec7a expression decreased with neutrophil 
differentiation (Figure 5.2).  However, day 4 neutrophils from these cells still showed greater 
Clec7a expression than the empty vector transduced neutrophils (Figure 5.2).   The levels of 
Clec7a in day 4 neutrophils were noticeably different in cell lines transduced with the two 
different isoforms.  Those differentiated with Clec7a.A showed a much greater cell surface 
expression of the receptor than those differentiated with Clec7a.B (Figure 5.2). 
The Clec7a-/- cell line was similarly reconstituted with Clec7a as described above, using the 
different isoforms.  Expression of Clec7a on neutrophils derived from these cell lines was 
confirmed via RNA extraction and reverse transcriptase polymerase chain reaction (RT-PCR).  
The RT-PCR showed that MyPH8-B6 derived wild type neutrophils predominantly expressed 
the B isoform of Clec7a.  The Clec7a-/- cell line neutrophils did not show any Clec7a 
expression (Figure 5.3.A).  Clec7a expression on the transduced cell lines was compared to 
that on primary neutrophils, and while neutrophils derived from the Clec7a.A cell line 
showed higher Clec7a expression than primary neutrophils, neutrophils derived from cell 
lines transduced with Clec7a.B showed comparable expression levels (Figure 5.3.B). These 
expression differences of the two isoforms were consistent in repeat transductions (see also 
Figure 5.2).   
Due to the wild type cell line predominantly expressing the Clec7a.B isoform, and the 
comparable levels of expression produced by cell lines transduced with this isoform, it was 
decided that all further studies would be conducted using only this isoform.  This decision 
was further supported by a functional assay, where zymosan binding was examined and this 
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showed that zymosan binding by the neutrophils derived from the Clec7a.A transduced cell 
line showed much higher binding than wild type cells (Figure 5.4.).  Although this could be 
attributed to the isoform itself, it is likely that it is the increased expression of the receptor 
that produces this effect.  
 In order to examine the contribution of CD11b to neutrophil recognition of fungal particles 
in the context of normal Clec7a expression, the MyPH8-B6.Itgam-/- cell line was transduced 
with the Clec7a.B isoform (or empty control vector) and Clec7a expression analysed via flow 
cytometry.  Neutrophils derived from this cell line also showed levels of Clec7a expression 
comparable to primary neutrophils (Figure 5.3.B). 
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Figure 5.1: Cell surface expression of Clec7a and CD11b on 4 day in vitro generated neutrophils produced 
from conditionally-immortalised neutrophil progenitor cells line.  Red histogram show cell surface expression 
of indicated receptor and white histogram shows isotype control. The cell lines from the Itgam
-/-
 and Clec7a
-/-
 
also confirm the specificity of the antibodies.  The wild type MyPH8-B6 cell line expresses CD11b and low levels 
of Clec7a.  The CD11b knockout cell line expresses Clec7a but not CD11b and the Clec7a knockout cell line 
expresses CD11b but not Clec7a.  Data representative of 2 independent experiments 
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Figure 5.2: Four day differentiation flow cytometry plots of MyPH8-B6:Clec7a.A, MyPH8-B6:Clec7a.B and 
MyPH8-B6:pMXs-IZ.  Ly6B.2 was used as a marker of neutrophil differentiation and Clec7a cell surface 
expression was determined at each time point.  Ly6B.2 expression increases steadily and by day 4 all cell lines 
show expression of Ly6B.2.  By day 4 the cell lines transduced with Clec7a show a marked increase in Clec7a 
than the empty vector control cell line.  Although Clec7a expression decreased in the cell lines transduced with 
Clec7a, the expression of the cell surface receptor was still greater than seen in the empty vector control cell 
line. Note that the quadrants delineate Ly-6B.2 positivity and an arbitrary vertical reference line that marks the 
lower limit of expression of Clec7a by the Clec7a.B transduced cells (middle row). The Clec7a.B expression can 
be seen to cross this arbitrary vertical marker line after in vitro differentiation.  Data representative of 3 
independent experiments. 
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Figure 5.3:  mRNA and expression of Clec7a on in vitro generated, Ly-6G+, neutrophils derived from 
conditionally-immortalised cell lines. A) mRNA expression of Clec7a splice-forms on neutrophils derived 
from conditionally-immortalised cell lines as determined via RNA extraction followed by RT-PCR (methods 
chapter 2.4.6).  MyPH8-B6 wild type cells are shown to express predominantly the “B” isoform.  The knockout 
cell line MyPH8-B6.Clec7a
-/-
 shows no expression and the knockout cell lines that were transduced show 
expression of the Clec7a isoform they had been transduced with. B)  Histograms showing expression of Clec7a 
on in vitro generated, Ly-6G
+
, neutrophils derived from conditionally-immortalised cell lines. The red histogram 
denotes Clec7a expression and the white histogram shows the negative control.  Primary neutrophils were 
extracted from the peritoneal cavity of mice 18 hours after an i.p. injection with 1ml 2% (w/v) BIOgel. 
Neutrophils from MyPH8-B6.Clec7a
-/-
 cells transduced with Clec7a.A shows a noticeably increased expression 
of Clec7a than primary neutrophils and neutrophils derived from cell lines transduced with Clec7a.B, which 
show comparable levels of Clec7a expression.  As expected, neutrophils derived from the empty vector control 
cell line show no expression of Clec7a. 
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5.4. Assay Development: Zymosan Binding 
A zymosan binding time course assay, using fluorescently labelled zymosan particles 
(100µg/ml), was performed with neutrophils derived from conditionally-immortalised cell 
lines (Figure 5.4). The percentage of cells bound to zymosan reached a stable plateau within 
the first 90 seconds of the assay.  This was seen with all cell lines and demonstrated the 
relatively short amount of time required for such an assay.  
Temperature dependency of this assay was also examined.  There were no differences in the 
results obtained with non-opsonised particles when the assay was conducted at either 4oC 
or 37oC and only a slight increase in binding at 37oC with opsonised particles, compared to 
4oC (Figure 5.4).  The higher temperature was used for future assays partly as it showed an 
increase in binding but most importantly it allowed for the measurement of cellular 
response to the cell:particle interaction as it was physiologically relevant. 
For both temperatures, opsonised particles showed much greater binding than non-
opsonised particles.  Neutrophils derived from the cell line transduced with Clec7a.A, were 
the only cells able to show a greater than background level of binding of non-opsonised 
zymosan. Neutrophils derived from the Itgam-/- cell line, unsurprisingly, showed only 
background levels of binding for both non-opsonised and opsonised zymosan particles.  For 
all subsequent studies fungal particles were both opsonised and non-opsonised. 
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Figure 5.4: Zymosan binding time course of neutrophils derived from conditionally-immortalised cell lines.  
Neutrophils were pre-warmed or pre-chilled to the appropriate temperature, then mixed with either non-
opsonised or serum opsonised zymosan and binding examined with acquisition over time.  Only MyPH8-
B6:Clec7a.A neutrophils were able to bind non-opsonised zymosan above a background level at both 
temperatures.  Neutrophils from all cell lines except the CD11b deficient cell line were able to bind opsonised 
zymosan at both temperatures.  Data represents mean ± SEM of 3 replicates and is representative of 2 
independent experiments. 
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5.5. Assay Development: Respiratory Burst 
In order to study the response of cells to fungal pathogens, a time course assay looking at 
the production of ROS in response to fluorescently labelled zymosan was performed 
(methods 2.7.2)(Figure 5.5).  Neutrophils derived from the MyPH8-B6 cell line were pre-
loaded with 3’-(-p-aminophenyl) fluorescein (APF), a substance that becomes fluorescent in 
the presence of certain ROS (methods 2.1.4) produced during the respiratory burst.  The 
cells were then stimulated with opsonised fluorescently labelled zymosan and ROS 
production measured over time.  Cells that showed no association with zymosan also 
showed no increased production of ROS (Figure 5.5.A).  However, some zymosan associated 
cells showed a marked increase in ROS production, which after a steep rise began to level 
out (Figure 5.5.B/C).   These preliminary experiments showed that zymosan association had 
reached a plateau within 90 seconds and within 10 minutes, the ROS generation had 
reached a point where ROS production was being drastically limited, possibly by the physical 
ability of the cell to make ROS.  An endpoint assay where the cells were stimulated for 15 
minutes prior to flow cytometric analysis was proposed for future analysis as this was 
deemed sufficient to fully measure zymosan association and ROS production.  It was also 
decided that the concentration of zymosan used (100 µg/ml) was sufficient to stimulate a 
measurable cellular response and that an internal control for APF production was possible 
using the neutrophils that had not associated with the fluorescently labelled particle. 
 
 
 
 
186 
 
 
Figure 5.5:  Neutrophils derived from MyPH8-B6 cell line were stimulated with fluorescently labelled 
opsonised zymosan particles.  A) Flow cytometric representation of neutrophils that showed no association 
with zymosan and showed no increase in the production of ROS.  B)  Flow cytometric representation showing 
that some neutrophils that were associated with zymosan showed a steep increase in ROS production, which 
began to level out within 10 minutes.  C) Graphical representation of the percentage of cells producing ROS 
over time.  Data representative of 2 independent experiments. 
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5.6. In Vitro Study of the Function of Clec7a on Neutrophils Derived from 
Conditionally-immortalised Cell Lines 
Neutrophils derived from conditionally-immortalised cell lines were loaded with APF then 
stimulated with fluorescently labelled zymosan or live C. albicans SC5314 for 15 minutes, at 
37°C (methods 2.7.2).  When mixed with non-opsonised zymosan, both wild type and Clec7a 
deficient neutrophils showed background levels of zymosan binding (Figure 5.6).  On 
opsonisation of the particles, levels of zymosan binding significantly increased (Figure 5.6).  
However with live C. albicans, Clec7a deficiency resulted in a significant decrease in binding 
for both non-opsonised and opsonised C. albicans (Figure 5.6).  Clec7a deficiency also 
impaired the ability of in vitro generated neutrophils to respond to non-opsonised and 
opsonised zymosan interactions by the production of ROS.  This was not seen with C. 
albicans and instead a significant increase in ROS production was seen with Clec7a deficient 
cells as a response to non-opsonised C. albicans (Figure 5.6).  However, this latter result was 
not reproduced in a second experiment.   
Although, these results show a role for Clec7a on neutrophils in fungal particle recognition 
and cellular response, the expression of Clec7a on MyPH8-B6 wild type generated 
neutrophils is very low (Figure 5.1) and not comparable to that seen on primary neutrophils 
(Figure 5.3).   Neutrophils from the Clec7a deficient cell line that had be reconstituted with 
Clec7a.B did show more comparable levels of the protein expression so this assay was 
repeated using neutrophils derived from this cell line, the Clec7a-/- deficient cell line and a 
Itgam-/- cell line that had been transduced with Clec7a.B (Figure 5.7). 
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Figure 5.6: Graphical analysis of the recognition and response to zymosan and C. albicans of MyPH8-B6 and 
MyPH8-B6:Clec7a
-/-
 neutrophils.  Neutrophils were stimulated with either serum opsonised or non-opsonised 
zymosan particles or serum opsonised or non-opsonised live C. albicans.  Clec7a deficiency did not impair 
binding to non-opsonised and opsonised zymosan, however its deficiency did impair the response of these 
cells to the stimulant.  Opsonisation of zymosan significantly increases the percentage of cells binding zymosan 
and the percentage of these interacting cells that respond by producing ROS.  In cells stimulated with C. 
albicans, Clec7a deficiency impairs binding to both opsonised and non-opsonised C. albicans. Opsonisation of 
C. albicans significantly increases the percentage of neutrophils that bind C. albicans.  Unops = non-opsonised; 
Ops = opsonised. Data shown is representative of 2 independent experiments and data shown represented the 
mean±SEM of triplicates of one experiment.  Analysis by two-way ANOVA with Bonferroni post-tests. I = 
Interaction; D = significance of the effect of Clec7a; C = significance of effect of complement opsonisation.  P 
values: *=P<0.05; **=P<0.01; *** = P<0.001.   
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Curdlan microparticles (curdlan mp) are a selective Clec7a agonist (Rosas et al. 2008).  
Clec7a deficient neutrophils show no response when stimulated with curdlan mp, however, 
Clec7a deficient cells that were reconstituted with the B isoform were able to respond 
(Figure 5.7.A).  Interestingly, CD11b deficient neutrophils that had been transduced with 
Clec7a.B showed a significantly greater response to curdlan mp than either of the previous 
neutrophil types (Figure 5.7.A).  This could be due to the slightly higher clec7a expression on 
these cells due to the fact that they already expressed low levels of Clec7a prior to 
transduction. 
When stimulated with non-opsonised and serum opsonised zymosan, MyPH8-B6.Clec7a-/-
:Clec7a.B neutrophils showed a significant increase in zymosan binding and ROS production, 
compared to both MyPH8-B6.Itgam-/-.Clec7a.B neutrophils and the empty vector control 
neutrophils (Figure 5.7.B).  Opsonisation of the zymosan particles significantly increased the 
percentage of neutrophils binding zymosan, however, opsonisation did not affect the ROS 
production of those cells that did bind the particle (Figure 5.7.B).  When stimulated with C. 
albicans, MyPH8-B6.Clec7a-/-:Clec7a.B neutrophils showed greater binding than the other 
two cell lines.  Serum opsonisation of the yeast resulted in significantly increased binding in 
all cell lines except the CD11b deficient cells (Figure 5.7.B).   Again serum opsonisation had 
no effect on the ROS production of neutrophils that had bound the C. albicans. 
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Figure 5.7:  Graphical analysis of the recognition and response to curdlan mp, zymosan and C. albicans of in 
vitro-derived neutrophils.  A) Percentage of cells stimulated with curdlan mp that respond by producing ROS.   
The Clec7a deficient neutrophils showed no response to curdlan mp but both cell lines with Clec7a.B were able 
to respond.  B) Neutrophils were stimulated with either serum opsonised or non-opsonised zymosan or live C. 
albicans.  Clec7a deficiency impairs binding and response to non-opsonised and opsonised zymosan in 
neutrophils.  Opsonisation of zymosan increases the percentage of cells that bind zymosan in all cell line 
except the CD11b deficient cells.  When stimulating with live C. albicans, Clec7a deficiency impaired only the 
binding of non-opsonised zymosan to the neutrophils.  Clec7a deficiency and opsonisation of C. albicans had 
no effect on the response of the neutrophils to the live C. albicans.  Unops = non-opsonised; Ops = opsonised. 
Data are representative of 3 independent experiments and data shown represented the mean±SEM of 
triplicates of one experiment.  (A) Analysis by two tailed t test. (B) Analysis by two-way ANOVA with Bonferroni 
post-tests (asterisks). I = Interaction; D = significance of the genetic deficiencies; C = significance of effect of 
complement opsonisation.  P values: *=P<0.05; **=P<0.01; *** = P<0.001.   
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 5.7. Reconstitution of Itgam-/- Cell Line with Human CD11b 
An Itgam-/- neutrophil precursor cell line was reconstituted with two forms of the human 
Itgam gene as described in chapter 3 and chapter 2.5.5.  The expression of CD11b on the in 
vitro generated neutrophils was compared to CD11b expression on primary neutrophils 
(Figure 5.8).  Both of the transduced cell lines appeared to express CD11b and the empty 
vector control cell line showed no expression of CD11b (Figure 5.8).  Although expression of 
human CD11b appeared to be lower than mouse CD11b on primary cells, this could not be 
concluded as both of the antibodies (either clone 5C6 or M1/70) used to determine CD11b 
expression were anti-mouse antibodies that were used purely because of their known cross-
reaction with human CD11b.  
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Figure 5.8: Expression of CD11b on primary cells and in vitro generated neutrophils derived from transduced 
Itgam
-/-
 cell lines.  The cell lines transduced with human CD11b isoforms (‘G230’ and ‘A230’) both show similar 
expressions of CD11b which are ‘lower’ than that seen on primary neutrophils.  The empty vector control cell 
line showed no expression of CD11b.  The red histogram denotes CD11b expression and the white histogram 
shows the negative control.  Data representative of 2 independent experiments. 
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5.8. Restored Function of CD11b on Reconstituted Cell Lines 
Neutrophils derived from the MyPH8-B6.Itgam-/-:G230, MyPH8-B6.Itgam-/-:A230 and 
MyPH8-B6.Itgam-/-:pMXs-IZ cell lines were preloaded with APF then stimulated with 
fluorescently labelled zymosan or live C. albicans for 15 minutes, at 37°C (methods chapter 
2.7.2).  All three cell lines showed poor binding of non-opsonised zymosan but the 
reconstituted CD11b cell lines were able to bind serum opsonised zymosan (Figure 5.9).  
Opsonisation was also able to significantly increase the ROS production of zymosan 
associated cells.  The empty vector control cell line showed the low levels of binding and 
ROS production observed for non-opsonised particles (Figure 5.9). 
When stimulated with non-opsonised C. albicans, neutrophils derived from the G230 and 
A230 cell lines showed significantly increased binding to C. albicans compared to 
neutrophils derived from the empty vector control cell line.  The CD11b reconstituted cell 
lines, but not the empty vector control, showed a significant increase in C. albicans binding 
when the yeast was serum opsonised.  ROS production in response to non-opsonised C. 
albicans is significantly increased in the A230 reconstituted cell line, but not in the G230, in 
comparison to the empty vector control (Figure 5.9), which contrasts previously published 
data (MacPherson, Lek et al. 2011).  Serum opsonisation of C. albicans significantly 
increased ROS production in both reconstituted cell lines in comparison to the control cell 
line. 
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Figure 5.9:  Graphical analysis of the recognition and response to zymosan and C. albicans of in vitro 
neutrophils.  Neutrophils were stimulated with non-opsonised or serum opsonised zymosan or live C. albicans.  
Very low binding of non-opsonised zymosan was observed with all cell lines.  However, opsonisation of 
zymosan resulted in a significantly increased level of binding in the MyPH8-B6:Itgam
-/-
.G230 and MyPH8-
B6:Itgam
-/-
.A230 cells but not in the empty vector control cells.  Response of these cells to zymosan was also 
significantly increased by opsonisation in the cells reconstituted with CD11b.  Levels of binding and response to 
C. albicans was increased by opsonisation of the live yeast in the reconstituted cell lines but not in the empty 
vector control.  Unops = non-opsonised; Ops = opsonised. Data representative of 3 independent experiments 
and data shown represented the mean±SEM of triplicates.  Analysis by two-way ANOVA with Bonferroni post-
tests (asterisks). I = Interaction; R = significance of the effect of the transduced receptor; C = significance of 
effect of complement opsonisation.  P values: *=P<0.05; **=P<0.01; *** = P<0.001. 
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5.9. Conclusion 
In this chapter, neutrophils derived from conditionally-immortalised precursor cell lines 
were used to model innate immunity.  The decision to use reconstituted Clec7a-/- cells as 
opposed to wild type cells was predominantly based on the difference of Clec7a expression 
between the wild type MyPH8-B6 neutrophils and primary neutrophils.  In vitro generated 
wild type neutrophils showed low expression of Clec7a, suggesting that they are not quite 
fully matured murine neutrophils but this was addressed in a controlled manner suitable for 
the model being explored.  Neutrophils derived from the Clec7a-/- cell line showed a similar 
impairment in the recognition and response to zymosan and C. albicans as that seen with 
primary neutrophils in chapter 4.  Reconstitution of these deficient cells with Clec7a was 
able to restore the lost function.  Also opsonisation of the stimulating particles, increased 
recognition of both zymosan and C. albicans, with the exception being the CD11b deficient 
cells, as CD11b is a subunit of complement receptor 3 (CR3), which recognises serum 
opsonised particles. 
CD11b deficient cells were successfully reconstituted with two different isoforms of human 
CD11b.  The reconstitution of CD11b restored the increased recognition and response to 
opsonised zymosan and C. albicans.  Interestingly, human CD11b transduced cell lines did 
not exhibit CD11b surface expression until they were differentiated, suggesting that surface 
expression could not be achieved until differentiation induced expression of its partner 
molecule (CD18) had occurred.  Additionally these experiments depended upon an 
association between human CD11b and mouse CD18 and these results provided 
circumstantial evidence that this occurs and that this heterodimer is functional.  Contrary to 
previously published data (Macpherson et al. 2010), which suggests that cells homozygous 
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for the A230 allele are impaired in their immune response, the results seen here suggest the 
A230 allele has a slight advantage in its ability to recognise and respond to zymosan and 
C.albicans.  There are several factors to be taken into account when looking at these results.  
Firstly, neither fungal particles nor serum-opsonised fungal particles are specific for CD11b 
and mouse serum was used to opsonise, which most likely has altered affinity for human 
CD11b.  Also the cross-species mouse CD18:human CD11b heterodimer, whilst functional 
may not be truly represent the activity of the human heterodimer and the cell lines 
expression may differ as a consequence of in vitro passage and not solely as a consequence 
of CD11b polymorphism.  Ideally these experiments need to be repeated with selective 
CD11b ligands, and verified with a separate set of cell lines.  In the context of the 3Rs, this 
shows that this type of model is a useful, but experiments need to be carefully controlled.   
Since completion of these studies the MyPH8-B6.Clec7a-/- parental cell line transduced with 
either Clec7a.B or the empty vector control has been used to model a novel immune 
regulatory function of Clec7a (Karsten, Pandey et al. 2012). These studies with the cell line 
derived neutrophils gave very similar results to primary cells, both validating this cell line 
approach and showing the advantage of being able to genetically alter neutrophils to tackle 
difficult scientific questions.  
In summary, these studies demonstrate the ability of neutrophils derived from 
conditionally-immortalised cell lines to model innate immunity, but with some specific 
limitations and considerations that must be considered in experimental plans.  The relative 
ease with which these cells can be successfully genetically modified increases the scope of 
neutrophil study and the study of human proteins in a mouse model. 
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Chapter 6: Discussion 
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The study of neutrophil biology is primarily achieved through the use of primary neutrophils 
obtained from human donor blood or tissues (Yamamoto, Saeki et al. 1991; Adams 2004; 
Marks, Radulovic et al. 2007; Nauseef 2007), or experimental animal models (Cowburn, 
Condliffe et al. 2008).  Although directly relevant these primary cells are short lived, can be 
difficult to handle for experimental purposes and can lead to a large loss in animal life.  To 
address some of these issues a myeloid progenitor cell line was developed (Wang, Calvo et 
al. 2006).  However, extensive functional characterisation was not performed and this thesis 
aimed to address this deficiency and to determine if these cells could be a useful 
replacement for the animals in neutrophil research.   
The cell line was generated by the conditional immortalisation of lin- bone marrow cells by 
the expression of mouse Hoxb8 fused to an oestrogen-receptor binding domain.  This gene 
prevents the progenitor cells from terminal differentiation and allows the cell line to be kept 
in culture indefinitely, provided a growth factor is present.  However, the transcriptional 
activity of Hoxb8 is only active in the presence of oestrogen, hence it’s conditional nature, 
and removal of the oestrogen allows for the cells to terminally differentiate producing 
neutrophils.  This makes this cell line distinct from other cell lines, in that the immortalising 
factor is removed before differentiation possibly leading to more mature neutrophils being 
produced (Collins, Gallo et al. 1977; Collins, Ruscetti et al. 1978; Guchhait, Tosi et al. 2003; 
Fleck, Romero-Steiner et al. 2005; Wang, Calvo et al. 2006).   
The removal of the immortalising factor also makes these cells particularly suitable for 
adoptive transfer into live animals as once in the animal they won’t persist leading to 
possible problems with tumour formation.  The successful i.v injection of these cells into live 
mice and their recruitment from the peritoneal cavity, show that in an in vivo system, these 
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cells are able to behave like endogenous cells and can pass from the blood stream and 
extravasate into other tissues of the body.  Differences in the functional behaviour of 
different cells were still noticeable, as CD11b deficient cells were less able to bind zymosan 
particles used to recruit the cells in the peritoneal cavity and were present in higher 
numbers as previously reported in the knockout animals (Coxon, Rieu et al. 1996). 
Wang et al. reported that conditional-immortalisation with Hoxb8 in the presence of SCF 
resulted in a precursor cell line could be manipulated to produce other myeloid cells, i.e. 
eosinophils and macrophages (Wang, Calvo et al. 2006) by the manipulating of 
differentiation cytokines.  I specifically examined IL-5 treated cultures for the presence of 
eosinophils, as IL-5 is a known growth factor for eosinophils (Lopez, Begley et al. 1986; 
Sanderson 1990; Wang, Calvo et al. 2006), but did not observe cells with the morphology of 
eosinophils (as compared to the peritoneal lavages from naive mice) after eosin, methylene 
blue staining (data not shown). Over the time (6 days) and culture conditions used there 
was little evidence of macrophage differentiation, with differentiated cells being non-
adherent and predominantly F4/80-.  This data suggests that the progenitors produced are 
already committed to the neutrophil lineage. The differences seen with the cells produced 
by Wang et al. could be due to a less homogenous progenitor population, where a few 
progenitors are not yet committed to the neutrophil lineage so are still able to produce the 
eosinophils and macrophages seen. 
MyPH8-B6 neutrophils that had been differentiated in SCF alone, as original performed by 
Wang and colleagues (Wang, Calvo et al. 2006) and in SCF+G-CSF were chosen for further 
study due to the observation that they produced large numbers of cells with a high (>80%) 
neutrophil purity.  Their expression of different cell surface markers was examined and they 
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were shown to express several different myeloid, and specifically, neutrophil markers.  
However, the expression patterns seen suggest that although SCF alone and the SCF+G-CSF 
differentiated cells are neutrophils, they have slightly different phenotypes.  Primary 
neutrophils express Clec7a and CD88 (Chenoweth and Hugli 1978; Taylor, Brown et al. 
2002).  Cells differentiated in SCF alone do not express these markers and this suggests they 
are perhaps not as mature as primary neutrophils. However, cells that were differentiated in 
SCF+G-CSF show a low level of expression of both these markers, relative to primary cells. 
Additionally, compared to primary cells, these in vitro generated cells exhibited low 
expression of Ly-6G (and hence Gr-1).  Overall, this meant that in studies of Clec7a where 
these in vitro generated neutrophils were used, in order to achieve physiologically relevant 
levels of Clec7a expression, Clec7a knockout cell lines were reconstituted with Clec7a. The 
reason for choosing to reconstitute Clec7a knockout cells rather than simply overexpress 
Clec7a in wild type cells is that this allowed direct comparison of the knockout cells with the 
same parental cell line reconstituted with Clec7a without the risk of artefacts created by 
differences between distinct cell lines. 
The functional behaviour of MyPH8-B6-derived neutrophils was assessed.  These 
neutrophils were able to bind and phagocytose zymosan particles and respond with 
respiratory burst.  A flow cytometric assay showed that neutrophils stimulated with 
ionomycin exhibited a strong increase in intracellular calcium ion levels.  Similarly, zymosan 
was also able to induce an increase in intracellular calcium ions.  A limitation to this 
approach is that it only provides a snapshot of cell activity as the cells are excited and 
detected by the flow cytometer.  An alternative way to examine the kinetics of calcium 
mobilisation would be to continuously monitor individual cells over a period of time.  A 
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single live-cell microscopy assay allowed for individual cells to be identified and introduced 
to a zymosan particle by micromanipulation techniques (Dewitt and Hallett 2002), and for 
the subsequent calcium ion changes and phagocytosis of the particle to be monitored.  This 
assay also allows for a direct correlation between calcium ion changes and the progress of 
phagocytosis to be observed.  The in vitro generated neutrophils were found to produce a 
calcium ion signal similar to that seen by human primary neutrophils (Dewitt and Hallett 
2002; Dewitt, Laffafian et al. 2002), when introduced to a zymosan particle. 
Primary neutrophils have a very short life span and are terminally differentiated (Cowburn, 
Condliffe et al. 2008).  This makes them almost impossible to genetically modify.  This 
method of producing neutrophil precursors allows for the generation of genetically 
modified precursor cells that can be used to generate neutrophils.  I have shown that the 
progenitor cells can be transduced with a viral construct containing the gene of interest and 
differentiated into neutrophils that also contain the gene. This has been similarly seen with 
conditionally-immortalised macrophage precursors (Wang, Calvo et al. 2006; Rosas, Osorio 
et al. 2010) as well as SCF differentiated neutrophil precursors (Koedel, Frankenberg et al. 
2009).  There is a reduction of transgene expression, which can perhaps be attributed to 
terminal differentiation and reduction in RNA production and new protein synthesis, as 
differentiation occurs, but by the end of the differentiation process, expression of the gene 
is still detectable at levels which confer functional alterations upon the cells.  This is one of 
the key advantages of this method of neutrophil production as it expands the scope of 
studying neutrophil biology immensely.   
The contribution of Clec7a to neutrophil recognition and response to fungal infection has 
been recently explored.  Clec7a deficient murine neutrophils show decreased zymosan 
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binding and an attenuated respiratory burst in response to zymosan (Taylor, Tsoni et al. 
2007).  On human neutrophils, Clec7a has been shown to promote fungicidal activity 
towards C.albicans (Kennedy, Willment et al. 2007).  However, this is complicated as 
blocking Clec7a activity  on human neutrophils has no effect on C. parapsilosis phagocytosis 
even though it reportedly shows more β-glucans on its surface than C.albicans (Linden, 
Maccani et al. 2010).  If a model to demonstrate the role of Clec7a on neutrophils could be 
developed, it would be a useful model in which to test the efficacy of in vitro generated 
neutrophils in modelling innate immune responses and to analyse the contribution of Clec7a 
to neutrophil activation. A time course experiment in wild type 129S6/SvEv mice using 
zymosan peritonitis generated a useful model for the response of the immune system to 
zymosan.  Zymosan particles (2x107) injected i.p. encounter tissue resident cells first, 
including macrophages that were able to phagocytose some of the particles.   In this model, 
inflammation is triggered by a number of systems including macrophage activation (Brown 
and Gordon 2001; Underhill 2003), complement activation (Pillemer, Blum et al. 1954; 
Mizuno, Ito et al. 2009) and mast cell activation (Kolaczkowska, Seljelid et al. 2001). The 
chemokines and other inflammatory mediators, such as C5a, that are produced recruit 
neutrophils.  In these studies, this manifested itself in a rapid increase in neutrophil 
presence in the peritoneum, which coincided with the ‘disappearance’ of tissue resident 
macrophages, and the high dose of zymosan ensures that enough zymosan persists for the 
neutrophils to phagocytose. Neutrophil numbers decreased over a matter of hours and 
numbers of infiltrating monocytes and macrophages began to gradually increase.  These 
macrophages and monocytes, particularly those monocytes that arrive earlier in the 
inflammatory cascade would be able to phagocytose any residual zymosan particles as well 
as apoptotic neutrophils and 7 days after initial injection, the absolute numbers of 
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macrophages had almost recovered completely.  Since neutrophil presence in the peritoneal 
cavity was notable and increasing at 4 hours and this was deemed a suitable time point at 
which to explore the effect of Clec7a deficiency on neutrophil interactions with zymosan in 
vivo. 
Deficiency in Clec7a diminishes the recruitment of neutrophils and their ability to associate 
with zymosan.  It was unclear as to whether this is due to an intrinsic role of Clec7a on the 
neutrophils or perhaps just a defect in inflammation in response to zymosan (a ligand of 
Clec7a). A defect in cellular activation in general in the absence of Clec7a is suggested by the 
reduction in IL-6 observed in the peritoneal washouts of Clec7a-deficient mice when 
compared to the wild type controls and this is consistent with Clec7a being a major receptor 
for the non-opsonic recognition of  β-glucan containing particles such as zymosan (Brown, 
Taylor et al. 2002).  Tissue resident macrophages express alternate receptors for zymosan, 
including the DC-SIGN homologue SIGNR1 (Taylor, Brown et al. 2002; Taylor, Brown et al. 
2004) as well as alternate scavenger receptors and lectins that may play, perhaps lesser, but 
important potential roles in fungal recognition.  To explore whether Clec7a is a major 
receptor for the non-opsonic recognition of β-glucan, an ex vivo assay looking at primary 
neutrophil recognition of zymosan was developed.  When conducted with inflammatory 
neutrophils, it was found that although Clec7a deficiency does impair the ability of 
neutrophils to bind and respond to zymosan particles; however serum-opsonisation of the 
zymosan particles was much more important for neutrophil-mediated recognition.  This 
suggests that Clec7a does have a role to play in recognition of fungal particles but 
opsonisation and CD11b have a larger role, making the role of Clec7a appear partially 
redundant.  Live C. albicans interactions with neutrophils were also explored and similar 
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observations and conclusions were made.  In contrast, peripheral blood neutrophils showed 
no dependency on Clec7a for the recognition of fungal particles.  This obvious difference 
between inflammatory neutrophils and whole blood neutrophils could be down to the 
nature of the cells.  Inflammatory neutrophils have been recruited through the endothelial 
barrier in response to different cytokine signals and are primed and activated to respond, 
which could enhance the receptor specific responses seen.  Whole blood neutrophils have 
not been through this priming process and this could contribute to some of the differences 
seen.  One possible limitation of this assay is the presence of large numbers of red blood 
cells.  The red blood cells are not lysed prior to the assay to avoid priming of the blood 
neutrophils; however, the red blood cells could result in steric inhibition of neutrophil 
activity.  This limitation is not present in the inflammatory neutrophil assay and would allow 
for a greater response.  Another possible limitation is the use of heparin in this assay.  
Heparin, an anticoagulant used to stop the blood from clotting, is reported to have anti-
inflammatory properties (Young 2007).    
To test the limitations of this assay, curdlan microparticles, specific Clec7a agonists, were 
used to stimulate the cells and whole blood samples were spiked with inflammatory BIOgel 
neutrophils, which could be distinguished with an allotypic marker.  This resulted in a 
lowering of the response of the inflammatory neutrophils and supports the idea that red 
blood cells are interfering with the curdlan microparticle and neutrophil interaction and 
lowering the ROS response.  However, heparin may also be having an anti-inflammatory 
effect on these neutrophils (Young 2008). Testing whether the use of heparin affected our 
assay, showed that inflammatory cells that had been exposed to heparin had a decrease in 
ROS production compared to those that had not been exposed.  A different anti-coagulant, 
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sodium citrate, and lysis of the red blood cells was used to address these issues, however, 
this resulted in no difference being seen between inflammatory neutrophils and quiescent 
blood neutrophils, as the blood neutrophils had increased the percentage of cells 
responding 3-fold. There are two possible reasons for the results seen.  Firstly, lysis of the 
red blood cells removes any interference between the neutrophils and curdlan 
microparticles, thereby allowing more blood neutrophils to interact and respond.  Also the 
process of lysing the red blood cells could activate the previously quiescent blood 
neutrophils, increasing their ability to interact and respond to curdlan microparticles.  
Distinguishing between these two reasons would be extremely technically difficult and 
highly purified quiescent blood neutrophils would need to be isolated before this limitation 
could be addressed.  There is a study that purports to produce such highly purified 
quiescent blood neutrophils (Cotter, Norman et al. 2001). My results suggest that although 
heparin may affect the response of cells to curdlan microparticles, the interference of red 
blood cells is a much bigger limitation in this assay.    
This ROS response assay was applied to human neutrophils to determine if there was a 
functional difference between the murine model and human model of response.  Obtaining 
suitable inflammatory human neutrophils proved to be a significant challenge as the 
methods we used each had their own limitations.  The saliva contains large amounts of 
neutrophils that have extravasated from the blood and are mixed with potential microbial 
material and are therefore primed.  Collection of these neutrophils was simple and large 
amounts could be obtained, however, the background ROS response was prohibitively high 
and would make subtle differences in response very difficult to see.  This can probably be 
attributed to bacteria and other microbial material that is found in the mouth that the 
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neutrophils have already been activated by.  Another method of obtaining inflammatory 
human neutrophils involved using a “skin window” by lightly removing the top layer of skin 
using sand paper and collecting the infiltrating cells on filter paper soaked with PBS (Marks 
et al. 2007).  This method produced far less neutrophils than the saliva and obtaining the 
cells requires injury to the donor, which is not a desirable side effect.  These cells also 
showed a high background ROS response which would cause significant problems when 
examining the low level of non-opsonic recognition of yeast and glucan particles by human 
neutrophils. Human peripheral blood neutrophils were easily obtainable in sufficient 
numbers and the ROS response background levels were minimal.  The main problem when 
attempting to apply this model to human neutrophils was the lack of Clec7a-deficient 
patients in Cardiff.  Methods of blocking Clec7a activity were investigated and two different 
blocking antibodies were looked at but neither had any noticeable effect on the neutrophil 
binding to zymosan, in contrast to the Clec7a-dependency seen with murine neutrophils.  
Also, laminarin, a soluble β-glucan, which has been used previously to inhibit Clec7a activity 
(Brown, Taylor et al. 2002), had no effect on the non-opsonic zymosan binding to 
neutrophils.  Increasing neutrophil: zymosan interaction through the centrifugation (Voyich 
and DeLeo 2002; Kennedy, Willment et al. 2007) could have helped remove these 
limitations, however, the questionable physiological relevance of a forced interaction was 
the deciding factor in forgoing this step. 
A murine model looking at the role of Clec7a on neutrophils was developed and results 
indicate that the role of Clec7a on neutrophils is complicated.  Clec7a deficiency does impair 
fungal particle recognition and ROS production, which shows an important role for Clec7a 
on neutrophils, however, opsonisation of the fungal particles is able to largely restore 
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recognition and ROS production showing that there is a level of redundancy in the system 
and that the role of Clec7a in response to fungal infection is part of a large framework of 
responses, rather than a protein with one distinct function.  The ubiquitous nature of 
complement in the body perhaps gives it a more significant role in fungal recognition than 
Clec7a.  This is consistent with the observation that although Clec7a deficient humans may 
have higher recurrent instances of fungal infections, they are not highly susceptible to 
invasive fungal disease and show no defect in fungal killing (Ferwerda, Ferwerda et al. 
2009).  Recent studies have shown that Clec7a activates CR3 but that this is likely to also be 
redundant as the immune system has other mechanisms, such as other PRR, that can 
compensate for the lack of Clec7a (Li, Utomo et al. 2011).   
Neutrophils derived from conditionally immortalised cell lines were used to replicate the 
studies performed on the role of Clec7a on primary neutrophils, as a proof of concept study.  
Clec7a knockout cells were used and reconstituted with both the Clec7a isoforms (Clec7a-A 
and Clec7a-B); because it was felt that the expression of Clec7a by the wild type cells was 
lower than that seen on primary neutrophils.  The reconstitution was successful and after 
flow cytometric studies comparing Clec7a expression on these cells to primary neutrophils, 
it became evident that the Clec7a-A isoform reconstituted cell line expressed noticeably 
more Clec7a expression than the Clec7a-B reconstituted cell line, which had expression 
levels comparable to primary neutrophils.    RNA extraction and RT-PCR analysis showed 
that MyPH8-B6 wild type cells primarily express the B isoform, similar to the primary 
macrophages isolated from the same parental strain of mice (C57BL/6) (Heinsbroek, Taylor 
et al. 2006).  Some initial zymosan binding studies were performed using wild type cell line-
derived neutrophils that had been transduced with the different Clec7a isoforms.  Taking 
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into consideration that MyPH8-B6-derived neutrophils primarily express the Clec7a-B 
isoform and that the Clec7a-/- cell line that had been reconstituted with Clec7a-B showed 
comparable levels of expression to the primary neutrophils, all further studies were 
performed only with this cell line and not the Clec7a-A reconstituted cell line whose 
activities would have to be considered physiologically irrelevant, due to the fact that it is 
overexpressed on the cell line neutrophils, in comparison to primary wild type neutrophils.  
Attempts to flow-cytometrically cell sort low expressers from the Clec7a-A expressing cells 
failed and the population stabilised with high expressing soon after.  In conjunction with the 
Clec7a-B reconstituted cell line empty vector containing Clec7a-/- cells were also made and 
for direct comparison the same two vectors were also transduced into the Itagm-/- cell line.  
These studies were able to replicate the results seen with primary mouse neutrophils in that 
although Clec7a deficiency does impair binding and response to both zymosan and C. 
albicans, the effect is limited and serum opsonisation seems to play a much bigger role in 
recognition and response.   
Further proof of concept studies were performed using Itgam-/- in vitro derived neutrophils.  
These cells were reconstituted with 2 polymorphic variants of human CD11b.  These 
neutrophils were assessed for their ability to bind and respond to opsonised zymosan and C. 
albicans.  The reconstitution of CD11b on these cells was able to restore binding to 
opsonised particles, confirming that human CD11b could effectively partner with mouse 
CD18.  Also these studies demonstrate the versatility of these cells in that human as well as 
mouse genes may be studied and manipulated on these cells. 
To summarise, neutrophils derived from conditionally immortalised are morphologically and 
functionally similar to primary neutrophils.  They can be genetically modified and provide a 
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biologically relevant model for the study of neutrophil biology. However, extreme caution 
should be taken not to over-interpret data that could also be explained, by defects in 
maturation of in vitro-derived neutrophils or by non-physiological expression levels of 
transgenes.  Maturation defects have also been seen in ex vivo neutrophils generated from 
CD34+ human stem cells which impaired their ability to kill E.coli and S. pneumoniae (Dick, 
Prince et al. 2008).  Although, those cells were functional similar to peripheral blood 
neutrophils, in that they were able to recognise and phagocytose pathogens, they contained 
immature granules which impaired their killing ability.  This technique of producing in vitro 
generated neutrophils is novel and increases the scope of the study of neutrophil biology. 
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